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Abstract 
 
Bladder cancer is the second most common urological cancer after prostate cancer 
and is one of the leading causes of cancer mortality in most western countries.  For 
organ-confined, muscle-invasive disease, the standard of care, in terms of definitive 
cure, remains radical surgery (cystectomy) with lymphadenectomy.  However, 
survival rates remain poor following supposedly curative treatment.  Radical 
radiotherapy and more recently, multimodality treatment incorporating chemo-
radiotherapy, are alternatives which allow bladder preservation in those choosing not 
to undergo or are unsuitable for radical surgery.  However, survival rates following 
radiotherapy are generally lower relative to radical cystectomy and multimodality 
treatments can only be offered to select cases in few institutions.  Biomarkers which 
can accurately predict tumour response to radiotherapy or chemotherapy can aid the 
selection of patients who are likely to respond well to treatment options 
incorporating radiotherapy and/or chemotherapy, as alternatives to radical 
cystectomy, in the management of bladder cancer.  Such a strategy would allow 
personalised cancer care with patients likely to benefit from treatments that they are 
likely to respond well to and concomitantly avoid complications arising from other 
treatments less likely to benefit them. 
 
This thesis investigated the novel tumour suppressor gene, AIMP3 which is involved 
in the DNA damage response (DDR) pathway following exposure to genotoxic 
insults such as irradiation and chemotherapy.  The expression and cellular 
localisation of AIMP3 protein was characterised in a panel of bladder cancer cell viii 
 
lines.  Expression of AIMP3 was altered by gene knockdown with siRNA 
transfection and survival outcomes assessed following irradiation and chemotherapy. 
 
The predictive value of AIMP3 expression in determining survival outcome of 
patients with muscle-invasive bladder cancer who had undergone radical 
radiotherapy, with or without carbogen supplementation, in the BCON trial, was 
assessed.  Prognostic significance was evaluated by interrogating a control cohort of 
patients who had undergone radical cystectomy and had not had exposure to 
radiotherapy or either neoadjuvant or adjuvant chemotherapy.  Reportedly important 
DDR proteins, including Mre11, p53 and ERCC1, were also interrogated in the 
BCON, Radical Cystectomy, Neodjuvant and LaMB trial TMA datasets.  
 
Clonogenic survival outcomes following AIMP3 knockdown were also investigated 
in cisplatin-sensitive (RT112) and cisplatin-resistant (RT112CP) cell lines following 
cisplatin exposure.  Survival outcome, stratified for AIMP3 as well as ERCC1, 
Mre11 and p53 status, were interrogated in the Neoadjuvant set, which incorporated 
a cohort of patients who had undergone cisplatin-based neoadjuvant chemotherapy 
prior to radical treatment.  This was validated in a second cohort of patients who had 
undergone cisplatin-based chemotherapy as part of the LaMB trial.ix 
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1.1  Cancer 
Cancer can be regarded as a large spectrum of diseases characterised by unregulated, 
neoplastic cellular proliferation and transformation, which is distinct from the tightly 
controlled morphology and physiology of normal cells in the tissues from where 
they arise.  Such malignant neoplasms may grow to disrupt the normal functions of 
the affected organ.  In the course of malignant growth, which is a multi-step process 
called tumour pathogenesis, some cancer cells may acquire the ability to penetrate 
and infiltrate adjacent normal tissues – a process often called “local invasion”.  In 
some cases, cancer cells proceed to penetrate blood or lymphatic vessels, becoming 
circulating tumour cells, and can metastasise to more distant organs of the body.  
During this process of transformation and evolution, from normal cells to metastatic 
cancer cells, the cells acquire a multitude of distinct capabilities, sometimes referred 
to as “hallmarks of cancer” or “hallmark capabilities”, which enable them to become 
tumorigenic and ultimately, metastatic (Hanahan and Weinberg, 2011).  These 
capabilities include the ability to: sustain proliferative signalling; evade growth 
suppressors; resist cell death; enable replicative immortality; induce angiogenesis; 
and, activate invasion and metastasis. 
 
Cancer is increasingly becoming a prominent disease globally with rising prevalence 
and associated economic burden.  Worldwide, approximately 12.7 million cancer 
cases and 7.6 million cancer deaths are estimated to have occurred in 2008 (Jemal A 
et al, 2011).  In terms of causation, environmental and lifestyle factors (e.g. tobacco 
smoking, diet, physical activity, infections, radiation, environmental pollutants, etc.) 3 
 
are thought to account for 90-95% of cases, while a small percentage, of around 5-
10% of cancers, are attributed to inherited genetic defects (Anand P et al, 2008).   
 
In the genetic context, the multi-step process of tumour pathogenesis involves the 
accumulation of multiple genetic aberrations.  These commonly involve the 
activation of oncogenes, inactivation of tumour-suppressor genes (TSGs) and 
alteration of microRNA genes (Croce CM, 2008).  These genetic aberrations can 
often arise as a result of the aforementioned environmental factors.  Except in the 
scenario of hereditary or familial cancers, aberrations in a single gene are rarely 
sufficient for the development of a malignant tumour. 
 
1.1.1  Molecular basis of cancer: oncogenes and tumour suppressor genes 
1.1.1.1  Oncogenes 
Oncogenes were originally identified in cancer-causing viruses.  A viral 
transforming gene, v-src, in the Rous sarcoma virus which causes sarcoma in 
chickens, was noted to be derived from normal cellular gene (Stehelin D, 1976).  
Normal cellular genes, from which viral oncogenes (v-onc) were derived, were then 
referred to as proto-oncogenes (c-onc).  Subsequently, many of the viral oncogenes 
have been identified independently in tumours that arise spontaneously without viral 
transformation.  In spontaneously arising non-viral tumours, proto-oncogenes, rather 
than being activated by viral transduction, are activated by other means such as 
mutations, chromosomal translocation and amplifications, and become tumour-
inducing oncogenes.  The implication of this is that, in every cell in the human body, 
there are genes with the potential to be activated or altered with the consequent risk 4 
 
of contributing to the rise of malignancy.  The products of oncogenes can be 
categorised as: chromatin remodelers, growth factors, growth factor receptors, 
transcription factors, signal transducers and apoptosis regulators (Croce CM, 2008). 
 
One of the most common oncogenes in human cancers is the Ras set of genes 
(including HRas, KRas and NRas).  Ras encodes for small GTPases involved in 
cellular signal transduction and its mutation leads to permanently activated protein 
products which, in turn, lead to continuous cell proliferation and growth (Godsell 
DS, 1999).  Another common oncogene in human cancers is the Myc gene, which is 
a transcription factor capable of regulating cell growth and proliferation (Oster SK et 
al, 2002).  There are numerous oncogenes, in addition to the ones briefly mentioned 
above, which are involved in cancer initiation and progression. 
 
1.1.1.2  Tumour suppressor genes 
In contrast to oncogenes, tumour suppressor genes (TSGs), as their name suggests, 
represent genes that tend to exert a negative regulatory role in controlling cell 
growth and help inhibit tumour development.  Whereas activated oncogenes act in a 
dominant manner and an activating event is usually required, TSGs act in a recessive 
manner where genetic alterations result in gene inactivation.  As such inactivating 
mutations may be inherited (through germline transmission in all cells), TSGs are 
commonly implicated in the development of familial cancers owing to loss of the 
second functional allele (somatic mutation) in a “two-hit” manner as hypothesised 
by Knudson for retinoblastoma (Knudson AG, 1971).  Mutations in TSGs also occur 
frequently in sporadic (non-inherited) tumours and, in accordance with the “two hit” 
hypothesis, both somatic mutations need to occur in the same cell. 5 
 
 
Tumour suppressor genes were initially identified through somatic cell fusion 
(hybrid) experiments where fusion of a normal cell to a malignant one resulted in the 
hybrids having their malignant phenotype suppressed to a normal phenotype 
(reviewed by Harris H, 1988).  These studies lent support to the statistical analysis 
provided by Knudson in his “two-hit” hypothesis in retinoblastoma cases.  When the 
retinoblastoma gene (RB1) was subsequently cloned and was demonstrated to be 
altered in retinoblastoma, the “two-hit” hypothesis was established as a model and 
also provided proof that TSGs could be identified by studying chromosomal 
deletions and by analysing genetic linkage in familial cancers (Friend SH et al, 
1986).  Subsequently, such strategies proved helpful in identifying other important 
TSGs such as p53, BRCA1, APC and BRCA2 (Baker SJ et al, 1989; Smith SA et al, 
1992; Levy DB et al, 1994; Gudmundsson J et al, 1995). 
 
Besides retinoblastoma, inherited RB1 mutations are found in a broad range of 
tumours (Burkhart and Sage, 2008).  Cells with deficient functional RB1 protein 
(pRB) demonstrate altered: (a) regulation of gene expression in proliferating cells 
through transcription factors; (b) differentiation through cell cycle stops and exit 
(leading to senescence); (c) maintenance of genomic stability through response to 
DNA damaging genotoxic stressors; and, (d) cell survival through regulation of 
apoptosis (reviewed in: Gordon and Du, 2011). 
 
As with RB1, p53, which is encoded by the TP53 gene, is an important TSG and is 
the most frequently inactivated gene in human cancers (Olivier M et al, 2002).  The 
loss of wild-type p53 expression in tumour cells confers a selective survival 6 
 
advantage.  Due to this and its central role in many signaling pathways regulating 
cell fate, p53 is regarded as the “guardian of the genome” and much research has 
been dedicated to elucidating its roles in many cancers.  P53 was initially identified 
in cells transformed by simian virus 40 (SV40) (Linzer and Levine, 1979; Melero JA 
et al, 1979).  As p53 formed stable complexes in these SV40 transformed cells, it 
was assumed to be an oncogene; however, the demonstration that these were in fact 
mutant forms of p53 led to the suggestion of a tumour suppressor role (Finlay CA et 
al, 1989).  Heterozygosity of p53 in the germline of patients with Li-Fraumeni 
syndrome, a rare syndrome characterised by early-onset occurrence of a variety of 
tumours, and subsequent somatic loss of the remaining wild-type p53 allele, 
confirmed p53 as a tumour suppressor (Malkin D et al, 1990).  The increased 
incidence of tumours in p53-null mice and their increased sensitivity to radiation- 
and chemical-induced tumorigenesis also indicated an important tumour supressing 
role (Donehower LA et al, 1992).  
 
There are many well-studied TSGs such as APC, BRCA1, BRCA2 and PTEN.  It is 
beyond the scope of this thesis to expand in detail about them and the 
aforementioned summaries on the salient points relating to RB and p53 serve simply 
to illustrate the important principles of TSGs – AIMP3, which is the focus of this 
research, is a reported TSG. 7 
 
 
 
1.2  ARS (Aminoacyl-tRNA synthetase) – interacting multifunctional 
protein (AIMP) 
 
1.2.1  Introduction to the AIMP family 
Protein biosynthesis is a complex process requiring numerous factors to ensure that 
the genetic code is translated with fidelity.  Aminoacyl-tRNA synthetases (ARSs) 
are essential enzymes which are evolutionarily highly conserved and play a critical 
role in protein synthesis by catalysing the attachment of specific amino acids to their 
cognate tRNAs (Schimmel and Soll, 1979) (Ko YG et al, 2002; Park SG et al, 
2010).  In this group of enzymes, there is conservation in their catalytic functions 
across different species; however, there are certain characteristics that distinguish 
higher eukaryotic ARSs from their prokaryotic counterparts.  Among these, one of 
the key distinguishing features is the presence, in eukaryotes, of a macromolecular 
protein complex called AIMP (ARS-Interacting Multifunctional Protein).   
 
AIMP comprises eight different ARSs including bifunctional glutamyl-prolyl-tRNA 
synthetase (EPRS), isoleucyl-tRNA synthetase (IRS), leucyl-tRNA synthetase 
(LRS), methionyl-tRNA synthetase (MRS), glutaminyl-tRNA synthetase (QRS), 
lysyl-tRNA synthetase (KRS), arginyl-tRNA synthetase (RRS), and aspartyl-tRNA 
synthetase (DRS) and three non-enzymatic factors.  The three non-enzymatic factors 
are designated AIMP1 (p43), AIMP2 (p38) and AIMP3 (p18) depending on their 
sizes where AIMP1 is 43kDa, AIMP2 is 38kDa and AIMP3 is 18kDa, respectively. 
 8 
 
The entire structure and the full range of functional interactions of this 
macromolecular complex are not yet completely understood; however, there is 
cumulating evidence to suggest that this complex may work as a molecular hub with 
a central role in coordinating protein biosynthesis, through its catalytic ARS 
domains, as well as by playing an important role in the regulation of diverse 
signalling pathways through its non-enzymatic, AIMP co-factors (Park SG et al, 
2010; Kim KJ et al, 2008).  These non-enzymatic pathways, which are separate from 
the canonical pathway of protein synthesis, have been investigated recently and have 
been implicated in human pathophysiology including cancer, infection, 
inflammation and metabolic abnormalities. 
 
1.2.2  Structural design of the multiprotein complex 
The currently accepted model of the architecture of the multiprotein complex 
consists of three domains (Figure 1.1A) (Norcum and Warrington, 1998).  In this 
model, domain 1 harbours MRS (Methionyl-tRNA synthetase), QRS (Glutaminyl-
tRNA synthetase) and DRS (Aspartyl-tRNA synthetase); domain 2 harbours KRS 
(Lysyl-tRNA synthetase) and RRS (Arginyl-tRNA synthetase); domain 3 harbours 
EPRS (Glutaminyl-prolyl-tRNA synthetase), IRS (Isoleucyl-tRNA synthetase) and 
LRS (Leucyl-tRNA synthetase).  Systematic depletion studies, by specific depletion 
of each component with its siRNA (small-interfering RNA), have demonstrated that 
the cellular stability of the components depend upon their interdependence (Han JM 
et al, 2006).  In this model, the three subdomains are thought to be linked by the 
three AIMPs.  In particular, AIMP2 appears to play a central role by acting as the 
scaffolding protein for the complex assembly and the components can be grouped 
into two subdomains based on their associations with AIMP2.  So, RRS, QRS, and 9 
 
AIMP1 form one subdomain by interacting with the N-terminal region of AIMP2; 
the C-terminal domain of AIMP2 links the remainder of the components (Kim J Y et 
al, 2002) (Figure 1.1B). 
 
Figure 1.1A 
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Figure 1.1B 
 
 
 
 
Figure 1.1:  Interaction network and molecular arrangement of ARSs and AIMPs in the 
multiprotein complex (taken from: Park S G et al, 2010).  
A: The interaction network between the components is indicated by arrows. The pairs of 
proteins whose stability are mutually dependent are marked by double-headed arrows (e.g. 
EPRS and IRS; IRS and LRS). If the stability of one component depends on the other 
partner, it is linked by single arrow dotted line (e.g. KRS and RRS; KRS and QRS). The 
three AIMPs are multiply linked to most of the enzyme components.   
B: The components of the multi-tRNA synthetase complex can be also grouped into two 
subdomains based on their affiliation to AIMP2. RRS (R), QRS (Q), and AIMP1 form one 
subdomain through the interactions with the N-domain (not shown in diagram) of AIMP2. 
The rest of the components of the complex MRS (M), IRS (I), DRS (D), KRS (K), EPRS 
(EP), and LRS (L) are clustered with the C-domain (not shown in diagram) of AIMP2. 
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1.2.3  The role of AIMPs in the structure and stability of the multiprotein complex 
Although the three AIMPs are relatively small in the context of the whole complex, 
they appear to be integral to the assembly and stability of the complex.  AIMP2 
appears to interact with the majority of the tRNA synthetase enzymes (Robinson JC 
et al, 2000; Kim JY et al, 2002).  Each AIMP appears to have their preferential 
enzymes but they also appear to interact with other enzymes less tightly (Quevillon 
S et al, 1999; Robinson JC et al, 2000; Quevillon and Mirande, 1996).  All three 
AIMPs appear to be tightly linked to each other and their cellular stabilities also 
appear to be interdependent (Han J M et al, 2006).  On electron microscopy, after 
specific immunogold antibody labeling, AIMP1 appears to be near the centre of the 
multiprotein complex (Norcum and Warrington, 2000).  In turn, AIMP1, along with 
RRS and QRS, interacts with the N terminus domain of AIMP2, which in turn 
interacts with the other tRNA synthetases via its C terminus domain (Kim J Y et al, 
2002). 
 
1.2.4  AIMP1/p43 
AIMP1 is the largest of the auxiliary, non-catalytic proteins, being 43kDa in size.  It 
has been reported to perform a number of diverse roles in both the intracellular and 
extracellular compartments (Lee SW et al, 2008).  In the cytosol, it is involved in 
protein synthesis through its interaction with RRS within the multiprotein complex 
(Park SG et al, 1999).  It is also found to locate in the endoplasmic reticulum (ER) 
and binds to gp96 (96 kDa glycoprotein) whilst suppressing autoimmune responses 
(Han JM et al, 2007).  Gp96-based immunotherapy is being evaluated in phase III 
clinical trials for many cancers (Wood CG et al, 2009).  AIMP1 also binds to 
Smurf2 in the nucleus whilst downregulating TGFβ (transforming growth factor β) 12 
 
signalling (Lee YS et al, 2008).  Regulation of TGFβ signalling plays an important 
role in the progression of many human cancers (Samanta D et al, 2012). 
 
AIMP1 is also involved extracellularly through its secretion as a cytokine (Lee SW 
et al, 2008).  It has diverse effects in different cells including immune response (Kim 
E et al, 2006), angiogenesis (Park SG et al, 2002) and wound healing (Park SG et al, 
2005).  Interestingly, on the basis of its involvement in immune response and 
angiogenesis, systemic injections of purified recombinant human AIMP1 were 
performed in mouse xenograft models which demonstrated significant anti-tumour 
activity (Lee YS et al, 2006).  Secreted AIMP1 has also been shown to act like a 
hormone, in a glucagon-like manner, through its pancreatic involvement in the 
regulation of glucose metabolism (Park SG et al, 2006).  In this study by Park SG et 
al, compared to wild-type mice, AIMP1-deficient mice were shown to have reduced 
plasma glucose levels, increased liver glycogen accumulation and reduced glucose 
tolerance. 
 
1.2.5  AIMP2/p38 
 
In addition to its intricate structural relationship with other components of the multi-
ARS complex, AIMP2/p38 appears to also have an important role in determining 
cell fate by behaving as a tumour suppressor gene.  It has been shown to mediate 
TGFβ signaling for c-myc downregulation by translocating into the nucleus and 
binding to FUSE (far upstream element)-binding protein (FBP) upon TGFβ 
stimulation (Kim M J et al, 2003).  FBP is the transcriptional activator of the proto-13 
 
oncogene c-myc (Avigan MI et al, 1990).  Therefore, there is transcriptional 
suppression of c-myc through AIMP2 activation of TGFβ.  
 
AIMP2 can also exert pro-apoptotic activity in response to DNA damage via 
interaction with p53 (Han J M et al, 2008).  DNA damage activates AIMP2 and 
causes it to translocate to the nucleus to bind to p53 and this binding is thought to 
prevent p53 from MDM2 (murine double minute 2)-mediated destruction.  MDM2 is 
a negative regulator of p53 as it mediates the degradation of p53 (Haupt Y et al, 
1997).  
 
AIMP2 also modulates cell fate via the TNFʱ signalling pathway (Ko HS et al, 
2005).  This interaction was demonstrated to occur through TRAF2 (tumour necrosis 
factor receptor associated factor 2) which is targeted for ubiquitylation by AIMP2 
(Choi JW et al, 2009).  TNFʱ signaling is pro-apoptotic and, therefore, 
downregulation of TRAF2 via AIMP2 promotes apoptosis.  In addition to these 
tumour suppressor roles of AIMP2 through regulation of cell proliferation and 
apoptotic pathways, knockdown studies in mice have demonstrated that AIMP2 
heterozygosity (AIMP2 +/-) predisposes to susceptibility to various tumours  (Choi J 
W et al, 2009). 
 
1.2.6  AIMP3/p18 
1.2.6.1  Introduction to AIMP3 
AIMP3/p18 is the smallest molecule in the multi-ARS complex.  It was shown to 
demonstrate sequence homology with β and γ subunits of elongation factor-1 (EF-1) 14 
 
over a decade ago (Quevillon and Mirande, 1996).  The implication of this was that 
AIMP3 had a potential role in linking the aminoacylation of tRNA and protein 
synthesis in the ribosome because EF-1 (elongation factor-1) is a multi-protein 
complex that is involved in elongating the amino acid sequence during protein 
synthesis.  EF-1 is comprised of ʱ, β, γ and δ subunits, which work together to 
ensure the delivery of aminoacyl-tRNAs to the ribosome, thereby elongating mRNA.  
Elongation is one of three critical sequences of steps occurring during protein 
synthesis; the sequence is: (i) initiation, conducted by eukaryotic initiation factor 
(eIF), (ii) elongation, conducted by eukaryotic elongation factor (eEF), and (iii) 
termination, conducted by eukaryotic release factor (eRF). AIMP3, through its role 
in elongation, is also referred to as EEF-1 ε1 (eukaryotic translation elongation 
factor 1 epsilon-1).  It is a 174 amino acid protein and shares sequence similarity 
with the amino-terminal ends of the β and γ subunits of EF-1 (Quevillon and 
Mirande, 1996). 
1.2.6.2  Overall structure of AIMP3 
The three-dimensional structure of human AIMP3 has been determined by X-ray 
crystallography (Kim KJ et al, 2008).  AIMP3 consists of seven ʱ-helices and three 
β-strands and is divided into two structural domains (Figure 1.2).  The 56 amino-
acid N-terminal domain (AIMP3-N) spanning residues from M1 to N56, contains 
two ʱ helices (ʱ1 and ʱ2) and three anti-parallel β strands.  The 111 amino-acid C-
terminal domain contains a bundle of five helices (T64-Y152) followed by coiled 
region (P153-L169). 
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Figure 1.2 A 
 
 
 
Figure 1.2 B 
 
Figure 1.2:  Structural characteristics of human AIMP3.  (taken from: Kim KJ et al, 2008) 
A  Ribbon diagrams of AIMP3 representing the N-terminal and C-terminal domains.  The 
N-terminal domain consists of a three-stranded anti-parallel β-sheets (β1, β2 and β3) and 
two ʱ helices (ʱ1 and ʱ2).   The C-terminal domain contains five ʱ helices (ʱ3 to ʱ7) with a 
long coiled structure at the C-terminus. Residues 84-88 are missing (residues D83 and N88 
are used as references in the diagram).  The left image is rotated by 180
o in the y-axis.  
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B  B-factor representation by colours.  The β-sheet at the N-terminal domain has higher B-
factor (orange colour) and helices ʱ5 and ʱ7 form a stable core (blue colour) at the C-
terminal domain.  Missing loop region connecting helices ʱ3 and ʱ4 are lined in grey colour.  
Three residues (K18, K21 and E27) with undefined side chains are shown as spheres.  [B-
factor is also known as the “temperature factor” or the “Debye-Waller” factor.  The higher 
the B factor, the less stable the configuration of the atoms in the crystal structure of the 
protein. This leads to more scatter of X rays (due to more dispersed electrons in the 
dispersed atoms) and a higher B factor value]. 
 
1.2.6.3  Important functional interactions of AIMP3 
GST (glutathione S transferase) homology domains are found in the N-terminal 
regions of two ARSs (MRS and EPRS) and two AIMPs (AIMP2 and AIMP3) (Lee 
SW, 2004).  The N-terminal appendix of MRS, which contains a GST homology 
domain, interacts with AIMP3; AIMP3 is required for the cellular stability of MRS 
but does not need MRS for its own stability (Han J M et al, 2006).  Since these GST 
domains are only detected in these complex-forming ARSs and AIMPs, and the N-
terminal appendix of VRS (valyl-tRNA synthetase) that also forms a complex with 
elongation factor, they are thought to be critical for the assembly of protein 
complexes (Negrutskii BS et al, 1999).  
 
Park BJ et al have produced several lines of evidence from animal models and 
cancer tissue material which strongly suggest a tumour suppressor role for AIMP3 
(Park BJ et al, 2005).  Park BJ et al investigated the effects of AIMP3/p18 knock-
down (p18 -/- and p18+/-) in mice.  Firstly, p18 null mice (p18 -/-) were unable to 
survive in utero indicating that AIMP3 plays a critical role in embryogenesis.  In the 
case of AIMP3 heterozygosity (p18 +/-), the mice were born alive with normal 
anatomical and morphological shape, but they showed higher susceptibility to 
spontaneous tumour development when compared to their wild-type (p18 +/+) 17 
 
littermates.  A broad range of common tumours (breast, lung, hepatocellular) were 
observed and the incidence of spontaneous tumour development was found to be 
significantly elevated as the mice got older (after 15 months).  It was suggested that 
this may have been due to the reduced activity of AIMP3, owing to reduced levels in 
the heterozygote state, leading to reduced function in the response against DNA 
damaging insults.  Indeed, generally reduced levels of AIMP3 were found in the 
tissues of most organs of these mice when compared to the corresponding tissues in 
the wild-type; however, the level of reduction was found to be variable between 
different tissues. 
 
Park BJ et al also demonstrated that AIMP3 regulates cell cycle and apoptosis 
indicating a tumour suppressor role for AIMP3 in vitro.  When comparing cell 
proliferation, by tritium-labelled thymidine incorporation, cell-counting and in situ 
fluorescence staining with Ki-67, in splenocytes and thymocytes from p18+/+ and 
p18+/- littermates, enhanced proliferation was observed in p18+/- cells compared to 
the wild type.  When cell cycle progression was measured by flow cytometry, p18+/- 
splenocytes showed a faster cell cycle progression than the wild-type.  When 
observing the expression of p18 during the different stages of the cell cycle, by 
firstly synchronizing the cells by serum starvation and then re-feeding the cells with 
cultured media, both Western analysis and FACS (fluorescence-activated cell 
sorting) demonstrated that p18 is significantly induced during the DNA synthesis 
phase (S phase). 
 
In addition, Park BJ et al also demonstrated that AIMP3 localises to the nucleus 
from a cytoplasmic location during S phase of the cell cycle.  Furthermore, AIMP3 18 
 
is also found to translocate to the nucleus in response to DNA damage and 
oncogenic stresses (Park BJ et al, 2005; Park BJ et al, 2006).  In the nucleus, AIMP3 
is shown to interact with ATM (ataxia telangiectasia mutated) and ATR (ATM-and-
RAD3-related), the upstream kinases of p53.  Thus, AIMP3 appears to work against 
DNA damage via p53 in cooperation with AIMP2, although its working mechanism 
is suggested to be distinct from AIMP2 (Han J M et al, 2008).  
 
AIMP3 (+/-) heterozygous cells are more susceptible to cell transformation induced 
by oncogenic stimulation such as Ras or Myc when compared with AIMP3 wild-
type cells.  These transformed AIMP3 +/- cells demonstrate abnormalities in cell 
division and nuclear structure and instability in their chromosomal structure (Park B 
J et al, 2006).  These findings lend further support to the notion that AIMP3 is a 
tumour suppressor whose absence or reduction can make cells more susceptible to 
oncogenic transformation.  As with AIMP2, AIMP3 is regarded as a haplo-
insufficient tumour suppressor.  Both are harboured within the multi-ARS 
translational machinery to perform their roles in the canonical enzymatic pathway 
but are also involved in the regulation of cell fate by acting as tumour suppressors. 
 
1.3  DNA damage response (DDR) pathway 
1.3.1  Introduction to the DDR pathway 
DNA damage can occur with varying severity and the most deleterious form of 
DNA damage is when double strand breaks (DSBs) occur.  DSBs can occur by 
exposure to extracellular agents (e.g., ionising radiation, reactive chemicals such as 
chemotherapeutic agents) or due to intracellular by-products of metabolism (e.g., 
reactive oxygen species) (Michel B et al, 1997; Sun H et al, 1989; Ward JF et al, 19 
 
1988).  DSBs, if left unrepaired, can lead to either cell death or cell survival with 
mutations leading ultimately to cancer (Khanna and Jackson, 2001).  Therefore, 
when DSBs occur, there needs to be a mechanism in place, within the cell 
machinery, to detect these and enable DNA damage repair whilst coordinating the 
repair process with cell-cycle progression.  To enable this mechanism, the cell cycle 
is slowed to allow damage repair to occur.  This ensures that an accurate copy of the 
genome is passed on to the next generation of cells when DNA damage is repairable 
and, when not repairable, by triggering apoptosis, inaccurate copies are not 
transmitted to the offspring (Su TT et al, 2006).  The DDR pathway is the sequence 
of events within the cell that takes place to ensure this.  Therefore, this DDR 
machinery is highly conserved in eukaryotes.  Defective DDR machinery can lead to 
DNA damage sensitivity and genomic instability with consequent increase in 
mutations that, in turn, increases cancer susceptibility in humans.  This is observed 
in people with genetic instability conditions, such as Lynch or Li-Fraumeni 
syndromes, which are caused by defective DDR genes and which result in a 
significantly increased cancer incidence (Srivastava S et al, 1990; Malkin D et al, 
1990; Lynch and de la Chapelle, 1999). 
 
The DDR pathway involves a multitude of serine/threonine phosphorylation events 
which encompass three major groups of proteins: (1) sensors, which detect DNA 
damage directly or indirectly, (2) transducers, which involve proximal and distal 
kinases that relay and amplify the damage signal, and (3) effector proteins, that 
control cell cycle progression, chromatin restructuring, DNA repair and apoptosis 
(Kurz and Lees-Miller, 2004).  The main mechanisms of repair of DSBs include 
homologous recombination (HR) of sister chromatids, microhomology-mediated 20 
 
endjoining (MMEJ) or non-homologous end-joining (NHEJ) of the broken ends of 
the DNA strands (Khanna and Jackson, 2001; van Gent DC et al, 2001; Lieber M, 
2010).  NHEJ, which repairs DNA breaks without using a template, is the 
predominant, but error-prone, repair mechanism throughout the cell cycle and is 
particularly important during the G1 phase of the cell cycle (Rothkamm  K et al, 
2003; Chen BP et al, 2005).  HR is a more accurate repair mechanism and is mainly 
involved in repairing stalled replication forks but can also repair DSBs during the S 
and G2 phases when an undamaged sister chromatid is available to act as a template 
for repair (Arnaudeau C et al, 2001; Beucher A et al, 2009).  Whereas NHEJ, also 
referred to as “classical end joining”, requires the presence of proteins such as DNA-
PK, Ku70-Ku80, and DNA ligase IV-XRCC4 heterodimers, MMEJ is also referred 
to as the “alternative end joining” mechanism because it is independent of the DNA-
PK pathway and characteristically utilizes microhomologous sequences of 
approximately 5-25 nucleotides as templates for repair (reviewed in: McVey and 
Lee, 2008). 
 
The major sensor of DNA damage is believed to be the Mre11/Rad50/Nbs1 (MRN) 
complex as it is located early at sites of DSBs and has been shown to be required for 
the ataxia telangiectasia mutated (ATM) signaling pathway and is placed upstream 
of ATM (Stracker et al, 2002; Berkovich et al, 2007, Shirata et al, 2005).  In 
addition to its role as a sensor of DNA damage, MRN is also implicated in triggering 
downstream signal transduction and coordinating the repair process. 
 
The major proximal kinases include (ATM) and ATM-and-RAD3-related (ATR).  
ATM and ATR belong to the phosphoinositide 3-kinase (PI3K)-related protein 21 
 
kinases (PIKKs) family, which also includes DNAPKcs (DNA dependent protein 
kinase catalytic subunit), mTOR (mammalian target of rapamycin), and hSMG1 
(human suppressor of morphogenesis in genitalia-1) (reviewed in:  Lovejoy and 
Cortez, 2009).  DNAPK is closely involved in NHEJ repair of DSBs (Smith and 
Jackson, 1999).  If cells lack DNAPK, they are more sensitive to DNA damage by 
ionising radiation and chemotherapeutic agents (Jeggo PA, 1998).  Conversely, 
increased DNA damage resistance can result in cancers through overactivation of 
DNAPK (Muller C et al, 1998).  mTOR plays a central role in the signaling pathway 
that regulates cell growth and proliferation (Wullschlegger S, 2006).  Inappropriate 
amplification of the mTOR signalling pathway is implicated in a variety of cancers 
(Shaw and Cantley, 2006).  hSMG1 is involved in the surveillance of DNA integrity 
and, in particular, it is critical in the nonsense-mediated mRNA decay (NMD) 
pathway which degrades premature termination codon (PTC)-containing transcripts 
(Yamashita A et al, 2001; Brumbaugh KM et al, 2004).  PIKK family members have 
similar structural domains (Figure 1.3) and get activated by associating with protein 
complexes (Lovejoy and Cortez, 2009).   
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Figure 1.3:  PIKK family members.  The PIKK family members have a C-terminal protein 
kinase domain flanked on either side by an N-terminal FAT (FRAP, ATM, TRRAP) domain 
and FAT-C (C-terminal of FAT) domain.  The N-termini are largely composed of HEAT 
(huntingtin, elongation factor 3, A subunit of protein phosphatase 2A and TOR1) repeats. 
(taken from: Derheimer and Kastan, 2010). 
 
According to one of the currently accepted models of ATM and ATR activation, 
ATM is activated directly by DSBs and relays/amplifies the damage signal by 
phosphorylating checkpoint protein kinase 2 (Chk2 kinase) and many other DDR 
proteins (Shiloh Y, 2006).  In contrast, ATR responds primarily to stalled replication 
forks on single-stranded DNA (ssDNA) during S phase and relays/amplifies the 
signal by phosphorylating Chk1 kinase and a large subset of ATM substrates 
(Cimprich and Cortez, 2008).  However, there are many similarities between ATM 
and ATR including a functional overlap in the downstream proteins which are 
phosphorylated to effect cell cycle arrest and DNA repair.   
 
Whereas Chk2 and Chk1 are distal kinases, which relay the signal of proximal 
kinases such as ATM and ATR to cause cell-cycle arrest and allow DNA repair, 
other effectors such as p53 and structural maintenance of chromosomes 1 (SMC1) 
enforce cell cycle arrest directly.  Others such as p53 binding protein 1 (53BP1) 
affect the cell cycle by amplifying the damage signal.  Furthermore, there are 
proteins, such as histone H2AX and KAP-1 (KRAB (Kruppel associated box 
domain)-associated-protein-1)), which are thought to facilitate DNA repair, in 
response to DNA breaks, by inducing chromatin changes that allow repair proteins 
access to sites of damage (Ziv et al, 2006; Pandita and Richardson, 2009). 
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1.3.2  Mre11/Rad50/Nbs1 (MRN) complex 
The MRN complex can be considered as a heterohexameric hub made up of a 
“head”, “coils”, a “hook” and a “flexible adapter” unit comprising of Mre11, Rad50 
and Nbs1 proteins (Figure 1.4) (reviewed in: Williams GJ, et al  2010). 
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Figure 1.4:  Overall MRN assembly and key domains. (A) MRN can assemble as a 
heterohexamer and consists of 4 key regions: the processing “head”, formed by the Mre11 
dimer and two Rad50 ABC ATPase domains (indicated by dotted line), the “coils” and 
“hook” encoded by the region of Rad50 separating the N- and C-terminal ABC ATPase 
halves, and the Nbs1 “flexible adapter” (indicated by dotted line) that provides the key link 
to signaling functions.  (B) Schematic representations of the MRN subunits Mre11, Rad50 
and Nbs1 showing key domains, coloured as in other figures.  The approximate locations of 
reported methylation sites are indicated by M and DNA damage inducible phosphorylation 
sites by P (see text for details).  The major sites corresponding to inherited human disorders 
associated with each gene are indicated by a red triangle, with amino acid substitutions 
labelled for Mre11 and Rad50 (X is a stop codon) and 657del5 representing the major Nbs1 
mutation responsible for >90% of NBS cases. (taken from: Williams GJ et al, 2010) 
 
The “head” region consists of a DNA-binding Rad50-Mre11 complex formed from 
two Rad50 units combined with two Mre11units (Figure 1.4A).  Mre11 can bind 
DNA and has ssDNA endonuclease and 3’-5’ dsDNA exonuclease activities 
(Hopfner et al, 2001).  Rad50 can also bind DNA and has adenylate kinase and 
ATPase activities (Bhaskara V et al, 2007; Paull TT et al, 1999).  The Rad50-Mre11 
complex is evolutionarily highly conserved which indicates its importance (de Jager 
M et al, 2004). 
 
The “coil” region is a long, anti-parallel coil, formed by the coding of the 
intervening region between the ATPase domains of Rad50 (Figure 1.4).  The coil 
extends from the Rad50-Mre11 complex to form the Zinc “hook” region (Figure 
1.4).  Nbs1 forms the “flexible adaptor” region of the MRN complex and has several 
important roles including the nuclear localisation of the MRN complex in response 
to DNA damage and activation of ATM and ATR in response to DSBs and 
replication fork stalling, respectively. 25 
 
 
Mre11, in its functional state when bound to DNA, is dimeric in structure (Williams 
RS et al, 2008).  Rad50 has a unique architecture with a long anti-parallel coil 
separating an ATPase domain at one end and a Zn-hook domain at another (Figure 
1.4).  The MRN head contains the Mre11 dimer combined with two Rad50 ATPase 
domains and undergoes conformational changes depending upon the status of 
binding or hydrolysis of ATP (Hopfner KP et al, 2000).  Mutations that disrupt 
Rad50 ATPase activity can render cells sensitive to DSB causing agents (Chen L et 
al, 2005).  Nbs1 consists of an FHA (fork head associated) domain and a tandem 
repeat BRCT ((Breast carcinoma associated protein 1 (BRCA1) C-terminal)) domain 
(Figure 1.4); these domains on Nbs1 can interact with the Mre11-Rad50 complex 
through a host of other proteins such as CtIP (C terminal binding protein interacting 
protein), MDC1 (mediator of DNA damage checkpoint protein 1), and ATR 
(reviewed in: Williams GJ et al, 2010).  CtIP is important in homologous 
recombination (HR) repair by initiating end resection of DSBs in S and G2 phases 
(Sartori AA et al, 2007).  CtIP has also been shown to promote MMEJ repair in G1 
phase (Yun and Hiom, 2009).  CtIP, along with a host of proteins such as MDC1 and 
53BP1 (p53 binding protein 1), are among the earliest proteins found to assemble at 
foci of DNA damage (reviewed in: van den Bosch et al, 2003). 
 
The importance of the MRN complex is underscored by the fact that it is 
evolutionarily highly conserved and human disorders arise if there is misregulation 
or inherited mutation in any of the components.  Nijmegen breakage syndrome 
(NBS) occurs in patients with mutations in Nbs1 (Carney JP et al, 1998).  Mutations 26 
 
in Mre11 cause ataxia-telangiectasia-like disorder (ATLD) (Stewart GS et al, 1999) 
and NBS-like disorder results from a mutation in Rad50 (Waltes R et al, 2009). 
 
1.3.3  ATM 
Ataxia–telangiectasia (A–T) is a rare, autosomal-recessive, inherited disorder which 
occurs due to mutations in the ATM (A-T mutated) gene (Savitsky K et al, 1995).  
ATM patients show features including neural degeneration in the cerebellum, 
immunodeficiency, growth retardation, premature aging, cancer predisposition, and 
severe sensitivity to ionizing radiation (Shiloh Y, 2003).  ATM-deficient mice 
display many of these phenotypes (Xu and Baltimore, 1996; Xu Y et al, 1996).  
Cells taken from A-T patients exhibit defects in checkpoint activation in the DDR 
pathway, radiation hypersensitivity and an increased frequency of chromosome 
breakage (Shiloh Y, 1997; Petrini JH, 2000). 
 
In common with other members of the PIKK family such as DNAPKcs, mTOR, 
hSMG1 and ATR, the ATM protein is a serine/threonine protein kinase.  ATM 
exists as an inactive dimer under normal conditions but undergoes monomerisation 
when activated by autophosphorylation on Ser1981 following DNA damage 
(Bakkenist and Kastan, 2003).  When DNA damage is detected by the MRN 
complex, MRN interacts directly with ATM and stimulates an increase in the kinase 
activity of the substrates of monomeric ATM such as p53 and Chk2 (Lee and Paull, 
2005).  The requirement of ATM for the efficient induction of p53 following 
irradiation had been demonstrated previously (Kastan MB et al, 1992).  One of the 
important roles of p53 is to effect a G1 to S phase entry checkpoint in cells exposed 27 
 
to irradiation (Kastan MB et al, 1991).  P53 induces p21, a cyclin dependent kinase 
(CDK), which inhibits Cyclin-E/CDK2 resulting in cell cycle arrest between G1 and 
S phase.  Thus, ATM plays a critical role in cell cycle progression through its 
activation of p53. 
 
However, one of the characteristic features of cells lacking ATM is that they 
demonstrate “radioresistant DNA synthesis (RDS)” by undergoing reduced 
inhibition of DNA synthesis during S phase following ionising radiation (Painter and 
Young, 1980).  As p53 is involved in the G1/S checkpoint, and not in an intra-S 
arrest, other effectors have been implicated amongst which is the Nbs1 protein, part 
of the MRN complex (Lim DS et al, 2000).   BRCA1 is also implicated in effecting 
an intra-S arrest in response to irradiation through phosphorylation at serine 1387 by 
ATM (Xu B et al, 2002).  Furthermore, phosphorylation of BRCA1 at serine 1423 
by ATM was demonstrated to cause G2/M arrest following irradiation (Xu B et al, 
2001).   
 
In addition to a role in cell cycle progression, ATM also appears to be important for 
DNA damage repair.  The histone variant H2AX is phosphorylated to γH2AX in 
response to irradiation and is present at foci surrounding DSBs (Rogakou EP et al, 
1998).  The subsequent disappearance of γH2AX from these sites is an indirect 
indicator of DNA damage repair (Lobrich M et al, 2010).  In the absence of ATM, 
γH2AX is persistent at foci of DSBs following irradiation suggesting that ATM has 
an important role in the repair process itself (Riballo E et al, 2004).  Furthermore, it 
has been demonstrated that, following irradiation, ATM can contribute to the 28 
 
phosphorylation of H2AX to γH2AX (Burma S et al, 2001).  γH2AX then binds 
MDC1, which contains BRCT domains, which in turn gets phosphorylated by ATM 
(Lukas C et al, 2004).  It is thought that this binding and activation of γH2AX and 
MDC1 by ATM along with components of the MRN complex creates a multi-
molecular docking complex for other components of the DDR pathway to localise at 
sites of DSBs (Figure 1.5).  For instance, RING-finger ubiquitin ligases, RNF8 and 
RNF168, are recruited into the complex by the phosphorylation of MDC1 and, in 
turn, RNF8 phosphorylates γH2AX and helps to recruit 53BP1 and BRCA1 
(Mailand N et al, 2007; Doil C et al, 2009).  RNF168 helps to maintain γH2AX in 
the ubiquitinated state thereby stabilising 53BP1 and BRCA1 in the complex. ATM 
phosphorylates both 53BP1 and BRCA1 (Lavin MF, 2008).  Thus ATM plays a 
central role in the DDR pathway by influencing cell cycle progression and DNA 
repair mechanisms. 
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Figure 1.5:  Recruitment of DNA damage response proteins to a DNA double-strand 
break.  Prior to DNA damage ATM exists as an inactive dimer.  Following the induction of 
a DNA double-strand break, ATM undergoes auto-phosphorylation producing active ATM 
monomers.  ATM and MRN are rapidly recruited to the site of the DNA double-strand 
break. Upon recruitment, ATM phosphorylates MRE11, NBS1, and H2AX. The 
phosphorylation of H2AX leads to the recruitment of MDC1.  MDC1 is phosphorylated by 
ATM and phosphorylated MDC1 serves as a docking site recruiting the RING-finger 
ubiquitin ligase RNF8.  RNF8 mono-ubiquitinates cH2AX resulting in the recruitment of 
53BP1, BRCA1, and RNF168.  The RING-finger ubiquitin ligase RNF168 maintains the 
ubiquitinated status of cH2AX, aiding in the stabilization 53BP1 and BRCA1 at the break 
site. (taken from: Derheimer and Kastan, 2010) 
 30 
 
1.3.4  ATR 
ATR is so named because of its sequence homology with ATM and Rad3 (A-T and 
Rad 3-related) and, due to this homology, has many overlapping functions with 
ATM.  ATR phosphorylates Chk1 preferentially whilst ATM phosphorylates Chk2 
but there is some crosstalk in the network (Kastan and Bartek, 2004).  The functional 
differences of ATM and ATR have been demonstrated by studies of ATM and ATR 
null mice.  ATM null mice are viable and demonstrate infertility and growth 
retardation (Barlow C et al, 1996; Elson A et al, 1996).  In contrast, knock-out of 
ATR results in early embryonic lethality and the mice demonstrate a phenotype 
which resembles “mitotic catastrophe” (Brown EJ, 2000; de Klein A, 2000).  ATR 
may be essential for life due to its additional role in monitoring DNA replication in 
mitosis during cell division (Kimprich and Cortez, 2008).  In humans, mutations in 
ATR predispose to Seckel’s syndrome which is characterized by dwarfism, 
microcephaly and mental retardation (O’Driscoll M et al, 2003).  Although 
increased incidence of tumours have not been demonstrated in humans due to lack of 
ATR, haploinsufficiency of ATR in mice has been demonstrated to cause enhanced 
tumorigenesis (Elson A, 1996; Kastan and Bartek, 2004). 
 
Although a variety of DDR signals including DSBs can stimulate ATR activation, it 
is thought that single-stranded DNA (ssDNA), formed during DNA replication and 
DNA repair, is the major activator of ATR (Zou and Elledge, 2003).  Replication 
protein A (RPA) coats ssDNA arising from DNA damage and localizes ATR to 
those sites by interacting with ATRIP (ATR interacting protein) (Cotez D et al, 
2001; Ball HL et al, 2007).  Although RPA-coated ssDNA is essential for localizing 
the ATR-ATRIP complex to DNA damage sites, the activation of ATR is dependent 31 
 
upon the co-localization of Rad9-Rad1-Hus1 (9-1-1) complex, a ring-shaped 
heterotrimeric molecule that recognizes DNA ends adjacent to RPA-coated ssDNA 
(Parrilla-Castellar ER et al, 2004; Kanoh Y et al, 2006).  9-1-1 recruits TOPBP1, 
which contains BRCT domains, and which strongly activates ATR (Kumagai A, 
2006; Lee J et al, 2007).  However, the mechanism of activation of ATR is not as 
well defined as the activation of ATM.  Indeed, although RPA-ssDNA mediated 
interaction with ATR-ATRIP and 9-1-1, is believed to be the main activation 
pathway of ATR, other RPA-independent pathways have been described, including 
that involving AIMP3 (Park BJ et al, 2005; Roche KC et al, 2007; Sivasubramaniam 
S et al, 2008). 
 
As with ATM, ATR is also involved in cell cycle regulation (mainly through 
activation of Chk1 – described below) and DNA repair at sites of stalled replication 
forks.  ATR has been shown to phosphorylate a number of proteins involved in 
DNA repair including BRCA1, WRN (Werner), FANCD2 (Fanconi Anaemia 
Complementation Group D2) and XPA (Xeroderma pigmentosum A) (Tibbetts RS 
et al, 2000; Pichierrie P et al, 2003; Andreassen PR et al, 2004; Wu X et al, 2007).  
WRN phosphorylation, either by ATM or ATR leads to its activation at sites of 
replication blocks during the S phase of the cell cycle.  FANCD2 phosphorylation by 
ATR leads to its monoubiquitination and localization to DNA damage foci.  XPA is 
a nucleotide excision repair protein, and its phosphorylation by ATR is important for 
its intracellular localization, which indicates that ATR is involved in other types of 
DNA damage in addition to ssDNA exposed at replication forks. 
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1.3.5  ATM and ATR 
The relationship between ATM and ATR in the DDR pathway is not a simple, 
mutually exclusive one.  There is considerable interdependence and crosstalk 
between the pathways at multiple levels.  At the upstream level, although ATM 
responds primarily to DSBs and ATR to ssDNA at replication forks, they have both 
been demonstrated to respond to a variety of DNA damages.  ATR can also respond 
to DSBs after the induction of ATM as the ATM-mediated process requires DSB 
end-resection which reveals ssDNA (Jazayeri A et al, 2006; Myers and Cortez, 
2006).  For instance, ATM and ATR are both activated in response to ionizing 
radiation.  However, ATM is activated quickly and throughout the cell cycle 
whereas ATR is slower and occurs predominantly at the G2/M checkpoint. 
 
Whereas ATR can also be activated by DSBs, there is some evidence that ATM can 
also be activated at stalled replication forks but it is unclear whether this signalling 
occurs specifically due to ssDNA in the absence of the generation of DSBs at 
replication forks (Brown and Baltimore, 2003).  It can be difficult to establish 
causality with certainty because one type of DNA damage can be converted to 
another during the process of repair.  For instance, ssDNA can be converted to DSBs 
by the action of nucleases downstream of ATM and ATR, there is crosstalk at 
multiple levels.  One early interaction is at the level of TOPBP1, which is 
phosphorylated by ATM, and phosphorylated TOPBP1, in turn, results in the 
phosphorylation of ATR (Yoo HY et al, 2007).  Further downstream, many proteins 
such as BRCA1 and p53 are phosphorylated by both ATM and ATR (Cortez D et al, 
1999; Tibbetts RS et al, 1999).  However, there appears to be some substrate 
specificity in that ATM targets Chk2 and ATR targets Chk1. 33 
 
1.3.6  ATM and Chk2 
ATM, once induced by DSBs, phosphorylates Chk2 at threonine 68 (T68) (Ahn JY 
et al, 2000).  Following activation, Chk2 undergoes homo-dimerisation to become 
more activated.  Activated Chk2 subsequently phosphorylates CDC25 phosphatases 
(Figure 1.6) (Blasina A et al, 1999; Falk J et al, 2001).  CDC25 phosphatases 
regulate cell cycle transitions by removing inhibitory phosphorylations on cyclin 
dependent kinases (CDKs); therefore, their inhibition by phosphorylation by Chk2 
ultimately results in slowing of the cell cycle.  Chk2 has also been suggested to 
cause p53-mediated cell cycle arrest because activated Chk2 has been shown to 
phosphorylate p53 (Shieh SY et al, 2000).  Furthermore, Chk2 has been implicated 
in inducing apoptosis in a p53-independent manner by phosphorylation of 
transcription factor E2F-1 (Yang S et al, 2002). 
 
1.3.7  ATR and Chk1 
ATR activates Chk1 by phosphorylating it at serine 317 (S317) and S345 (Liu Q et 
al, 2000; Lopez-Girona A et al, 2001).  ATR and Chk1 are brought into proximity at 
sites of replication fork arrest by Claspin, a “mediator” protein which is found at 
replication forks (Kumagai and Dunphy, 2000).  Once phosphorylated, however, 
Chk1 is liberated from chromatin to inhibit CDC25 phosphatases (Figure 1.6) 
(Smits VA et al, 2006; Sanchez Y et al, 1997).  Thus, ATR-dependent Chk1 
activation leads to an overall reduction in cell cycle progression through activation 
of the CDC25 phosphatase-CDK pathway. 
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Figure 1.6:  The G1/S and G2/M checkpoint regulation network following upstream 
ATM/ATR activation.  Detection of DNA damage results in the activation of ATM/ATR 
followed by activation of Chk2/Chk1.  Cell cycle regulatory proteins (for example, Cyclins, 
CDKs and CDC25 phosphatases) are then activated/deactivated to influence progression 
through the G1/S and G2/M cell cycle checkpoints (taken from: Poehlmann and Roessner, 
2010). 
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1.3.8  DNA damage repair of cisplatin lesions 
Cisplatin (cis-diamminedichloroplatinum, CDDP) is a platinum compound that was 
accidentally discovered to inhibit the growth of Escherichia coli and was 
subsequently found to kill tumor cells as well (Rosenberg B, 1973).  It is commonly 
used as an anti-tumour agent to treat a variety of malignancies including bladder 
cancer.  It is one of the most potent anti-tumour agents available on account of its 
ability to induce DNA damage via the formation of intra-strand and inter-strand 
cross-links (ICLs) which result in the blockage of cellular processes such as 
replication and transcription, particularly in highly replicating cells such as tumour 
cells (Siddik ZH, 2003; Wang and Lippard, 2005; Kelland L, 2007).  Due to its 
mechanism of forming DNA-adducts, it is commonly classified as an alkylating 
agent; however, it does not possess an alkyl-group and is more accurately referred to 
as “alkylating-like” anti-tumour agent.  Cisplatin’s mechanism is believed to be cell 
cycle-independent; however, in some cases, a prolongation of the G2 phase cell-
cycle arrest may occur (Roberts and Pascoe, 1972; Siddik ZH, 2003; Kelland L, 
2007).   
 
Cisplatin induces toxicity in a concentration-dependent manner and cell death is 
caused by both necrosis and apoptosis mechanisms (Gonzalez et al, 2001; Nguewa, 
et al, 2003).  Necrosis is reported to involve the hyper-activation of Poly (ADP 
ribose) polymerase (PARP) (Nguewa PA et al, 2003).  Apoptosis is reported to 
occur as a result of activation of caspases (Gonzalez VM et al, 2001). 
 
Repair of cisplatin-induced DNA lesions occurs via different mechanisms in the 
DDR pathway.  It is established that intra-strand adducts are excised and repaired by 36 
 
the nucleotide excision repair (NER) pathway using the other DNA strand as a 
template (Jalal S et al, 2011).  Inter-strand cross-links (ICLs) represent a major 
challenge for repair as both strands are damaged and other repair enzymes are 
required.  Two major pathways are involved in ICL repair.  One involves 
homologous recombination (HR) which is cell cycle dependent and the other is 
cycle-independent and occurs via DNA polymerases (Jalal S et al, 2011).  DDR 
mediators such as DNA-PK, ATM and ATR have been implicated in the process of 
cisplatin-adduct repair (Liu S et al, 2012; 66. Cruet-Hennequart S et al, 2008).  Chk1 
and Chk2 phosphorylation are also thought to occur directly or indirectly as a result 
of cisplatin-induced DNA damage (Colton SL et al, 2006).   ATR is responsible for 
Chk1 activation (Figure 1.6) and ATR has been implicated in cell cycle arrest and 
apoptosis in cisplatin-induced DNA damage response (Lewis KA et al, 2009).   This 
DDR pathway via ATR, in cisplatin-induced damage repair, has also been reported 
to be p53-dependent (Sangster-Guity N et al, 2011).  However, where p53 status is 
concerned, there are conflicting reports of cisplatin sensitivity (da Silva GN et al, 
2010).   
 
1.3.9  ERCC1  
DNA damage caused by genotoxic agents, such as Cisplatin or radiation, requires 
the interplay of a complex group of DDR factors for repair.  Amongst the many 
factors involved, excision repair cross-complementation group protein -1 (ERCC1) 
is considered to play an important role, particularly in the NER pathway (Parker RJ 
et al, 1991).  The interplay of ERCC1 with xeroderma pigmentosum (XPF) protein, 
via hetero-dimerisation into the ERCC1-XPF complex, is thought to play a key role 
in excising and repairing bulky DNA-adducts (Li L et al, 1994; Bessho T et al, 37 
 
1995; Choi YJ et al, 2005; Tripsianes K et al, 2005; Tsodikov OV et al, 2005).  In 
addition to the NER pathway, ERCC1-XPF is also thought to be important in the 
repair of inter-strand crosslinks (ICLs) and DNA double-strand breaks (DSBs) 
commonly induced by ionising irradiation (Kuraoka I et al, 2000; Niedernhofer LJ et 
al, 2004).   
 
Expression of ERCC1 in tumours has been correlated to survival outcome due to the 
altered sensitivity to cisplatin mediated DNA damage (Shirota Y et al, 2001).  
Polymorphisms in ERCC1 have been demonstrated to alter ERCC1 expression and 
affect cisplatin sensitivity (Chen P et al, 2000; Zhou W et al, 2004).  In the clinical 
setting of cisplatin treatment, survival has been correlated to ERCC1 expression 
status in a variety of cancers including testis, lung, gastric, head and neck, and 
melanoma (Olaussen K et al, 2005; Simon GR et al, 2005; Jun HJ et al, 2008; Kim 
MK et al, 2008; Matsubara J et al, 2008; Usanova S et al, 2010; Song L et al, 2011).  
In bladder cancer, ERCC1 expression status has been correlated with survival 
outcome following cisplatin treatment in a number of studies (Bellmunt J et al, 
2007; Hoffmann AC et al, 2010; Kim KH et al, 2010; Kawashima A et al, 2011; 
Sun JM et al, 2012; Ozcan MF et al, 2013; Sakano S et al, 2013).  However, a few 
studies have not found a significant correlation between ERCC1 expression and 
survival in cisplatin treated bladder cancer (Matsumura M et al, 2011; Choueiri TK 
et al, 2014; Shilkrut M et al, 2014).   
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1.4  The role of radiation in the treatment of bladder cancer 
1.4.1  Introduction to bladder cancer: epidemiology, pathological staging and treatment 
options for muscle-invasive disease 
In the UK, bladder cancer is the second most common urological malignancy after 
prostate cancer, with approximately 12,000 new cases annually and accounts for 
around 5,000 deaths annually (CRUK cancer statistics).  Treatment depends upon 
the grade and stage of the disease.  Table 1.1 outlines the 2002 Tumour, Nodes, 
Metastases (TNM) classification approved by the Union for International Cancer 
Control (UICC) (Sobin DH et al, 2002). 
 
Table 1.1:  2002 TNM classification of urinary bladder cancer 
T  Primary tumour 
Tx  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
Ta  Non-invasive papillary carcinoma 
Tis  Carcinoma in situ: ‘flat tumour’ 
T1  Tumour invades subepithelial connective tissue 
T2  Tumour invades muscle: 
T2a  Tumour invades superficial muscle (inner half) 
T2b  Tumour invades deep muscle (outer half) 
T3  Tumour invades perivesical tissue: 
T3a  Microscopically 
T3b  Macroscopically (extravesical mass) 
T4  Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, 
abdominal wall 
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Grading of tumours is based on a classification (Table 1.2) proposed by the World 
Health Organization (WHO) and the International Society of Urological Pathology 
(ISUP) (1998 WHO/ISUP classification) and published by the WHO in 2004 (Sauter 
G et al, 2004).  The 2004 WHO classification was an update from the 1973 WHO 
classification.  The majority of trials reported in the literature are based on the 1973 
version and the 1973 version is still widely used internationally. 
 
 
 
T4a  Tumour invades prostate, uterus or vagina 
T4b  Tumour invades pelvic wall or abdominal wall 
   
N  Lymph nodes 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis in a single lymph node 2 cm or less in greatest dimension 
N2  Metastasis in a single lymph node more than 2 cm but not more than 5 cm in 
greatest dimension, or multiple lymph nodes, none more than 5 cm in 
greatest dimension 
N3  Metastasis in a lymph node more than 5 cm in greatest dimension 
   
M  Distant metastasis 
MX  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 40 
 
Table 1.2:  WHO grading of bladder cancer in 1973 and 2004 
1973 WHO grading 
Urothelial papilloma 
Grade 1: well differentiated 
Grade 2: moderately differentiated 
Grade 3: poorly differentiated 
 
2004 WHO grading 
Flat lesions 
Hyperplasia (flat lesions without atypia or papillary aspects) 
Reactive atypia (flat lesion with atypia) 
Atypia of unknown significance 
Urothelial dysplasia 
Urothelial CIS 
Papillary lesions 
Urothelial papilloma (completely benign lesion) 
Papillary urothelial neoplasm of low malignant potential (PUNLMP) 
Low-grade papillary urothelial carcinoma 
High-grade papillary urothelial carcinoma 
 
 
The mainstay of treatment of non-muscle invasive (<T2) disease is by trans-urethral 
resection of the bladder tumour (TURBT) with or without adjuvant treatment 
depending upon the risk profile of the disease.  For instance, non-muscle invasive 
bladder cancer (NMIBC) with a “high risk” profile such as high-grade (G3), 
multiple foci of tumours or recurrence of tumours may receive adjuvant treatment 
(e.g. with intravesical BCG) following TURBT.  On the other hand, NMIBC with a 
“low risk” profile such as a new tumour which is solitary, small (<1cm diameter) 
and is histologically low-grade (G1), TURBT alone may suffice but one dose of 41 
 
intravesical mitomycin instillation immediately following TURBT is usually 
recommended.  For muscle-invasive bladder cancer (MIBC) which is “organ-
confined” (T2-4a without nodal involvement or metastasis), radical cystectomy (RC) 
is currently accepted as the “gold standard” modality for treatment.  RC involves 
removal of the bladder along with adjacent organs, i.e. prostate and seminal vesicles 
in men, and uterus and adnexa in females.  However, such radical treatment, 
delivered with a curative intent, still imparts only around 50% survival at 5 years 
post-cystectomy (Bassi P et al, 1999; Dalbagni G et al, 2001; Ghoneim MA et al, 
1997; Stein JP et al, 2001; Stein and Skinner, 2006).  Furthermore, the peri-
operative mortality is around 3%; early complications (within 3 months of 
cystectomy) occur in around 25%; and there are notable late complications 
depending upon the type of urinary diversion such as stomal complications in those 
with ileal conduits and anastomotic strictures in those with continent orthotopic 
neobladder urinary diversions.  In addition, radical surgery can have an adverse 
impact on the psycho-social status of patients due to urinary incontinence and 
erectile dysfunction, body image dissatisfaction and difficulties with activities of 
daily living (Zietman AL et al, 2003; Shipley WU et al, 2003; Zietman AL et al, 
2001). 
 
1.4.2  Radical radiotherapy and radio-chemotherapy as organ-preserving options 
In view of the issues discussed above, there is an ongoing effort to develop means of 
improving the treatment modality of muscle-invasive, organ-confined disease such 
that survival is improved and the morbidity reduced.  In this regard, rather than 
radical surgery, radiation exposure has been explored in the last few decades as an 
alternative, radical treatment modality for bladder cancer.  However, there are no 42 
 
randomised, controlled trials (RCT) which compare RC with radiotherapy (RT).  
One recent attempt to examine this issue, in a RCT setting, was the SPARE 
(selective bladder preservation against radical excision) trial, which closed 
prematurely due to poor accrual of patients (Huddart RA et al, 2010).  However, 
there is a recent Cochrane review of published clinical series which suggested that 
RT alone, as a mono-therapy, confers less survival benefit compared to RC (Shelley 
MD et al, 2002).  Therefore, RC remains the “gold standard” option under normal 
circumstances (Stenzl A et al, 2009).  However, if the patient is deemed unfit for 
surgery or if the patient chooses not to have surgery, most centres regard RT as a 
valuable curative alternative.   A recent retrospective study comparing RC with RT, 
in  169 patients in a large U.K. teaching hospital, found that there were indeed no 
significant differences in overall, cause-specific, and distant recurrence-free survival 
between the two groups even though those in the RT group were significantly older 
(Kotwal S et al, 2008).  Given that bladder cancer patients are an increasingly 
elderly population, this study highlighted the need for RT to be considered a viable 
radical treatment modality. 
 
There is also a drive towards incorporating irradiation as part of a multimodal 
treatment in an effort to cure organ-confined MIBC (T2-4a) with the rationale of 
providing bladder preservation.  Such bladder-sparing multimodal therapies often 
involve an initial TURBT followed by irradiation and systemic chemotherapy.  
These multimodal treatments (MMTs) are often also referred to as “trimodality 
treatment (TMT)” or “combinational modality treatment (CMT)”.  Chemotherapy is 
usually with a cisplatin-containing regimen, usually combined with paclitaxel or 
fluorouracil, and is given at the time of RT to increase the radiosensitisation of 43 
 
tumours.  A few weeks following TURBT and concomitant chemo-RT, a cystoscopy 
is performed to evaluate the response.  If there is complete response (CR), either 
macroscopically or microscopically, further consolidation chemo-RT is usually 
given with the intent of sparing the bladder.  However, if there is microscopic or 
macroscopic tumour on cystoscopy, the multimodal regimen is abandoned and 
salvage cystectomy is usually performed.  The 5-year survival (overall survival, OS) 
with such MMTs has been reported to be 45-54% (Rodel C et al, 2002; Shipley WU 
et al, 2002; Shipley WU et al, 2003).  Such series have also reported the 
achievement of CR in 60-85% of patients and, after accounting for those who 
undergo salvage cystectomy for poor response to chemo-RT, 5-year survival rates 
with an intact bladder are quoted to be around 40-45% in these patients undergoing 
bladder-sparing MMT. 
 
When considering bladder-preservation, the drive towards MMT comes from an 
accumulation of evidence that mono-therapy with either TURBT, radiotherapy or 
chemotherapy alone does not produce acceptable oncological outcomes.  Mono-
therapy measures are unlikely to cure muscle-invasive disease compared to RC.  
When “limited surgery” (as opposed to RC) with either TURBT or partial 
cystectomy alone was used, local disease control was only possible in approximately 
20% of cases (Hall HW, 1987; Henry K et al, 1998).  When systemic chemotherapy 
alone was used, with a combination of cisplatin, epirubicin, vinblastine and 
methotrexate, the outcomes were not much better with only around 19% of patients 
enjoying a 3-year recurrence-free survival (Hall RR et al, 1990).  When RT alone 
was used, local control was surprisingly better at about 40% but was still 
significantly lower compared to RC (around 80-90%) and the 5-year survival rates 44 
 
were 38-59% for T2 disease and 14-39% for T3-4a disease (Jenkins BJ et al, 1988; 
Gospodarowicz MK et al, 1989; De Neve W et al, 1995; Mameghan H et al, 1995).  
However, there have been improvements in delivering RT in the last decade and this 
has reflected in better outcomes whereby the results are similar to RC (Kotwal S et 
al, 2008; Hoskin PJ et al, 2009; Huddart RA et al, 2013; ). 
 
When a combination of modalities is considered, comparing RT alone against a 
combination of RT and cisplatin, in patients with T3 disease in a randomised 
controlled trial,  there was an improvement in local disease control from 47% 
(radiotherapy) to 67% (radiotherapy and cisplatin) (Coppin CM et al, 1996).  In a 
similar vein, combining TURBT and chemotherapy nearly doubled the CR rate to 
33-56%, compared to either modality alone but was still significantly less than 
radical cystectomy (80-90%) (Hall RR et al, 1984; Prout GR et al, 1990; Herr HW 
et al, 1998).  Following these encouraging outcomes resulting from a combinational 
approach, the North American Radiation Therapy Oncology Group (RTOG) 
conducted a phase II study involving 42 patients (Tester W et al, 1993).  The 
patients were treated with cisplatin and once-daily RT (40Gy) concurrently.  
Complete responders were treated with further cisplatin and consolidation RT 
(24Gy).  Non-responders underwent RC.  The CR rate was 66% and the 5-year 
survival was 52% with 42% surviving with an intact bladder.  Other groups, such as 
those at Massachusetts General Hospital (MGH) and the Medical Research Council 
(MRC), have looked at the potential benefit of neoadjuvant chemotherapy prior to 
RT or prior to chemo-RT (Kaufman DS et al, 1993; International Collaboration of 
Trialists, 1999).  The results did not demonstrate a clear benefit in favour of 
administering chemotherapy in a neoadjuvant fashion.  However, it is noteworthy 45 
 
that, when considering chemotherapy in a neoadjuvant setting prior to radical 
cystectomy (not as part of MMT regimen), there is an approximately 5% absolute 
improvement in survival at 5 years (Stenzl A et al, 2009).  This has led many 
Urological societies to issue a firm recommendation advocating the use of cisplatin-
based, neoadjuvant chemotherapy to all eligible patients with bladder cancer 
undergoing radical treatment (RC or RT). 
 
Following lack of evidence in support of neoadjuvant (versus concurrent 
chemotherapy), for the purpose of MMT, groups have also looked into optimising 
the protocol of RT delivery.  Twice-daily, fractionated RT has been investigated as 
an alternative to the once-daily RT regimen but there does not appear to be a clear 
benefit in favour of a twice-daily regimen (Housett M et al, 2005; Horwich A et al, 
2005).  The rationale for fractionation is that there is potential for increased 
biological response and faster completion of induction rendering quicker 
identification of non-responders; however, due to lack of clear benefit, different 
groups tend to prefer one or the other RT strategy. 
 
There have also been trials attempting to improve the efficacy of chemotherapy by 
adding other chemotherapeutic agents such as paclitaxel and gemcitabine to 
cisplatin.  RTOG investigated a concurrent chemotherapy regimen involving 
cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine (Kaufman 
DS et al, 2009).  They demonstrated an impressive CR of 81% with a 5-year overall 
survival of 56% and disease specific survival of 71%.  Others, such as the University 
of Erlangen group, which has one of the oldest series on multimodal treatment, have 
added 5FU (5-fluorouracil) to cisplatin and have found an increase in CR from 82% 46 
 
to 87% and an improvement in overall survival from 62% to 65%, at 5 years (Weiss 
C et al, 2007).  RTOG are currently investigating the relative efficacies of paclitaxel 
against 5FU when added to cisplatin.  In a recently published study, where patients 
were randomised to RT alone versus RT with concurrent 5FU and mitomycin, there 
was no significant difference in survival but there was a significant difference in 
loco-regional recurrence (James ND et al, 2012). 
 
However, complete response (CR) is not achieved in approximately 12-40% of 
patients undergoing MMT; consequently, they are candidates for immediate salvage 
cystectomy (reviewed in: Rene NJ et al, 2009).  However, even in those deemed to 
have achieved CR and have completed MMT, approximately 14-50% will go on to 
fail locally with most recurrences occurring within 12-24 months.  Most local 
recurrences are superficial (non-muscle invasive), occurring in approximately 60% 
of patients, and are usually managed with TURBT.  The remaining 40% are muscle-
invasive and are considered for salvage cystectomy.  Overall, following MMT, 5-
year survival with an intact bladder is approximately 38-51% which represents 
around 80% of those who had committed to a bladder-sparing regimen. 
 
One of the main objectives of current MMT trials is to improve the selection of 
patients such that those selected are likely to have a CR to chemo-RT.  There is a 
suggestion that completeness of response to chemo-RT is predictive of the 
likelihood of the development of metastases and, therefore, predictive of 
survival.  The University of Erlangen group found that in those who had 
achieved CR, the 5-year and 10-year survival, free from metastases, were 79% 
and 70% respectively.  However, if response was incomplete, these figures 47 
 
decreased to 52% and 48% respectively (Rodel C et al, 2002).   Similarly, 
Housset et al demonstrated that 5-year overall survival decreased significantly 
from 78% in those with CR to 29% in whom the response was incomplete 
(Housset M et al, 2005).  These results suggest that the biological behaviour of 
tumours can be predicted on the basis of their response to chemo-RT.  If tumours 
respond well to chemo-RT, the patients are likely to do well long-term in terms 
of survival.  Therefore, it can be argued that, if tumours can be selected which 
are likely to respond well to chemo-RT, those patients can be subjected to MMT.  
Those which are unlikely to respond well to MMT can be stratified into RC 
straight away so that there is no delay to their definitive treatment and also that 
they are not exposed to the possibility of adverse effects of a treatment (MMT) 
which is ultimately unlikely to benefit them.  For instance, there is a concern that 
RT can cause tissue change and render orthotopic substitution cystoplasty very 
difficult when patients undergo salvage RC after MMT. 
 
In this regard, there are several biological markers, involved in the DNA damage 
response (DDR) pathway, which have been reported to predict biological 
responsiveness to chemotherapy and/or radiotherapy.  X-ray repair cross 
complement group 1 protein (XRCC1) and human apurinic/apyrimidinic 
endonuclease (APE1) are proteins involved in the base excision repair (BER) 
process following ionising radiation-induced DNA base damage (Vidal AE et al, 
2001).  XRCC1 acts as a scaffold for APE1 which has enzymatic activity in 
producing BER (Mortusewicz and Leonhardt, 2007).  High levels of XRCC1 or 
APE1 have been shown to be predictive of responsiveness to RT and to overall 
survival (Sak SS et al, 2005).  Similarly, the excision-repair cross-complementing 48 
 
group 1 (ERCC1) protein expression has been shown to correlate with efficacy of 
response to chemo-RT (Kawashima A et al, 2010).  ERCC1 is important in the 
nucleotide excision repair (NER) pathway and its deficiency has been demonstrated 
to result in sensitivity to ionising radiation (Park CH et al, 1995; Ahmad A et al, 
2008).  Lack of ERCC1 is also reported to correlate with sensitivity to cisplatin 
treatment because ERCC1, as part of the NER pathway, is involved in the removal 
of cisplatin from DNA adducts (Olaussen KA et al, 2006; Bellmunt J et al, 2007).   
 
Another DDR pathway protein reported to have predictive value in radiosensitivity 
to bladder cancer treatment is Mre11 (Choudhury A et al, 2010).  Mre11 is part of 
the MRN complex and plays a crucial role in the detection and repair of DNA 
double strand breaks.  Choudhury et al demonstrated reduced expression of Mre11 
to correlate with poor outcomes in patients who had undergone radical radiotherapy 
for MIBC.  However, protein expression of Rad51 and Nbs1, also part of the MRN 
complex, did not have similar predictive value.  Other proteins involved in the DDR 
pathway, such as ATM, γH2AX and p53, also did not reveal a correlation with 
outcomes in their study.  The lack of correlation between p53 expression and 
radiosensitivity or treatment outcomes is not novel as there are conflicting reports in 
the literature.  Some studies have demonstrated a correlation of TP53 mutations with 
radio-sensitivity and improved outcomes (Ribeiro JC et al, 1997; Rotterud R et al, 
2001).  In contrast, other studies have reported radio-resistance and poor outcomes 
as a result of TP53 mutations (Hinata N et al, 2003; Poeta ML et al, 2007).  A recent 
systematic review of the literature on p53 status and outcomes in colorectal cancers 
concluded that a definitive correlation could not be made due to publication bias and 
heterogeneity of reports (Munro AJ et al, 2005). 49 
 
 
Specifically in relation to multiple modality treatment (MMT) in bladder cancer, one 
RTOG study has demonstrated a significant correlation between Her-2 expression 
and poor response to chemo-RT (Chakravarti A et al, 2005).  Others have reported 
that the apoptotic index and Ki-67 expression, but not p53 or bcl-2 expression, are 
related to complete response (CR) after MMT (Rodel C et al, 2002).  Matsumoto et 
al have reported that Ki-67 expression and Bax to Bcl-2 ratio are predictive of CR 
following MMT (Matsumoto H et al, 2004). 
 
There is therefore a rationale for formulating a panel of biomarkers which can have 
predictive or prognostic value in determining the outcomes of MMT in a bladder-
sparing regimen.  It is worth interrogating the predictive value of a panel of 
biomarkers, incorporating ones listed above as well as those involved in the DDR 
pathway, such as AIMP3, in the selection of appropriate patients for MMT.  
Selection of those patients likely to respond well to MMT would ensure preservation 
of bladder, reduction of side-effects attributable to radical surgery, without 
necessarily compromising the oncological outcomes.  This strategy may lead to a 
shift in the paradigm of bladder cancer management, from radical surgery to a less-
invasive one, akin to the recent shift in the management of breast cancer from 
radical surgery to a far less aggressive regimen involving lumpectomy, local 
irradiation and systemic chemotherapy with the addition of anti-Her-2 depending 
upon expression status of Her-2. 
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1.5  Background work by group: identification of AIMP3 as a 
dysregulated gene in bladder cancer suitable for investigation 
 
The current project builds upon work carried out by our group in discovering and 
investigating novel biomarkers in bladder cancer.  Leading up to this project, our 
group had completed a genomic analysis of muscle invasive bladder cancer (MIBC) 
and non-muscle invasive bladder cancer (NMIBC) by expression array and array 
comparative genomic hybridisation (aCGH).  In an initial genome-wide survey, 
using aCGH at 1Mb resolution, our group identified copy number gains and 
amplifications of Mouse Double Minute 4 (MDM4) and gain of Aurora kinase A 
(AURKA) associated with an aggressive phenotype in bladder cancer 
(Veerakumarasivam A et al, 2008; Veerakumarasivam A et al, 2008).  These genes 
are currently the subject of early phase trials in advanced bladder cancers.  In order 
to identify potential tumour suppressor genes (TSGs), copy number loss (regions 
with hemi and homozygous deletions) was annotated across the dataset.  By this 
method, multiple potential hits were identified; however, it was noted that many loci 
spanned gene-poor regions which were less likely to harbour significant TSGs.  
Using a bioinformatic approach, the search strategy was altered to combine CGH 
along with expression array data generated using an Agilent human 21K chip; the 
datasets were analysed by incorporating independent sets and whole genome 
libraries.  
 
In addition, through collaboration with Oncomethylome Sciences (OMS), a 
methylation library containing a whole genome map representing CpG-rich gene 
promoter sites was interrogated.  For the analysis, expression array data was 
normalised and ranked to identify low level transcript expression in MIBC and 51 
 
NMIBC; ranked transcripts were screened using the CpG promoter site library.  It 
was postulated that the targets identified by this process may be TSGs which are 
epigenetically silenced, especially if accompanied by hemizygous deletions.  Using 
this strategy, a number of potential targets were identified which warrant further 
analysis (Table 1.3).  Table 1.3 lists the gene ontologies (GOs) that represent the 
identified targets; expressed as molecular function of gene products, their role in 
multi-step biological processes, and their localization to cellular compartments.  
Many of the identified target genes are involved in basic cellular homeostasis 
processes. 
 
One such target was amino acyl tRNA synthetase (ARS) – interacting protein 3 
(AIMP3).  AIMP3 was confirmed, by quantitative RTPCR, as demonstrating low 
expression in bladder cancer (unpublished, Figure 1.7).  Furthermore, AIMP3 was 
found to have a CpG-rich promoter which was potentially methylated.  In 
collaboration with OMS, a pilot study was conducted on a small number of cases 
which confirmed that AIMP3 was indeed hyper-methylated in bladder cancer 
(unpublished, Figure 1.7).  Although copy loss was not identified using aCGH 
(unpublished), the analysis suggested that hypermethylation of AIMP3 may play a 
role in the development of an aggressive phenotype and potentially in the 
progression from NMIBC to MIBC.   
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Table 1.3:  List of non-redundant gene ontologies (GOs) of lowest expressing genes. 
Gene Ontology (GO)  Example of genes 
Biological Process 
Regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process  
C20orf100,RBM15B,MTERF,NPAS2,RARB, 
RNA biosynthetic process   C20orf100,MTERF,NPAS2,RARB,TCEA3, 
Intracellular transport  IMMP2L,MRPL32,TRAPPC1,BNIP1,STARD3 
Protein modification  STK11,PRKCD,CHM,ARD1A,MINK1,CASK 
Translation   PELO,PABPC4,MRPL13,AIMP3,MRPL32 
Cell death   TPT1,IFNB1,BNIP1,SCIN,EEF1E1 
Phosphorylation   MINK1,CASK,STK11,PRKCD 
Blood coagulation   ENTPD2,PABPC4,TBXAS1,FGA 
DNA packaging  CHAF1B,L3MBTL2,ARD1A 
Cellular secretion  BNIP1,SCIN,TRAPPC1 
Molecular Function 
Zinc ion binding   L3MBTL2,ZNF138,APOBEC3G,PRKCD,TCEA3 
Protein kinase activity  CASK,PRKCD,STK11,MINK1 
ATP binding   STK11,MINK1,CASK,PRKCD 
Pyrophosphatase activity   RRAS,ENTPD2 
Symporter activity  SLC16A4,SLC25A18 
Iron ion binding   SC5DL,TBXAS1 
Double-stranded DNA binding  MTERF 
Phosphatidylinositol binding  SCIN 
Chloride transporter activity   SLC26A1 
Phosphatidylinositol-4,5-bisphosphate binding   SCIN 
Cellular Component 
Intracellular organelle   PRKCD,TCEA3,ZZZ3,NPAS2,NUP37,IMMP2L 
Intrinsic to membrane   JAM2,RNF133,LIME1,SLC25A36,GRIK3 53 
 
 
 
In a separate pilot study, the focus was on the optimisation of immunohistochemistry 
(IHC) using the AIMP3 polyclonal antibody (Abcam) on sections of normal (n=12) 
and cancer cases (n=123) embedded into a tissue microarray (TMA) (Figure 1.7).  
AIMP3 immunostaining was strongly positive in normal bladder and other normal 
tissues; however, staining was weaker in MIBC (Figure 1.7A).  This corroborated 
the AIMP3 gene expression findings at protein level; a trend was observed of a 
generalised reduction in AIMP3 expression in cancer compared to normal 
urothelium (Figure 1.7B).  The experiment was also useful to establish the staining 
methodology, appropriate controls and scoring method.  
 
 
Cytoplasm  SC5DL,CHAF1B,STARD3,AIMP3,SCIN 
Plasma membrane part  SLC16A4,PELO,FLRT3,AQP4,JAM2,CASK 
Ribonucleoprotein complex   MRPL13,MRPL32 
Synaptosome  CASK 
Aminoacyl-tRNA synthetase multienzyme 
complex 
AIMP3 
Outer membrane   AQP4 
SNARE complex   BNIP1 
Basal lamina   ENTPD2 54 
 
 
Figure 1.7:  Loss of AIMP3 is a feature of invasive bladder cancer and AIMP3 promoter 
methylation  is  cancer-exclusive.    (A)  Top:  Normal  urothelium  demonstrating  high 
expression  of  AIMP3  (Left  x20  magnification;  Right  x60  magnification);  Bottom: 
Expression of AIMP3 is lost in an invasive T2G3 tumour (Left x20 magnification; Right 
x60 magnification).  (B) There is a general loss of AIMP3 expression in cancer as compared 
to normal urothelium and a downward shift in the percentage of moderate/high expressing 
tumours  exists  with  stage/grade  progression.    (C)  Promoter  methylation  of  AIMP3  was 
detected in about 10% of tumours as well as cells in urine sediments derived from patients 
with tumours but was not detected in corresponding normal cells.  (D) Relative AIMP3 
mRNA  expression  stratified  by  tumour  stage/grade  and  methylation  status.    Methylated 
tumours  demonstrated  a  significant  loss  in  expression,  while  a  marked  difference  was 
observed between Ta/T1 and T2/higher tumours (p<0.001). Bars, (standard error) SE 
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1.6  Research hypothesis and objectives 
 
The foregoing review of the role of AIMP3 as a tumour suppressor involved in the 
DDR pathway, the main components of the DDR pathway, the need for biomarkers 
to predict outcomes of chemo/radio-therapy in bladder cancer and our preliminary 
findings of AIMP3 expression in bladder cancer resulted in the formulation of the 
following hypotheses: 
 
“AIMP3 is predictive of response to chemo- or radio-therapy in vitro in bladder 
cancer cell lines” 
 
“AIMP3 expression status may be predictive of clinical outcome following radio- or 
chemo-therapy in patients with muscle-invasive bladder cancer.” 
 
The main objectives of the research were as follows: 
A) To demonstrate whether downregulation of AIMP3 by siRNA transfection in a 
panel of bladder cancer cell lines impacts on functional outcomes (e.g. alters 
clonogenic survival) following exposure to radiotherapy. 
B)  To demonstrate whether expression status of AIMP3 predicts survival following 
radical radiotherapy in patients with muscle-invasive disease (e.g. in a cohort of 
patients enrolled in a radical radiotherapy trial such as BCON). 
C)  To investigate whether expression status of AIMP3 is predictive or prognostic by 
correlating expression status with survival in an “untreated/control” set of 
patients undergoing radical cystectomy (i.e. not treated with concurrent or 
adjunctive radical radiotherapy; not treated with either neoadjuvant or adjunctive 
chemotherapy). 56 
 
D) To investigate the predictive or prognostic value of other DDR proteins (e.g. 
p53, Mre11, ERCC1) which are reported to be significant. 
E)  To investigate whether siRNA downregulation of AIMP3 impacts on functional 
outcome (e.g. alters clonogenic survival) following cisplatin exposure in a panel 
of cisplatin-sensitive and cisplatin-resistant bladder cancer cell lines (e.g. RT112 
and RT112CP). 
F)  To investigate the predictive or prognostic value of AIMP3 in a group of patients 
treated with cisplatin-based neoadjuvant chemotherapy prior to radical treatment 
(e.g. either radical radiotherapy or radical cystectomy). 
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2  Chapter 2 
 
 
Materials and Methods 58 
 
 
2.1  Cells 
The choice of bladder cancer cell lines was as follows, with HeLa being used as a 
reported positive control for AIMP3 in most experiments (David A et al, 2011; 
Kwon NH et al, 2011; Park BJ et al, 2005): 
  T24 
  RT112 
  RT112CP 
  253J 
  RT4 
 
  HeLa 
 
All cell lines were obtained in-house from Professor John Masters with identities 
checked through STR (short tandem repeat) profiling.   All the cells were maintained 
as monolayers using RPMI 1640 media (Gibco Invitrogen, Paisley, UK) 
supplemented with 10% heat-inactivated FBS (fetal bovine serum) (Flow 
Laboratories, Irvine, UK) and 2mM L-glutamine (Gibco Invitrogen).  Cells were 
incubated at 37
oC in a humidified atmosphere of 5% CO2 in air.  When sub-culturing 
was required, the monolayers were detached using trypsin (0.01%) (Difco 
Laboratories, London, England) with versene (0.003%) (BDH Chemicals, Poole, 
England) in PBS (phosphate buffered saline) (Gibco Invitrogen).  Mycoplasma was 
not demonstrable in nutrient agar culture and with indirect fluorescent staining.   
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The characteristics of the bladder cancer cell lines are summarised in Table 2.1.  
T24 cell lines were originally derived from a grade III transitional cell bladder 
carcinoma in 1970 in Sweden from an 82 year old woman (Bubenik J et al, 1973).  
RT112 cells were originally established at the Institute of Oncology, University of 
London, from a grade I-II transitional cell carcinoma of the bladder (Masters JRW et 
al, 1986).  RT4 was originally derived from a recurrent grade I transitional cell 
bladder carcinoma (Rigby and Franks, 1970).  T24 is not tumorigenic in nude mice 
(Marshall CJ et al, 1977).  RT112 is clonogenic in nude mice (Marshall CJ et al, 
1977).  RT4 is not tumorigenic in nude mice (Marshall MJ et al, 1994).  T24 
contains p53 mutant protein while RT112 contains wild-type p53 (Cooper MJ et al, 
1994; Warenius HM et al, 2000).  RT4 was found to produce wild-type p53 (Cooper 
MJ et al, 1994).  RT4, RT112, 253J and T24 are reported to display phenotypes 
representative of a spectrum of well-differentiated, moderately-differentiated and 
poorly-differentiated urothelial carcinoma respectively where RT4 is well-
differentiated and T24 the least well-differentiated (Booth C et al, 1997).  RT4 and 
RT112 are reported to demonstrate a superficial pattern of growth and are regarded 
by some as models of non-invasive models of bladder cancer (Booth C et al, 1997).  
In contrast, T24 and 253J demonstrate aggressive, invasive growth patterns and are 
regarded as models of invasive bladder cancer (Davies G et al, 1999; Elliott AY et 
al, 1977).  RT112CP is a cisplatin-resistant subline of RT112 (Bedford P et al, 
1987).   
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Table 2.1:  Original characteristics of bladder cancer cell lines used 
Cell line  Origin  Clinical 
stage 
Histolog
ical 
grade 
Year culture 
established 
Sex of 
patient 
Patient’s 
prior 
therapy 
Population 
doubling 
time (hours) 
Tumorigenecity 
in nude mice 
P53 
status 
T24  Recurrence in 
bladder 
NR  G3  1970  F  None  21  No  mut 
253J  Retroperitoneal 
lymph node 
metastasis 
T4  G4  1972  M  NR  28  Yes  mut 
RT112  Bladder primary  NR  G1-2  1973  F  None  24  Yes  wt 
RT112CP 
 
Bladder primary 
(RT112 subline) 
NR  G1-2  1987  F  None  24  NR  NR 
RT4  Recurrence in 
bladder 
T2  G1  1967  M  Gold grains 
2 years 
earlier 
37  Yes  wt 
F=female; M=male; mut=mutant; NR=not recorded; wt=wild-type61 
 
 
2.2  Western blot analysis 
2.2.1  Protein extraction 
Cells for protein extraction were washed with cold PBS (phosphate buffered saline) 
(Gibco Invitrogen, Paisley, UK).  The cells were lysed in appropriate volumes (e.g. 
200 μl for T25 flasks; 600 μl for T75 flasks) of modified radioimmunoprecipitation 
(RIPA) buffer [50 mM Tris-HCl, pH 7.4, 1% TritonX-100, 150 mM NaCl, 1 mM 
EDTA, 1 mM NaF, 1  mM Na3VO4, 1 protease inhibitor cocktail tablet per 10 ml of 
RIPA buffer (Complete Mini, Roche Diagnostics, Mannheim, Germany).  The lysed 
cells were removed from the flasks using cell scrapers (BD Falcon, Bedford, MA, 
USA) and transferred into 1.5 ml Eppendorf tubes.  The lysates were left on ice for 
15 minutes and then centrifuged at 13,000 rpm for 15 minutes at 4C.  After 
centrifugation, the supernatants were collected in pre-chilled Eppendorf tubes ready 
for subsequent studies or for storage at -80C. 
 
2.2.2  Protein concentration measurement 
The  total  protein  concentrations  of  the  lysates  extracted  from  the  cells  were 
measured using the Modified Lowry Protein Assay Kit (PIERCE, Rockford, IL). 
Serial dilutions of Bovine Serum Albumin (BSA) were made from the BSA standard 
solution (2 mg/ml, supplied in the PIERCE Kit) as listed in Table 2.2.  Briefly, 125 
μl of the original BSA standard (2 mg/ml) is diluted with 375 μl of distilled water to 
obtain the initial concentration standard of 500 μg/ml (0.5 mg/ml) in Vial A; 200 μl 
of BSA from Vial A is diluted with 200 μl of distilled water to obtain 250 μg/ml 
standard in Vial B and so on in a serial dilutional method down to 31.25 μg/ml 62 
 
standard in Vial E.  Vial F contains no BSA (0 μg/ml) making it the “blank” for 
spectrophotometric purposes. 
 
Table 2.2:  BSA standards preparation 
Vials  Volume of BSA (μl)  Volume of diluents 
(μl) 
Final BSA 
concentration 
(μg/ml) 
A  125  375  500 
B  200  200  250 
C  200  200  125 
D  200  200  62.5 
E  200  200  31.25 
F  0  200  0 (blank) 
 
Ten microliters (10 μl) of each lysate sample was diluted 20 fold with 190 µl of 
distilled  water  (total  volume  200  μl).    One  millilitre  (1  ml)  of  Modified  Lowry 
Protein  Assay  Reagent  was  added  to  each  diluted  sample  or  BSA  standard  and 
mixed  gently.    The  mixture  was  then  incubated  for  exactly  10  minutes  at  room 
temperature.  2N Folin-Ciocalteu Reagent (supplied by the Kit) was diluted 50:50 
with distilled water (e.g. 2 ml reagent with 2 ml distilled water) to make the final 
reagent concentration of 1N.  At the end of the 10 minute incubation period, 100 µl 
of 1N Folin-Ciocalteu Reagent was added to each lysate sample or BSA standard 
and mixed gently.  The mixture was incubated for 30 minutes at room temperature.  
Afterwards, the samples were measured using the UV/Visible Spectrophotometer 
(Ultrospec 3100 Pro).  Standard curve was plotted automatically by the machine 63 
 
based  on  absorbance  readings  against  the  concentrations  of  BSA  standards.  
Readings of lysate samples were taken from the machine and concentrations were 
calculated by multiplying ×20 on account of the original 1:20 dilution of the lysates. 
 
2.2.3  SDS PAGE and protein blotting 
Equal amounts of total protein from lysate samples were normalized to the same 
volume using RIPA buffer.  Appropriate volume of 6x Sample Buffer (200 mM Tris, 
pH6.8, 60% glycerol, 12 mM EDTA, 12% SDS, 864 mM β-mercaptoethanol, 0.05% 
bromophenol  blue)  were  added  to  the  protein  samples  to  reach  the  final 
concentration  of  1x  SB.    The  mixture  was  heated  at  95C  for  5  minutes.    The 
denatured protein samples were then ready to be loaded onto the sodium dodecyl 
sulphate (SDS)-polyacrylamide gel with the concentration of acrylamide tailored to 
the size of the protein being investigated (e.g. 14% gel for p18; 8% for ATM/ATR). 
The recipe of SDS-polyacrylamide gel is listed in Table 2.3.  
 
 
 
 
 
 
 
 64 
 
Table 2.3:  Recipe of SDS-polyacrylamide gel. (A) Resolving gel, (B) Stacking gel 
A  Resolving gel 
  6%  8%  10%  12%  14% 
1 M Tris, pH8.8  3.75 ml  3.75 ml  3.75 ml  3.75 ml  3.75 ml 
30% Acrylamide  2 ml  2.67 ml  3.33 ml  4 ml  4.67 ml 
H2O  4.2 ml  3.53 ml  2.87 ml  2.2 ml  1.53 ml 
20% SDS  50 µl  50 µl  50 µl  50 µl  50 µl 
10% (APS)  100 µl  100 µl  100 µl  100 µl  100 µl 
TEMED  6 µl  6 µl  6 µl  6 µl  6 µl 
 
 
B Stacking gel     
1 M Tris, pH 6.8  375 µl   
30% Acrylamide  374 µl   
H2O  2.24 ml   
20% SDS  15 µl   
10% APS  30 µl   
TEMED  5  µl   
 
For one SDS-polyacrylamide gel, around 8 ml of resolving gel solution was poured 
into the assembled Mini-PROTEAN III (Bio-Rad) gel cassette.  Isopropranolol was 
added to the top of the resolving gel to ensure a sharp and uniform interface between 
the resolving and loading gels.  When the resolving gel was set, the isopropanolol 
layer was poured off, washed a few times with distilled water and the stacking gel 
solution was prepared and poured onto the top of the resolving gel.  The comb was 65 
 
placed into the stacking gel before the gel was set.  When the whole gel was set, 
boiled protein samples (in the sample buffer mixture) were loaded into the separated 
wells.  Ten microliters (10 µl) of Rainbow Molecular Weight Marker (Amersham, 
GE Healthcare) was loaded as the reference for molecular sizes.  
 
The  gel  was  then  subjected  to  electrophoresis  using  the  Mini  PROTEAN  III 
Electrophoresis System (Bio-Rad) at a constant current (20 mA per gel) in running 
buffer (diluted to 1x from 5x stock containing 37 g Trizma base, 7.5 g Glycine and 
0.5 g SDS made up to 500 ml distilled water) for 1-2 hours until the dye, from the 
sample buffer in the loaded samples, was running out from the bottom of the gel. 
 
2.2.4  Western blotting 
Immediately after the SDS-PAGE, proteins on the SDS-polyacrylamide gel were 
transferred onto  a Polyvinylidene fluoride (PVDF) membrane (Millipore, Sigma-
Aldrich, St Louis, MO).  The transfer sandwich, including the sponge, filter paper, 
gel and PVDF membrane, was assembled as illustrated below (Figure 2.1): 
                 
       
Figure 2.1:  Western blot transfer sandwich 66 
 
 
Every component of the transfer sandwich was rinsed in transfer buffer (diluted to 1 
x from 10 x stock containing: 37 g glycine and 7.5 g Trizma base made up to 500 ml 
with distilled water).  The PVDF membrane was pre-wet in 100% methanol for 15 
seconds and then rinsed in transfer buffer.  The transfer sandwich was placed into 
the  assembly  tray  of  the  Mini  Trans-Blot  Cell  (Bio-Rad)  which  was  filled  with 
transfer buffer.  The gel was closed to the cathode and the electrotransfer was carried 
out  at  a  constant  voltage  of  20  V  overnight  at  4  C.    After  electrotransfer,  the 
membrane was rinsed briefly in PBS-Tween 20 (PBS-T, 0.1% Tween-20 in 1x PBS) 
and blocked in 5% non-fat milk (in PBS-T) for 1 hour at room temperature. After 
blocking,  the  membrane  was  probed  with  5  ml  of  appropriately  diluted  primary 
antibody (the details of the antibodies used are listed in Table 2.4) in 1% non-fat 
milk (in PBS-T) and incubated for 1-2 hours at room temperature or over-night at 4 
C.  
 
After primary antibody incubation, the membrane was washed with PBS-T for 2 
minutes  four  times.    After  washing,  the  membrane  was  incubated  with  5  ml  of 
horseradish peroxidase (HRP)-conjugated secondary antibody diluted in 1% non-fat 
milk (in PBS-T) for 1 hour.  The membrane was then washed with PBS-T for 2 
minutes four times after which it was ready for enhanced chemi-luminescent (ECL) 
development. 
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Table 2.4:  Details of the antibodies used. 
Antigen against -   Manufacturer  Catalogue Number  Dilution Factor 
AIMP3 (p18/EEF1E1)  AbCam  Ab31543  1:10,000 
       
p53  Cell Signaling  2982  1:1,000 
       
Beta-Actin  AbCam  Ab6276  1:20,000 
       
GAPDH  Sigma-Aldrich  G9545  1:10,000 
       
Anti-Rabbit IgG-HRP  Santa Cruz  sc-2314  1:5,000 
       
Anti-Mouse IgG-HRP  Santa Cruz  sc-2030  1:5,000 
 
2.2.5  Chemi-luminescence 
The chemi-luminescent signals were detected using Pierce ECL Western Blotting 
Substrate (PIERCE).  Appropriate volume of mixture of Detection Reagents 1 and 2 
at a 1:1 ratio was added to the membrane and incubated for 5 minutes at room 
temperature.    The  membrane  was  then  placed  between  two  transparency  plastic 
sheets and set into a Kodak BioMax Cassette (Kodak).  The membrane was exposed 
to X-ray films (Kodak) in a dark-room and the films were developed and fixed using 
pre-diluted  developer  and  fixer  solutions  respectively  (Kodak).  The  films  were 
washed in water and dried in a drying-cupboard. 68 
 
 
2.2.6  Image blot analysis 
Developed images, of the Western blot bands on the X-ray films, were scanned as 
JPEG in 8bit grayscale format at 600dpi, and the pixel intensities were measured 
using ImageJ freeware from the National Institutes of Health 
(http://rsb.info.nih.gov/ij).  Pixel intensities were measured with corrections for 
background.  Digitised gel intensity data were exported into a database (Excel, 
Microsoft). 
 
2.3  Clonogenic survival assay 
Cells were plated in T75 flasks until approximately 90% confluent.  After removing 
the media from the flasks and washing the cells with PBS, 3 ml of trypsin was added 
per flask and the cells were re-suspended in media, pipetting several times, to obtain 
a single cell solution.  A suitable volume (e.g. 200 µl) of single cell suspension was 
treated with Trypan Blue (e.g. 200 µl) and the concentration of cells was counted 
using a haemocytometer under microscopy.  The cells were then plated in 60 mm 
petri dishes (Nunc), in triplicates, at different numbers ranging from 0 to 1000 (i.e. 0 
cells per petri dish, 100 cells, 200 cells, 500 cells, 750 cells, 1000 cells).  Five 
millilitres (5 ml) of RPMI 1640 media (Invitrogen) (supplemented with L-glutamine 
and FBS) were added to each dish and the dishes shaken gently to allow even 
mixing and distribution of cells.  The cells were then incubated for approximately 14 
days with a change of media at day 7.  Following the incubation period, the media 
was discarded from the dishes and the cells fixed with 70% IMS (industrial 
methylated spirit) for 5 minutes.  The IMS was replaced with 1% crystal violet to 69 
 
stain the cells.  After approximately 30 minutes, the crystal violet solution was 
washed off under gentle running tap water.  When dry, the colonies stained were 
counted under the dissecting microscope. 
 
The serial plating of cells allowed the optimal plating number for each of the cell 
lines to be deduced.  This was based on the maximal number of individual colonies 
(each colony consisting of >50 cells) that could be counted on each petri dish.  This 
was variable between cell lines due to the differing plating efficiencies of the cell 
lines as well as the size of their colonies. 
 
2.4  Irradiation 
Cells were grown to a logarithmic phase of growth at approximately 80% confluence 
in either T25 or T75 flasks.  The cells were then exposed to the dose of X-ray 
irradiation required (for instance, 0 Gy, 2 Gy, 5 Gy – see Table 2.5 below) using a 
CP320 Bipolar X-ray machine (Gulmay, Kent, UK).  Doses were adjusted by 
varying the duration of irradiation (2 Gy/min) while the voltage (250 kV), current 
(12.5 mA), X-ray filter (Sn, Cu, Al) and distance from X-ray source (30 cm) 
remained constant. 
 
 Following irradiation, cells were incubated to the length of time required (time 
points: 0 hours, 1 hour, 6 hours, 24 hours, 48 hours) post irradiation.  At the 
appropriate time-point, the cells were subjected to either Western blot analysis or 
Clonogenic assays.  For Western analysis, cells were washed with cold PBS quickly 
and lysed with appropriate volumes of modified RIPA buffer.  Cells were then 70 
 
scraped with cell scraper and the protein extracted, quantified and either used or 
stored as described above.  For Clonogenic assays, cells were washed with PBS, 
trypsinised into single-cell suspensions, counted and plated onto petri dishes at the 
relevant plating numbers. 
 
Table 2.5:  Irradiation parameters 
 
kV 
* 
mA 
 
Filter 
 
Distance 
Dose Rate 
Gy/min 
 
215 
 
12.5 
 
1 
30  1.31 
60  0.33 
90  0.14 
 
215 
 
12.5 
 
2   
30  3.30 
60  0.82 
90  0.37 
 
215 
 
12.5 
 
3 
30  6.40 
60  1.60 
90  0.71 
 
250 
 
12.5 
 
1 
30  2.04 
60  0.51 
90  0.23 
 
250 
 
12.5 
 
2 
30  4.52 
60  1.13 
90  0.50 
 
250 
 
12.5 
 
3 
30  9.90 
60  2.47 
90  1.1 
 
200 
 
10 
 
2 
30  2.08 
60  0.52 
90  0.23 
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*The mA is proportional to the dose rate therefore halving the mA will halve the dose rate 
  Filter 1 is 0.4 mm Sn + 0.15 mm Cu + 1.0 mm Al 
  Filter 2 is 0.25 mm Cu + 1.0 mm Al 
  Filter 3 is 1.0 mm Al 
Sn: selenium; Cu: copper; Al: aluminium; mA: milliamps; kV: kilovolts; Gy: grays 
2.5  Immunofluorescence 
Twenty-two millimetres (22 mm) X 22 mm coverslips were sterilised by exposing to 
ethanol & heat (Bunsen burner).  The coverslips were placed in 6-well plates 
(Nunc).  The cells for immunofluorescence studies were trypsinised so as to obtain 
single-cell suspensions. Cells were plated onto the coverslips in the 6-well plates and 
incubated overnight with 2 ml of RPMI media such that, after overnight incubation, 
approximately 40-80% confluence was achieved. 
 
On Day 2, after checking for viability and appropriate confluence, the cells were 
washed briefly with 2 ml of PBS and fixed by adding 2 ml of formaldehyde into 
each well.  After incubating at room temperature for 30 minutes, the formaldehyde 
was pipetted off and the wells washed with 2 ml of PBS.  The fixed cells were then 
ready for immediate use or could be stored at 4 degrees for subsequent studies. 
 
For immunofluorescence, the cells were incubated with 2 ml of Permeabiliser Buffer 
(0.5% TritonX, 1% BSA (bovine serum albumin), PBS) into each well.  After at 
least 10 minutes of incubation, the Permeabiliser buffer was washed off.  On clean 
strips of paraffin membranes, about 150 μl of primary antibody solution drops were 72 
 
placed separated out such that each drop would accommodate the 22 mm X 22 mm 
coverslips easily.  The Primary Antibody (AIMP3/p18) solution was prepared at 
1:500 dilution (e.g. 4 μl of AIMP3/p18 into 2 ml of Permeabiliser buffer).  The 
coverslips were removed from the 6-well plates and placed face-down onto the 
primary antibody drops on the paraffin strips such that the cells were in direct 
contact with the antibody solution.   
 
After incubating for at least 1 hour at room temperature, the coverslips were held 
with forceps and washed several times in PBS making sure of the orientation of the 
cells on the coverslips.  Incubation with secondary antibody solution was then 
carried out in a similar method on paraffin strips.  Appropriate FITC (fluorescein 
isothiocyanate) (e.g. Anti-rabbit FITC for AIMP3/p18 raised in rabbit) was prepared 
at 1:500 dilution as above (e.g. 4 μl of anti-rabbit FITC into 2 ml of Permeabiliser 
buffer).  After incubation for at least an hour at room temperature, the secondary 
antibody solution was washed off as previously by immersing several times into a 
beaker of PBS.  Further immunolabelling (e.g. with TRITC-phylloidin for Actin) 
was either carried out or fixation of the coverslips onto the microscope slides was 
performed.  For this, 20 μl of DAPI was added onto the microscope slides and the 
coverslips were placed face-down onto the microscope slides containing DAPI.  
Confocal microscopy was then performed. 
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2.6  siRNA transfection 
Cells were trypsinised into single-cell suspensions and plated onto 6-well plates with 
2 ml RPMI (Gibco, Invitrogen) media (supplemented with FCS & L-Glutamine) 
such that approximately 40-60% confluence was achieved overnight.  
For transfection work, 1X siRNA Buffer was prepared from the stock 5X siRNA 
Buffer (Thermo Fischer Scientific).  Final 5 nM concentrations, from 100 nM stock, 
of the siRNA (Thermo Fisher Scientific) were prepared for the 4 test conditions:  
 
(1) AIMP3/p18 siRNA   
(2) Non Targeting siRNA (negative control) 
(3) GAPDH siRNA (positive control)  
(4) No Treatment (only Dharmafect as a negative control) 
 
Tube 1 & Tube 2 were prepared (1.5 ml eppendorfs).  Into Tube 1 (siRNA), 10 μl of 
5 nM siRNA was added into 190 μl of Optimem (serum-free transfection medium) 
(Gibco, Invitrogen).  Into Tube 2 (DharmaFECT), 10 μl of DharmaFECT was added 
into 190 μl of Optimem.  Four-fold (4X) volumes, accounting for pipetting errors, of 
Tube 2 were prepared to account for each test condition (1) AIMP3/p18 siRNA; (2) 
Non-targeting negative control; (3) GAPDH positive control; (4) Untreated negative 
control with only Dharmafect. 
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Each Tube was gently mixed by pippetting 3-5X.  The Tubes were incubated at 
room temperature for 5 minutes.  Then Tube 1 was mixed with the corresponding 
Tube 2 (= 400 μl final volume of mixture).  After gently mixing by pippetting 3-5X, 
the mixtures were incubated for 20 minutes at room temperature.  The mixtures (400 
μl) were then added into respective wells (6-well plates).  Sixteen hundred 
micorlitres (1600 μl) of Optimem was added onto each well (final volume 2 ml per 
well) and the cells incubated.  After 12-24 hours of incubation with siRNA-
containing Optimem media, the cells were checked for viability.  The Optimem 
(serum-free) media was replaced with 2 ml of complete media containing serum 
(RPMI supplemented with FCS & L-glutamine). At appropriate time-points (24, 48, 
72, 96, 120 hours), cells were checked for viability (to ensure >80% survival for 
optimal effects) and subjected to further studies as appropriate.  For example, 
Western blot analysis could be carried out at 48-72 hours to demonstrate optimal 
downregulation of AIMP3/p18 protein expression following siRNA knock-down of 
AIMP3/p18 in the cells.  For clonogenic survival assays, the 6-well plates were 
exposed to X-ray irradiation at appropriate doses, trypsinised within an hour and 
replated at appropriate numbers onto petri dishes to allow colony formation to be 
counted at day 14. 
 
2.7  Cisplatin exposure 
2.7.1  Cisplatin dose response 
RT112 and RT112CP cells were trypsinised and seeded at 750 cells per 60 mm x 15 
mm petri dishes with 5 ml per dish of RPMI media supplemented with 10% FBS and 
L-glutamine.  Plating in petri dishes were done in triplicates.  Following incubation 
overnight, cells were treated with a range of doses of cisplatin (for example, 0 75 
 
µg/ml, 1 µg/ml, 2 µg/ml, 3 µg/ml, 4 µg/ml, 5 µg/ml, 10 µg/ml, 25 µg/ml, 50 µg/ml).  
Cisplatin (Sigma, UK) was prepared immediately prior to treatment by dissolving in 
sterile water to give a concentration of 1 mg/ml.  Treatment was for 1 hour by 
incubating the cisplatin-treated cells at 36.5
0C.   Following treatment, cells were 
washed with PBS and incubated in RPMI media for 14 days with media change at 
day 7.  At day 14, colonies were fixed in IMS, stained with crystal violet and 
counted (as described in Section 2.3 above).  Experiments were repeated at least 3 
times. 
 
2.7.2  Cisplatin sensitivity with AIMP3 knockdown 
RT112 and RT112CP cells were trypsinised into single-cell suspensions and plated 
onto 6-well plates with 2 ml RPMI (Gibco, Invitrogen) media (supplemented with 
FCS & L-Glutamine) to achieve sub-confluence after overnight incubation. 
 
For transfection work, 1X siRNA Buffer was prepared from the stock 5X siRNA 
Buffer (Thermo Fischer Scientific).  Final 5 nM concentrations, from 100 nM stock, 
of the siRNA (Thermo Fisher Scientific) were prepared for the 4 test conditions:  
(1) AIMP3/p18 siRNA   
(2) Non Targeting siRNA (negative control) 
(3) GAPDH siRNA (positive control)  
(4) No Treatment (only Dharmafect as a negative control) 
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siRNA transfection was carried out according to the protocol described above in 
Section 2.6.  Following transfection, at appropriate time-points (e.g. 24, 48, 72, 96, 
120 hours), cells were checked for viability and subjected to further studies as 
appropriate.  For example, Western blot analysis could be carried out at 48-72 hours 
to demonstrate optimal downregulation of AIMP3/p18 protein expression following 
siRNA knock-down.  
 
For cisplatin-sensitivity following siRNA knock-down, the 6-well plates were 
exposed to IC50 doses of cisplatin for 1 hour, washed with PBS, trypsinised into 
single-cell suspensions, replated at appropriate numbers onto petri dishes and 
incubated to allow colony formation to be counted on day 14.  Media changes were 
performed on day 7. 
2.8  Radiotherapy tissue specimens from the BCON trial 
2.8.1  Patient demographics 
The Bladder Carbogen Nicotinamide (BCON) trial was a Phase III, RCT which 
investigated the outcomes of patients with organ-confined bladder cancer 
randomised to treatment with either radical radiotherapy alone or radical 
radiotherapy supplemented with carbogen nicotinamide (CON).  The full clinical 
and pathological characteristics of all the enrolled patients are summarised in the 
original report (Hoskin PJ et al, 2010).  Of the 333 patients enrolled into the trial, 
adequate pathological tissues and complete clinical outcome data were available for 
217 cases – these are the subject of the current research analyses.  Only those cases 
with adequate tumour with detrusor muscle in the specimen and those without 
diathermy artefact were selected.  Hematoxylin and eosin (H&E) stained cores were 77 
 
examined with the pathologist.  Relevant clinico-pathological data for the 217 cases 
are summarised below (Table 2.6).  
Table 2.6:  Clinical and pathological characteristics of patients enrolled into the BCON 
trial included in the current research analyses 
 
RT: radiotherapy; CON: carbogen nicotinamide; Hb: haemoglobin; TURBT: transurethral 
resection of bladder tumour; g/dL: grams per decilitre 
 
Characteristic  All patients 
(n=217) 
Percentage 
% 
Age (years) 
     Median age 
     Range 
  
74 
51-90 
 
Sex 
     Male 
     Female 
  
174  
43  
 
80 
               20 
Tumour Stage 
     1 
     2 
     3 
     4 
  
22 
144 
41 
10 
 
10 
66 
19 
5 
Grade 
       2 
       3 
  
33 
184 
 
15 
85 
Preceding Tumour 
     No 
     Yes 
  
186 
31 
 
86 
14 
Preceding Tumour treatment 
   TURBT 
      - Complete 
      - Partial 
      - Biopsy only 
      - Unknown 
  
  
90 
66 
53 
8 
 
 
42 
30 
24 
4 
BCON randomisation 
     RT alone 
     RT + CON 
  
113 
104 
 
52 
48 
Hb (g/dL) 
     Median 
     Range 
  
13.6 
9.3-17.2 
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2.8.2  Tissue microarray characteristics 
Tissue microarray cores of 0.6 mm diameter were organised in quadruplicates in 
paraffin blocks; in other words, each case was represented by four cores on the TMA 
block.  The cores for the 217 cases included spanned four blocks in total.  Tissue 
cores from liver, lung and brain were embedded as orientation markers in each 
block.  At least one of the quadruplicate cores was available in all cases for the 
current  analysis.  Sample “maps” of the BCON TMA blocks are included in 
Appendix A-(i). 
 
2.9  Radical cystectomy tissue specimens 
2.9.1  Patient demographics 
All cases pertained to radical cystectomies performed at Southampton General 
Hospital (University of Southampton, UK) between the period 1
st January, 2001 and 
1
st March, 2012.  Cases performed for bladder cancer were included.  For the 
purpose of this study, all cases where patients had received neoadjuvant 
chemotherapy, adjuvant chemotherapy or adjuvant radiotherapy were excluded.  The 
rationale for this exclusion was to reduce the confounding effects of such treatments 
(i.e. chemotherapy and/or radiotherapy) on clinical outcome following radical 
cystectomy when comparing against a radical radiotherapy cohort (i.e. the BCON 
cohort).  Ideally, a true “control cohort” to compare the BCON cohort against would 
have been patients with the same disease but who did not receive any form of 
treatment at all; this was not possible because any such practice would be 
completely unethical.  Hence, the use of a “surgical cohort” as control which is valid 
because surgery achieves favourable clinical outcome based on the physical removal 79 
 
of the tumour rather than through the DNA-damaging, cytotoxic mechanism 
associated with radiotherapy or chemotherapy.   
 
With the inclusion of patients who had only had radical cystectomy, there were 151 
cases available for analysis for the present study.  The clinic-pathologic 
demographics of these cases are summarised below (Table 2.7). 
 
Table 2.7:   Clinical and pathological characteristics of patients in the radical cystectomy 
set  
 Characteristic  All patients 
(n=151) 
Percentage 
% 
Age, years  
Median age  
Range  
 
73 
33-87 
 
Gender 
Male  
Female  
 
118 
33 
 
78 
22 
Stage 
ӿ 
0 
is 
1  
2  
3  
4  
Node +ve 
 
7 
24 
8 
23 
58 
10 
21 
 
5 
16 
5 
15 
38 
7 
14 
Grade 
¥ 
2  
3  
 
10 
129 
 
7 
85 
 
ӿ pathological staging from radical cystectomy; 0 (pT0): no residual tumour following 
previous TURBT; is (pTis or CIS): carcinoma in situ 
¥ does not include pT0 and cases which were exclusively pTis  80 
 
2.9.2  Tissue microarray characteristics 
Tissue cores were obtained from pre-cystectomy TURBT specimens.  Tissue cores 
for each case were organised in triplicates on the TMA blocks.  Each core was 1 mm 
in diameter.  Sample “maps” of the radical cystectomy TMA are included in 
Appendix A-(ii). 
 
2.10  Neoadjuvant chemotherapy tissue specimens 
2.10.1  Patient demographics 
Ethics approval (reference: EC06.1; see Appendix B) was obtained from University 
College London (UCL) to collate pathology materials related to patients who had 
undergone cisplatin-based neoadjuvant chemotherapy prior to definitive radical 
treatment (either radical cystectomy or radical radiotherapy) for bladder cancer (see 
Appendix A-iii).  In order to match the Neoadjuvant cohort closely to the BCON 
and radical cystectomy cohorts, cases were selected from a similar era from January 
1
st 2000 to January 1
st 2012.  Similar to the Radical Cystectomy cohort, in order to 
reduce the confounding effects of other treatments, patients who subsequently 
received adjuvant treatments following definitive treatments were excluded.  In total, 
there were 86 patients from 6 institutions within the UK.  The clinico-pathologic 
details are summarised below (Table 2.8). 
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Table 2.8:  Clinical and pathological characteristics of patients in the Neoadjuvant set  
 Characteristic  All patients 
(n=84) 
Percentage 
% 
Age, years  
Median age  
Range  
 
66 
35-82 
 
Gender 
Male  
Female  
 
64 
20 
 
76 
24 
Stage 
ӿ 
0 
is 
1  
2  
3  
4  
Node +ve 
 
38 
6 
2 
16 
11 
0 
11 
 
45 
7 
2 
19 
13 
0 
13 
Grade 
¥ 
2  
3  
 
2 
39 
 
2 
46 
Treatment  
Cystectomy 
Radiotherapy 
 
46 
38 
 
55 
45 
 
ӿ pathological staging from radical cystectomy; 0 (pT0): no residual tumour following 
previous TURBT; is (pTis or CIS): carcinoma in situ 
¥ does not include pT0 and cases which were exclusively pTis 
 
 
2.10.2  Tissue microarray characteristics 
Tissue cores for each patient were organised as duplicates on the TMA blocks.  Each 
core was 1 mm in diameter.  Other tissue cores, such as from prostate, were used as 
orientation markers on the blocks.  Sample TMA maps are included in Appendix A-
(iii). 82 
 
 
2.11  LaMB trial tissue specimens 
2.11.1  Patient demographics 
LaMB is a phase II/III double-blind, randomised-control trial (RCT) 
(ISRCTN35418671) which assigns patients with locally-advanced or metastatic 
bladder cancer to receive, along with their systemic chemotherapy, either lapatinib 
or placebo.  Lapatinib is a tyrosine kinase inhibitor which inhibits tumour 
proliferation by blocking the epidermal growth factor receptors, HER1 and HER2.  
LaMB is a multi-centre trial within the UK and commenced accrual from 27
th 
January, 2009 and completed recruitment on 31
st December, 2013.  Full details of 
the trial are available online from the Cancer Research UK clinical trials website 
(http://cancerhelp.cancerresearchuk.org/trials/a-trial-looking-at-lapatinib-for-people-
with-bladder-cancer-that-has-spread). 
 
For the purpose of the current study, patients included in LaMB, regardless of 
whether they received Lapatinib or placebo, were considered provided they had 
adequate initial-diagnostic tissue specimens available to be included onto a TMA.  
There were 72 patients available for TMA purposes.  Their clinic-pathologic 
demographics are summarised below (Table 2.9). 
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Table 2.9:  Clinical and pathological characteristics of patients in the LaMB set 
 Characteristic  All patients 
(n=72) 
Percentage 
% 
Age, years  
Median age  
Range  
 
67 
42-82 
 
Gender 
Male  
Female  
 
59 
13 
 
 82 
18 
Treatment  
Standard 
Standard + Lapatinib 
 
33 
39 
 
46 
54 
 
2.11.2  Tissue microarray characteristics 
Tissue cores were organised in duplicates or triplicates on the TMA blocks.  Cores 
were 1 mm in diameter.  Other tissue cores, such as from appendix, were included as 
orientation markers within the blocks.  The TMA slides were obtained from the 
LaMB triallists (Dr T Powles).  Sample maps of the LaMB TMA are included in 
Appendix A-(iv). 
 
2.12  Control TMA 
A separate “control” TMA was created in order to incorporate other tissue cores 
which were reported positive or negative immunostaining controls for the various 
antibodies interrogated.  Secondly, the “control” TMA also included cases of 
bladder cancer with a broad range of pathological grades and stages.  The purpose of 
this was to investigate how the immunostaining for any particular antibody altered 
according to the pathological grade/stage of bladder cancers.  Cores were 1 mm in 
diameter.  Where adequate tissue material was available, some cases were included 84 
 
as duplicate cores.  A sample map for the Control TMA is included in Appendix A-
(v).  
 
2.13  Immunohistochemistry of tissue microarray slides 
2.13.1  Immunohistochemistry protocol 
Immunohistochemistry of all the TMAs (BCON, Radical Cystectomy, Neoadjuvant, 
and LaMB) were performed by the University College London Advanced 
Diagnostics (UCL-AD) laboratory.  UCL-AD is part of the UCL Cancer Institute 
and provides accredited research and clinical laboratory services internationally 
(http://www.uclad.com/). 
 
Immunohistochemistry was performed using the Bond Polymer Refine Detection kit 
with  Bond-III  automated  immunostaining  system  (Leica  Microsystems,  Milton 
Keynes, UK) following the manufacturer’s instructions.  In brief, the TMA slides 
were deparaffinized, rehydrated, washed and endogenous peroxidase was blocked 
using  Bond-III  “Dewax  Protocol  D”  following  the  manufacturer’s  instructions 
(Leica Biosystems, Newcastle, UK).  Epitope retrieval was achieved using Bond-III 
“Protocol H1(30)” (Leica).  
 
The slides were incubated with antibodies against AIMP3 (1:25) (Atlas Antibodies, 
Sigma-Aldrich, UK) at room temperature for 1 hour.  Incubation dilutions for the 
other antibodies were as follows: Mre11 (1:200) (Atlas Antibodies); ERCC1 (1:300) 
(Clone 8F1, Neomarkers, Thermo-Fisher Scientific, Cheshire, UK); p53 (prediluted) 85 
 
(Clone D07, Novocastra, Leica Biosystems, Newcastle, UK).  Antibody binding was 
detected  using  diaminobenzidine  (DAB)  with  haemotoxylin  counterstaining 
following Bond-max and Bond-x “IHC protocol F” (Leica).   
 
External positive controls for the markers were as follows: non-cancer colon tissue 
(AIMP3); non-cancer prostate tissue (Mre11); non-cancer tonsil tissues (ERCC1 and 
p53).  Non-cancer liver tissues were used as external negative controls.  
 
2.13.2  Immunohistochemistry image analyses 
The  stained  TMA  cores  were  examined  under  a  light  microscope  at  400x 
magnification, standardising the scoring according to the reference control cores.  
The reference material was assigned a staining intensity of 2, graded on a scale of 0 
to 3, against which the bladder cancer cores were compared.  Three independent 
investigators,  blinded  to  the  clinical  data,  assessed  the  cores  with  the  primary 
investigator scoring the staining a second time, after a time gap of at least one week, 
to assess intra-observer variance.  The whole area of each core was viewed and the 
proportion of cells in each core staining positively was assigned a proportion score 
(0 if 0%, 0.1 if 1% to 9%, 0.5 if 10% to 49%, and 1 if 50% to 100%).  A semi-
quantitative  histopathology  (H)  score  was  obtained  by  multiplying  the  staining 
intensity with the proportion score.  The median value of all H scores was defined as 
the cut-off value to categorize antibody staining in the cores as either positive or 
negative.    Cores  with  discordant  scores,  resulting  in  H  values  that  altered  the 
staining  status  stratification  were  assessed  by  a  third  investigator  to  reach  a 
consensus. 86 
 
2.14  Outcome data for TMA sets 
Overall survival (OS) was taken as the primary outcome measure for all TMA 
(BCON trial, Cystectomy series, Neoadjuvant series, LaMB trial) datasets.  Overall 
survival was chosen as this was felt likely to be the least biased measure in terms of 
definitive, objective outcome.  However, OS can be limited by the requirement of 
long periods of follow-up meaning that most randomised trials cannot be adequately 
powered to detect significant differences between arms.  This point considered, OS 
data were available for all the cases in the current study making its choice as 
outcome measure easier.   Cancer specific survival (CSS) data was incomplete in 
most datasets and was also felt likely to have inaccuracies in terms of attribution of 
cause of death.  Other outcome measures such as recurrence-free survival and 
progression-free survival were also not used as primary outcome measures for the 
same reasons.  Where recurrence data was available (e.g. BCON trial dataset) and 
appropriate to analyse, it was measured as a secondary outcome. 
 
2.15  Statistical analysis 
2.15.1  Laboratory data 
Statistical analyses were performed using SPSS, version 17.0 (SPSS Inc, IL, US).  
For in vitro work, differences in means between groups (at least 3 independent 
experiments) were measured using a two-tailed Student’s t-test.  Standard deviations 
(SD) and standard error of means (SE) were calculated where appropriate.  
Graphical plots were constructed using either Microsoft Excel 2010 or Sigmaplot 
(version 10) packages. 
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2.15.2  TMA data 
Statistical analyses were performed using SPSS, version 17.0 (SPSS Inc, IL, US).  
For the TMA datasets, agreement in the scoring of the stained TMA cores (inter- and 
intra- observer agreement) was measured using Kappa statistics.  Overall survival 
(OS)  was  estimated  using  the  Kaplan-Meier  method.    The  effect  of  the  tested 
antibody  (e.g.  AIMP3,  ERCC1)  by  staining  status  was  measured  using  a  Cox 
proportional hazards model  adjusted for relevant covariates such as age, gender, 
tumor grade (G2 or G3) and tumour stage (T1, T2, T3 or T4).  Hazard ratio (HR) 
and confidence interval (CI) calculations were based on the Cox model; p values of 
<0.05 were used to denote statistical significance. 
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3  Chapter 3 
 
 
Expression of AIMP3 in bladder cancer cell lines and altered sensitisation 
to irradiation following siRNA knockdown of AIMP3 89 
 
 
3.1  Introduction to Chapter 3 
AIMP3 (p18/EEF1E1) is a multifunctional protein, which in addition to its role in 
protein synthesis, behaves as a tumour suppressor (Park BJ et al, 2005).  Altered 
expression of AIMP3 was demonstrated in both human cancer cell lines and biopsy 
specimens (Park BJ et al, 2005).  Cell line studies demonstrated that AIMP3 is 
implicated in the DNA damage repair (DDR) pathway following exposure to 
irradiation and chemicals (Park BJ et al, 2005; Park BJ et al, 2006).  Alteration in 
AIMP3 expression, by gene transfection in cell lines, demonstrated altered cell 
survival in response to these DDR agents; downregulation of AIMP3 resulted in 
reduced survival and upregulation resulted in increased survival (Park BJ et al, 
2005; Han JM et al, 2008).  AIMP3 knockout (AIMP -/-) mice are embryonically 
lethal and heterozygosity (AIMP3 +/-) leads to early susceptibility to a broad range 
of common cancers, indicating that AIMP3 is an important gene with tumour 
suppressor function (Park BJ et al, 2005). 
 
The broad aim  the current project was to investigate the role of AIMP3 in bladder 
cancer.  In the UK, bladder cancer is the second most common urological 
malignancy accounting for around 12000 new cases and 5000 deaths in 2010 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bladder/ ).  Radical 
surgery is currently the “gold standard” treatment for the curative management of 
organ-confined, muscle-invasive bladder cancer (Stenzl A et al, 2009).  However, 
disease-specific survival following radical surgery is still low and has improved little 
over the last few decades.  Radical radiotherapy is the second-line treatment option 
in most countries for patients who are unfit for surgery or choose not to have 90 
 
surgery; however, survival is slightly less with radiotherapy alone and there is 
radiation-specific morbidity (Shelley MD et al, 2002).  Hence, the rationale for and 
increasing popularity of less radical treatment modalities, incorporating radiation 
and chemotherapy, in this setting to achieve similar, if not better, survival in these 
patients (Rodel C et al, 2002; Shipley WU et al, 2002; Shipley WU et al, 2003; 
Housset M et al, 2005).  Irradiation and chemotherapy (neoadjuvant or adjuvant) 
have the potential to be of curative value in the treatment of organ-confined, muscle-
invasive bladder cancer.  Furthermore, chemotherapy and radiotherapy already have 
a role in the palliative management of metastatic bladder cancer. 
 
The primary objective of our study was to measure the expression of AIMP3 in a 
panel of bladder cancer cell lines and correlate protein expression to outcomes in 
response to DDR agents such as irradiation and chemotherapy.  The translational 
relevance of any observed correlation (either decreased expression correlating to 
improved cell survival or vice versa) would be that bladder tumours in clinical 
practice may be stratified into those either likely or unlikely to respond to treatment 
with irradiation and chemotherapy.  The secondary objective was to localise AIMP3 
in the cell lines.  This would help provide a mechanistic explanation for any 
correlations in outcomes such as altered cell survival. 
 
3.2  AIMP3 expression in bladder cancer cell lines 
3.2.1  AIMP3 protein expression 
Western blot analyses demonstrated protein expression of AIMP3 in a panel of 
bladder cancer lines (Figure 3.1A); T24, 253J, RT112 and RT4 lines were chosen to 91 
 
represent a spectrum from aggressive (T24) to low-grade (RT4) disease respectively.  
When comparing AIMP3 expression between the cell lines, there was a significant 
difference in the mean expression in between the groups (p=0.0001, F=19.01, one-
way ANOVA).  
 
When compared to HeLa cells (positive control for AIMP3 expression), RT4 (0.54 
+/- 0.02) and 253J (0.70 +/- 0.13) cells expressed the most AIMP3 with 
approximately five-fold amount of AIMP3 relative to HeLa (Figure 3.1B); the 
difference in expression between HeLa (0.12 +/- 0.01)  and RT4 was statistically 
significant (p=0.001, two-tailed T-test) and, the difference in expression between 
HeLa and 253J was also statistically significant (p=0.04, two-tailed T-test).  There 
was no significant difference in AIMP3 expression between RT4 and 253J (p=0.32, 
two-tailed T-test).   
 
Of the bladder cancer cell lines, T24 expressed the least amount of AIMP3 (0.21 +/- 
0.05).  This was not statistically different to AIMP3 expression by HeLa (p=0.21, 
two-tailed T-test).  In other words, both T24 and HeLa expressed the least amount of 
AIMP3 and were similar in terms of AIMP3 expression.  As explained above, RT4 
and 253J expressed the highest level of AIMP3 in the panel of cell lines and they 
were similar in terms of AIMP3 expression.  When T24 was compared against RT4 
and 253J, there was a significant difference relative to each (p=0.01 and p=0.04, 
respectively).  In the panel of cell lines, RT112 was intermediate in terms of AIMP3 
expression with an expression level (0.32 +/- 0.06) between the low-expressing cell 
lines (HeLa and T24) and the high-expressing cell lines (RT4 and 253J); however, 92 
 
there was no statistically significant difference when comparing RT112 against each 
of the other cell lines (Hela, p=0.07; T24, p=0.24; 253J, p=0.08; RT4, p=0.05).  
 
 
 
Figure 3.1A:   
 
                         HeLa                  T24        253J       RT112     RT4 
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Figure 3.1B:   
 
 
Figure 3.1:  Western blot analysis of AIMP3 expression in the bladder cancer cell lines 
and quantitation of expression. 
3.1A:  Western blot analysis of AIMP3 protein expression in T24, 253J, RT112 and RT4 
bladder cancer cell lines (with HeLa in Lane 1 used as the positive control for AIMP3).  
3.1B:  Quantitation of AIMP3 protein expression in T24, 253J, RT112 and RT4 bladder 
cancer cell lines relative to HeLa.   Quantitation for AIMP3 for each cell line was calculated 
as ratio of Actin.  The experiments were repeated independently three times.  The mean and 
standard error of means (SEM) (error bars) from the three experiments are represented.  
HeLa (0.12 +/- 0.01); T24 (0.21 +/- 0.05); 253J (0.70 +/- 0.13); RT112 (0.32 +/- 0.06); RT4 
(0.54 +/- 0.02).  ӿ indicates significant differences where: ӿ is p=0.001 (between HeLa and 
RT4), ӿӿ is p=0.01 (between T24 and 253J), ӿӿӿ is p=0.04 (between HeLa and 253J), and 
ӿӿӿӿ is p=0.04 (between T24 and RT4).  
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3.2.2  AIMP3 protein expression after irradiation 
Colony survival assays were performed to characterise the dose-response 
radiosensitivity characteristics of the cell lines used and to calculate their IC50 
values (Figure 3.2).  When T24 cells were irradiated (X rays) at their IC50 values, 
there was no significant increase in the level of AIMP3 protein expression out to 
120 hours following irradiation (Figures 3.3A and 3.3B).  When comparing the 
mean AIMP3 expression between the time-points (0 to 120 hours), there was no 
significant difference in the means in between the groups (p=0.37, F=1.18, one-
way ANOVA).  Relative to the reference time-point (untreated or 0 hours), where 
AIMP3 protein expression was 0.25 +/- 0.06 (mean and SEM), AIMP3 expression 
at 24 hours (0.30 +/- 0.10) was not significantly different (p=0.55, two-tailed T 
test).  Similarly, relative to the reference time-point of 0 hours, expressions at 48 
hours (0.43 +/- 0.08; p=0.57), 72 hours (0.53 +/- 0.11; p=0.38), 96 hours (0.52 +/- 
0.12; p=0.36) and, 120 hours (0.47 +/- 0.16; p=0.19) were not significantly 
different.  In short, in T24 cells, following irradiation at IC50 dose, there appeared 
to be a marginal increase in protein expression, particularly after 48 hours, but any 
increase or change in the level of expression was not statistically significant. 95 
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Figure 3.2:  Log-linear plot of percentage colony survival at a range of doses (0-5Gy) of 
irradiation in the panel of bladder cancer cell lines (T24, 253J, RT112 and RT4; with 
HeLa used as control).  Untreated (not irradiated) cells were used as reference (100% 
survival) to calculate the proportion of surviving colonies at each irradiation dose (1, 2, 3, 
4 and 5Gy).  IC50 value was taken as the dose of irradiation at which there was 50% 
colony survival compared to the reference point of no irradiation (0Gy).  The IC50 values 
were: RT4 (4.6Gy), T24 (3.9Gy), RT112 (2.9Gy), 253J (2.7Gy); and HeLa (3.4Gy). 
Three independent experiments were performed. 
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Figure 3.4:  Western blot analysis of AIMP3 expression in T24 cells following 
irradiation and quantitation of time-course changes in expression. 
Fig 3.4A:  Western blot analysis of AIMP3 protein expression in T24 cells following 
irradiation.  Cells were irradiated at the IC50 dose and lysates extracted at 24 hour 
intervals out to 120 hours. 
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Fig 3.4B  Relative change in AIMP3 protein expression from 24 to 120 hours compared 
to the reference time-point 0 (not irradiated) in T24 cells. There was no significant change 
in AIMP3 expression (mean +/- SEM) out to 120 hours. 
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3.3  Subcellular trafficking of AIMP3 following irradiation 
Immunofluorescence was performed to characterise the sub-cellular localisation of 
AIMP3 in the cell lines used.  Immunofluorescence demonstrated a pan-cellular 
distribution of AIMP3 protein within both the cytosolic and nuclear compartments 
(Figure 3.5).  However, there appeared to be an increased localisation of AIMP3 
protein in the nuclear compartment relative to the cytosolic compartment at 1 hour 
following irradiation (X rays at IC50 doses).  This finding, together with the finding 
that there was negligible increase in the amount of AIMP3 protein expression out to 
120 hours following irradiation, suggests that AIMP3 is likely translocated from the 
cytosolic compartment into the nuclear compartment at an early time-point (within 
hours) following irradiation presumably to take part in the DNA damage response 
(DDR) pathway within the nucleus, the site of DNA damage (Figure 3.5).  In 
addition, following the sub-lethal dose of irradiation (IC50 dose), there is increased 
transcription of AIMP3 which is significantly apparent after 72 hours. 
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Figure 3.5:  Confocal immunofluorescence images demonstrating subcellular localisation 
of AIMP3 in bladder cancer cells with (IR+) and without (IR-) irradiation (x600).  AIMP3 
was conjugated with FITC (green-yellow); cytoskeletal actin was stained with TRITC (red-
pink); nuclear staining was with DAPI (blue); and, merged images were acquired of the 
three. Following irradiation, there is increased AIMP3 staining corresponding to the nuclear 
compartment in the bladder cancer cell lines: (A) T24, (B) 253J, (C) RT112, (D) RT4.  
 
3.4  Clonogenic survival following siRNA knock-down of AIMP3 and 
treatment with irradiation 
Downregulation of AIMP3 protein expression was achieved using 5nM siRNA to 
AIMP3 and was compared to AIMP3 expression in untreated (culture media only) 
cells, cells treated with siRNA to GAPDH and cells treated with non-targeting, 
scrambled siRNA (Figure 3.6).  Time-course experiments demonstrated maximal 
downregulation between 48 to 72 hours following transfection with siRNA (Figures 
3.7A and 3.7B).  After 96 hours, there was gradual reconstitution of AIMP3 
expression. 
 
The earliest time-point of 48 hours was chosen as the optimal time-point, for 
functional studies interrogating the effects of AIMP3 downregulation on outcomes 
such as clonogenic survival following treatment with irradiation or chemotherapy, as 
cell-death and off-target effects of siRNA transfection were reasoned to be likely to 
be lower at an earlier time-point compared to later time-points such as 72 hours or 
96 hours.  Therefore, 48 hours following siRNA knockdown of AIMP3, cells were 
irradiated at their IC50 doses and their clonogenic survival measured at day 14 
(Figure 3.8).  Relative to those irradiated at their IC50 dose, there was an increase in 103 
 
the clonogenic survival of all cells when AIMP3 expression was reduced.  This 
increase in survival was statistically significant in T24 (p=0.03), RT112 (p=0.01) 
and RT4 cells (p=0.02).  In 253J cells, there was an increase in survival from 56% 
+/- 7% (irradiated at IC50 dose) to 61% +/- 15% (siRNA AIMP3 and irradiated at 
IC50 dose) but this increase was not significant (p=0.62).   
 
 
                       
                       
                             
                             
                             
 
Figure 3.6:  Western blot analysis of reduction in the expression of AIMP3 (lane 2) 72 hours 
after siRNA knockdown in T24 cells.  Negative controls are in Lane 1 (untreated cells) and 
Lane 4 (scrambled, non-targeting siRNA).  siRNA to GAPDH is the positive control in Lane 
3.  β-actin is also demonstrated as a loading control as GAPDH expression may have been 
altered in Lane 3 (siRNA to GAPDH). 
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Figure 3.7A   
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Figure 3.7B:   
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Figure 3.7:  Western blot and quantitation of siRNA knockdown of AIMP3 expression in 
T24 cells 
3.7A:  Time-course of AIMP3 expression following siRNA knockdown of AIMP3 at 5nM 
in T24 cells.  There is significant (>50%) reduction in the level of AIMP3 from 24 to 96 
hours following siRNA transfection. 
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3.7B:  Quantitation of change in AIMP3 protein expression at 24 hour intervals out to 120 
hours following siRNA transfection (reference time-point 0) in T24 cells.  There was 
approximately 80% reduction in AIMP3 expression at time-points 48 hours and 72 hours 
following siRNA transfection of AIMP3. By time-point 120 hours, there was 79% +/- 14% 
reconstitution of AIMP3 expression relative to time-point 0. 
 
 
 
 
 
Figure 3.8:  Colony survival following siRNA knockdown of AIMP3 and irradiation at 
IC50 value.  There is an increase in colony survival when AIMP3 is reduced (Lane 3) 
compared to when AIMP3 is present (Lane 2).  Lane 4 represents cells which have only 
been treated with the transfection media (-ve control) and Lane 1 represents cells plated at 
their optimal plating numbers but not irradiated (referenced as 100% for subsequent 
irradiation at IC50 dose).  
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3.5  Discussion of results 
The findings outlined above in this chapter demonstrate a number of points in 
relation to AIMP3 in the panel of cell lines used.  Firstly, AIMP3 protein expression, 
as measured by Western blot analyses, was constitutively different in the panel of 
cell lines used.  T24 and HeLa expressed significantly lower levels of AIMP3 
compared to RT4 and 253J; RT112 expressed intermediate levels in this spectrum.  
HeLa was used as a reported positive control cell line for the expression of AIMP3.  
In the panel of bladder cancer cell lines, T24 is considered by some to be the least 
differentiated (high grade) and it was notable that AIMP3 expression was the lowest 
in T24 relative to the other bladder cancer cell lines used.  This finding was in 
keeping with our preliminary finding that AIMP3 mRNA and protein expression 
was low in high-grade bladder cancer tissues compared to low-grade bladder cancer 
tissues.  These observations allude to the possibility that AIMP3 expression may be 
altered or reduced during bladder cancer pathogenesis; however, our findings do not 
provide unequivocal proof of this.  Further supportive evidence will be required to 
prove this. 
 
Secondly, the radiosensitivity dose-response characteristics of the cell lines were 
plotted using clonogenic survival assays as the functional readouts.  This allowed 
IC50 values to be calculated for the cell lines.  RT4 was the most radioresistant with 
an IC50 value of 4.6Gy and 253J was the most radiosensitive with an IC50 value of 
2.7Gy.  The IC50 values for the other cell lines were as follows: T24 (3.9Gy), RT112 
(2.9Gy), and HeLa (3.4Gy).   If radiosensitivity was dependent on AIMP3 expression 
levels, one would expect either a positive or negative correlation.  This was not the 107 
 
case.  Therefore, AIMP3 expression levels do not adequately explain the 
radiosensitivity characteristics of the cell lines. 
 
When the expression of AIMP3 protein following irradiation was measured in T24 
cells, time-course experiments demonstrated that AIMP3 levels did rise marginally 
after 48 hours suggesting that irradiation may have induced increased transcription 
of AIMP3.  However, the increase was not statistically significant.  Therefore, it 
cannot be said conclusively that irradiation induces increased transcription of 
AIMP3 in bladder cancer cell lines.  Certainly, similar experiments would need to be 
performed in all the bladder cancer cell lines used.  Consequently, it cannot be 
assumed that increased AIMP3 transcription following irradiation is one of the 
mechanism by which cells may respond to DNA damage. 
 
Instead, the immunofluorescence experiments suggest that, rather than increased 
transcription as a possible mechanism of DNA damage response following 
irradiation, sub-cellular translocation of AIMP3 may be a possible mechanism.  At 
one hour following irradiation, there appears to be increased staining of AIMP3 
corresponding to the nuclear compartment relative to the cytosolic compartment.  
This suggests that nuclear translocation of AIMP3 occurs as an “early event” 
following irradiation so that AIMP3 can take part in the DNA damage response 
pathway within the nucleus where DNA damage is occurring.  The 
immunofluorescence experiments above have not quantitated the extent to which the 
cytosolic to nuclear translocation occurred. This was largely due to technical 
difficulties such as cellular and subcellular damage upon irradiation, even at sub-
lethal IC50 doses, precluding accurate quantitations of fluorescence of different 108 
 
subcellular compartments.   However, a recent study has elegantly demonstrated that 
AIMP3 is anchored to methionyl-tRNA synthetase (MRS) in the cytosol but is 
released to translocate to the nucleus upon DNA damage for DNA repair (Kwon NH 
et al, 2011).   
 
As AIMP3 is a reported tumour suppressor, it was important to interrogate whether 
alterations in AIMP3 expression would lead to any change in tumourogenic 
functional outcomes following irradiation.  The hypothesis was that reduction in 
AIMP3 levels within the cell lines would lead to increased survival when exposed to 
DNA damaging stimuli such as irradiation.  AIMP3 levels were knocked-down with 
the lowest level of siRNA feasible (5nM siRNA) and irradiation performed at the 
earliest time-point where knockdown was maximal (48 hours) so as to minimise off-
target effects and toxicity of siRNA transfection.  All cell lines were exposed to their 
standardised IC50 doses of irradiation.  There was a significant increase in 
clonogenic survival following irradiation in all cell lines when AIMP3 was knocked 
down except for 253J.  This lends support to the notion that AIMP3 may be an 
important tumour suppressor in bladder cancer as the above observations suggest 
that dimunition in AIMP3 enables cancerous cells to survive significant exposure to 
DNA damaging agents such as ionising radiation.  With respect to 253J, it is not 
entirely clear why there was no significant difference in survival.  There was an 
increase in survival but the increase was not statistically significant.  One possible 
explanation is that the 253J cell colonies are less discrete (“fuzzy”) meaning that the 
standard errors whilst counting the colonies are liable to be higher.  Consequently, 
the confidence intervals of the errors between the comparisons overlap resulting in 
non-significance. 109 
 
 
The implication of these findings is that tumour cell survival in response to DNA 
damaging agents such as irradiation may be influenced by expression of AIMP3.  In 
the clinical setting, it may be possible to predict likelihood of responsiveness to 
radiotherapy by the level of AIMP3 expressed in the tumour.  This would in turn 
mean that it may be possible to individualise therapy for patients with bladder 
cancer, depending on the AIMP3 expression status of their tumours, by allowing 
them to receive radiotherapy in the knowledge that they would most likely respond 
favourably to it.  Thus, correct stratification of patients likely to respond to a 
particular type of treatment modality such as radiotherapy, chemotherapy or surgery 
might be achieved.  Such a stratified approach would help change the current 
paradigm of the management of organ-confined, muscle-invasive bladder cancer. 
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4  Chapter 4 
 
 
AIMP3 expression is predictive of survival in patients treated with radical 
radiotherapy for muscle-invasive disease 111 
 
 
4.1  Introduction to Chapter 4 
The in vitro findings discussed in the preceding chapter (Chapter 3) indicated that, at 
the cell line level using our panel of bladder cancer cell lines (T24, RT112, 253J and 
RT4), AIMP3 expression status was predictive of cell survival following irradiation.  
Specifically, when AIMP3 expression was reduced, by siRNA transfection, 
clonogenic survival in the bladder cancer cell lines was increased following 
irradiation at the respective IC50 doses for the cell types.  The implication of this was 
that the loss of expression of an important tumour suppressor gene such as AIMP3, 
during bladder cancer pathogenesis, may confer a survival advantage to the AIMP3-
deficient tumour cells by decreasing their radiosensitivity.  Conversely, in AIMP3-
proficient cells, where siRNA transfection was not carried out or where only 
scrambled, non-interfering siRNA transfection was performed, clonogenic cell 
survival was not altered following irradiation at the same IC50 dose for the cell type. 
 
Therefore, it was hypothesised that AIMP3 expression in bladder cancer tissues would 
be predictive of response to radiation treatment and may be prognostic for patient 
survival following radiotherapy.  The main objective was to test this hypothesis by 
correlating the expression of AIMP3 in cancer tissue cores, obtained from 217 
patients enrolled into the BCON radiotherapy trial (ISRCTN45938399), to clinical 
outcomes such as tumour status at 6 months and overall survival. 
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4.2  Characteristics of BCON patients stratified by AIMP3 status 
Table 2.5 summarises the clinico-pathologic demographics of all BCON patients 
tested in the current study.  The characteristics of the 217 patients, as stratified by 
their AIMP3 staining status, are summarised below in Table 4.1. 
Table 4.1: Characteristics of patients in the BCON trial stratified by AIMP3 status 
Demographics   All patients 
treated in 
BCON 
(n=326) 
All patients 
tested in 
current study 
(n=217)  
AIMP3 
negative  
 
(n=106)  
AIMP3 
positive  
 
(n= 111)  
P value  
  Number (percent) 
Age, years  
Median age  
Range  
 
74 
51-90 
  
74  
51-90  
  
75  
53-88  
  
74  
51-90  
  
0.06
 ʱ  
Sex  
Male  
Female  
 
260 (80) 
66 (20) 
  
174 (80)  
43 (20)  
  
83 (78)  
23 (22)  
  
91 (82)  
20 (18)  
0.497 
‡  
Stage  
1  
2  
3  
4  
 
30 (9) 
214 (66) 
68 (21) 
14 (4) 
  
22 (10) 
144 (66) 
41 (19) 
10 (5) 
  
11 (10) 
70 (66) 
20 (19) 
5 (5) 
  
11 (10) 
74 (67) 
21 (19) 
5 (4) 
 0.997 
‡ 
Grade  
2  
3  
 
46 (14) 
280 (86) 
  
33 (15) 
184 (85) 
  
19 (18) 
87 (82) 
  
14 (13) 
97 (87) 
  
0.345
 ‡  
Preceding Tumour  
No  
Yes  
 
276 (85) 
50 (15) 
  
186 (86) 
31 (14) 
  
87 (82) 
19 (18) 
  
99 (89) 
12 (11) 
  
0.174
 ‡  
Preceding Tumour 
treatment  
TURBT  
-Complete  
-Partial  
-Biopsy only  
-Unknown 
 
 
 
126 (39) 
100 (31) 
87 (26) 
13 (4) 
  
  
  
90 (42) 
66 (30) 
53 (24) 
8 (4) 
  
  
  
35 (33) 
36 (34) 
28 (26) 
7 (7) 
  
  
  
55 (50) 
30 (27) 
25 (22) 
1 (1) 
 0.405 
‡ 
BCON 
randomisation  
RT alone  
RT + CON  
 
 
163 (50) 
163 (50) 
  
 
113 (52) 
104 (48) 
  
 
58 (55) 
48 (45) 
  
 
55 (50) 
56 (50) 
0.446 
‡  
Hb, g/dL 
Median 
Range 
 
13.7 
9.3-17.2 
  
13.6 
9.3-17.2 
  
13.5 
9.3-17.2 
  
13.9 
9.8-17.0 
0.08 
ʱ 
 
Abbreviations: TURBT, transurethral resection of bladder tumour; RT, radiotherapy; CON, carbogen 
and nicotinamide; Hb, haemoglobin  
α Mann-Whitney U test  ‡ Fisher’s Exact Test 113 
 
4.3  AIMP3 immuno-staining in the BCON TMA set 
AIMP3 protein expression was variable in the tissue microarray (TMA) cores 
obtained from the 217 patients in the BCON trial set.  As described in the “Materials 
and Methods” section (2.13.2 “Immunohistochemistry Image Analysis”), TMA cores 
were assigned staining scores based on the proportion of cells staining positive and 
the intensity of staining in order to obtain a semi-quantitative H score.  TMA cores 
were stratified as positive or negative using a median H score cut-off.  Examples of 
AIMP3-negative and AIMP3-positive TMA cores are demonstrated below (Figure 
4.1). 
 
 
 
 
 
 
 
 
 
 
Figure 4.1:  Differential expression of AIMP3 protein in the BCON TMA cores 
demonstrating weak staining (Top panel) and strong staining (Bottom panel) (Left panel 
images10x magnification; expanded Right panel images 200x magnification).  The tissue core 
in the Top panel is classified as AIMP3-negative as there is weak staining (H score of 0.2 due 
to a weak staining score of 1 out of 3 in less than 50% of cells, i.e., 1 multiplied by 0.2) below 
the median H score of 1 (range of H score is 0 to 3).  The tissue core in the Bottom panel  is 
AIMP3-positive as it has strong AIMP3 staining (H score of 3 due to a staining strength score 
of 3 out of 3 in greater than 50% of cells, i.e., 3 multiplied by 1) above the median H score of 
1. 
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4.4  Intra-observer and Inter-observer agreements of immunostaining 
scoring 
The immunostaining measurements of the TMA cores were performed by different 
observers.  Where scorings were repeated by the same observer in different 
experiments, intra-observer agreements were obtained.  Inter-observer agreements 
could be evaluated when scorings from different observers were available. 
4.4.1  Intra-observer scoring 
The scoring, as AIMP3-positive and AIMP3-negative, for each of the 217 TMA 
cores, for the same observer, is tabulated in Table 4.2. 
 
Table 4.2:  Cross-tabulation of Intra-observer scores.  Cross-tabulation of AIMP3-positive 
(-) and AIMP3-negative scores (+) in experiments 1 (Expt 1) and 2 (Expt 2) for the same 
observer 
AIMP3Expt2 and AIMP3Expt1 Scores Cross-tabulation 
      AIMP3  
Expt1 
Total 
      Negative 
(-) 
Positive 
(+) 
AIMP3 
Expt2 
Negative 
(-) 
88  18  106 
Positive 
(+) 
20  91  111 
Total  108  109  217 
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The Kappa value was calculated for the above (Table 4.2) scores to measure the 
intra-observer agreement.  There was good intra-observer agreement as 
demonstrated by a Kappa value of 0.650 (p<0.001) – see Table 4.3 below. 
Table 4.3:  Cross-tabulation for Kappa value calculation in the intra-observer scores 
      Kappa
Value 
Standard Error    Significance 
Measure of Agreement 
(Kappa) 
  .650  .052    .000 
Number of cases  217       
 
 
4.4.2  Inter-observer scoring 
AIMP3 scorings between different observers are tabulated below in Table 4.4 and 
Table 4.5. 
 
Table 4.4:  Inter-observer cross-tabulation.  Cross-tabulation of Observer 1 (Expt 2) versus 
Observer 2  
AIMP3Expt2 * AIMP3Observer2 Scores Cross-tabulation 
      AIMP3 
 Observer 2 
Total 
      Negative 
(-) 
Positive 
(+) 
AIMP3 
Expt2 
Negative 
(-) 
67  39  106 
Positive 
(+) 
20  91  111 
Total  87  130  217 
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Kappa value calculation for the above (Table 4.3) scoring is tabulated below in 
Table 4.4.  There was good agreement (Kappa value of 0.450) between the different 
observers (p<0.001). 
 
Table 4.5:  Kappa value calculation for inter-observer (Table 4.3) scores 
      Kappa 
Value 
Standard 
Error 
  Significance 
Measure of 
Agreement (Kappa)  
  .454  .060    .000 
Number of cases  217       
 
 
Inter-observer scoring between Observer 2 (PCRC) and Observer 3 (ST) is tabulated 
in Table 4.6 below. 
 
Table 4.6:  Cross-tabulation of AIMP3-positive and AIMP3-negative scores between 
Observer 2 and Observer 3  
AIMP3Observer3 and AIMP3Observer2 Scores Cross-tabulation 
      AIMP3Observer2  Total 
      (AIMP3 
negative) 
(AIMP3 
positive) 
AIMP3Observer3  (AIMP3 
negative) 
70  23  93 
(AIMP3 
positive) 
17  107  124 
Total  87  130  217 
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Kappa value calculations for the above inter-observer scores (Table 4.5) are cross-
tabulated in Table 4.6 below.  There was good inter-observer agreement (Kappa 
value of 0.621) and this was significant (p<0.001). 
 
Table 4.7:  Cross-tabulation for Kappa value calculation between Observer 2 and Observer 
3  
      Kappa 
Value 
Standard 
Error 
  Significance 
Measure of 
Agreement 
(Kappa) 
  .621  .054    .000 
Number of  Cases  217       
 
 
4.5  AIMP3 expression status and Overall Survival in the BCON set 
4.5.1  Kaplan-Meier estimates of Survival 
Kaplan-Meier plot of Overall Survival (OS), stratified by AIMP3 staining status, is 
depicted below (Figure 4.2).  There was a significant difference in OS (p<0.001) 
with higher survival in the AIMP3-positive group compared to the AIMP3-negative 
group.  Table 4.7A outlines the distribution of cases stratified by AIMP3 status and 
Table 4.7B tabulates the log-rank estimates for the Kaplan-Meier plot in Figure 4.2.  
The estimates for the median survivals for the AIMP3-positive and AIMP3-negative 
groups are calculated in Table 4.7C.   
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Figure 4.2:  Kaplan-Meier plot of Overall Survival by AIMP3 staining status.  Survival is 
greater in the AIMP3-positive group (green survival curve) relative to the AIMP3-negative 
group (blue survival curve).  The numbers at risk, for each time-point interval (e.g. 0, 20, 40 
months) are tabulated below the figure. 
 
The calculations for the K-M estimates above are tabulated below in Table 4.7 (A, B 
and C).  As evident from the K-M plots, there was a significant difference in the 
median survival estimates between the AIMP3-positive and AIMP3-negative cases.  
In the AIMP3-positive group, median survival was 67.9 +/- 5.0 months (95% CI: 
58.0 to 77.8 months) compared to 21.5 +/- 3.0 months (95% CI: 15.7 to 27.3 
months) in the AIMP3-negative group (Table 4.7C).  The p value for this log rank 
estimate was <0.001 (Table 4.7B). 
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Table 4.7:  Case-processing summary, log-rank estimates and median survival estimates in 
the BCON set stratified by AIMP3 status 
Table 4.7A:  Case-processing summary for K-M calculations 
AIMP3 status  Total  Number of Events  Censored 
Number  Percentage 
Negative (-)  106  72  34  32.1% 
Positive (+)  111  54  57  51.4% 
Overall  217  126  91  41.9% 
 
Table 4.7B:  Log-rank of the K-M estimates and significance 
   Chi-
Square 
  Significance 
Log Rank (Mantel-Cox)           22.277    .000 
 
 
Table 4.7C:  Median survival estimates and 95% Confidence Intervals around the 
estimates stratified by AIMP3 staining status 
Means and Medians for Survival Time 
AIMP3 
Status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence 
Interval 
Estimate  Standard 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Negative   34.945  2.892  29.277  40.614  21.500  2.960  15.698  27.302 
Positive   57.301  2.967  51.487  63.116  67.900  5.043  58.015  77.785 
Overall  47.266  2.346  42.668  51.865  40.800  9.423  22.330  59.270 
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4.5.2  Univariate analysis by Cox proportional hazards method 
When univariate analysis was performed based on AIMP3 staining status (Table 
4.8), there was a 57% survival advantage (0.57 = 1 minus 0.43) in favour of those in 
the AIMP3-positive group compared to the AIMP3-negative group.  The 95% 
confidence interval around this estimate (0.430) ranged from 0.300 to 0.617.  This 
was statistically significant (p<0.001) 
 
Table 4.8:  Univariate Cox modelling by AIMP3 staining status 
Variable    Standard Error      Significance  Hazard 
Ratio 
(HR) 
95.0% CI for Hazard 
Ratio 
   Lower  Upper 
AIMP3    .184      .000  .430  .300  .617 
 
 
4.5.3  Multivariate analysis by Cox proportional Hazards method 
When multivariate analysis was performed, taking into account all the relevant 
clinic-pathologic variables, AIMP3 staining status was still a significant predictive 
factor for survival (Table 4.9).  AIMP3-positivity conferred a 47% survival 
advantage (1 minus 0.53); 95% CI: 0.358 to 0.784 (p<0.002). 
 
Age and tumour status at 6 months were also significantly predictive of overall 
survival.  For every year of increase in age, there was a 4% increase in the risk of 
death in this cohort (p=0.003). 
Table 4.9:  Multivariate modelling of AIMP3 staining status 121 
 
Variables in Cox modelling 
     Standard 
Error 
    Significance  Hazard 
Ratio (HR) 
95.0% CI for 
Hazard Ratio 
   Lower  Upper 
Randomisation     .197      .851  .964  .655  1.417 
Tumour recurrence    .246      .000  8.841  5.462  14.311 
Previous cancer    .254      .055  1.630  .990  2.683 
Hb    .197      .417  .174  .797  728 
Stage           .545       
Stage 1    .415      .247  1.617  .717  3.648 
Stage 2    .459      .664  1.220  .496  3.000 
Stage 3    .603      .414  1.636  .502  5.330 
Grade    .63      .847  1.052  .628  1.763 
TURBT           .873       
TURBT complete    .267      .615  1.144  .678  1.931 
TURBT partial    .252      .674  1.112  .678  1.823 
Gender    .241      .327  .790  .492  1.266 
Age    .013      .003  1.040  1.013  1.068 
AIMP3 status    .200      .001  .530  .358  .784 
 
 
4.6  AIMP3 expression status and Tumour Recurrence in the BCON set 
 
In terms of tumour recurrence, cystoscopic recurrence at 6 months conferred an 8.8-
fold increase in the risk of death (HR: 8.84; 95%CI: 5.5 to 14.3; p<0.001).  Figure 
4.3 depicts a K-M plot of differences in survival in those with recurrence compared 
to those without recurrence. 
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Figure 4.3:  Difference in survival comparing those with tumour recurrence at 6 months 
(red) against those with no recurrence at 6 months (black) 
 
When tumour recurrence status was evaluated against AIMP3 staining status, there 
was a significant difference in the likelihood of recurrent tumours also being 
AIMP3-negative (Table 4.10).  Of the 40 cases (out of 217) with tumour recurrence, 
30 were in the AIMP3-negative group and 10 were in the AIMP3-positive group.  
This difference was statistically significant (p<0.001). 
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Table 4.10:  Cross-tabulation of tumour recurrence and AIMP3-status 
Cystoscopic tumour 
recurrence status 
All patients 
 
Patients with 
AIMP3-negative 
tumours 
Patients with 
AIMP3-positive 
tumours 
p value 
    Number (percent)     
 
     No recurrence 
     Recurrence 
 
177 (82) 
40 (18) 
 
76 (35) 
30 (14) 
 
101 (47) 
10 (4) 
<0.001 
ʱ 
α Fisher’s Exact Test 
 
 
4.7  Discussion of results 
The main objectives of the work presented in this chapter were to analyse the BCON 
dataset in relation to AIMP3 immunostaining, analyse AIMP3 immunostaining on 
the BCON TMA cores and to correlate the immunostaining status with clinical 
outcomes on the dataset.  The distribution of the clinico-pathological characteristics 
of the patients in the BCON are summarised previously (Table 2.5).  In brief, of the 
217 patients, 174 were males (80%) and 43 (20%) females, with a median age of 74 
years (range: 55 to 90 years).  When analysing by AIMP3 staining status, these 
patients were stratified into 106 in the AIMP3-negative group and 111 in the 
AIMP3-positive group (Table 4.1).  When analysing the differences in the clinic-
pathological characteristics between the AIMP3-negative and AIMP3-positive 
groups, there were no statistically significant differences between the variables 
(Table 4.1). 
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The immuno-staining properties of AIMP3 in the TMA cores were as expected.  The 
AIMP3-negative cores had negligible staining in the cells (Figure 4.1).  In contrast, 
AIMP3-positive cores had unequivocal staining of both the nuclear and cytoplasmic 
compartments (Figure 4.1).  In the AIMP3-positive cores, there was no false-
positive staining of cellular membranes and extracellular matrix.  There were strong 
intra-observer and inter-observer agreements in the scorings (Tables 4.2 to 4.5).   
 
Survival analyses demonstrated a significant difference between the AIMP3-positive 
and AIMP3-negative groups in the BCON set.  Median survival in the AIMP3-
positive group was estimated at 67.9 +/- 5.0 months (95% CI: 58.0 to 77.8 months) 
and this was significantly higher than 21.5 +/- 3.0 (95% CI: 15.7 to 27.3 months) in 
the AIMP3-negative group (p<0.001).  On multivariate analysis, AIMP3-positivity 
conferred a 47% survival advantage (1 minus 0.53); 95% CI: 0.358 to 0.784 
(p<0.002).  Of the other variables, “Age” and “Tumour Status at 6 Months” were 
also significant on multivariate analysis (Table 4.9).  The hazard ratio for Age was 
1.04 (95% CI: 1.01 to 1.07) suggesting a 4% increased risk of death for every year 
increase in age (p=0.003).  The hazard ratio for “Tumour Status at 6 Months” was 
8.8 (95% CI: 5.5 to 14.3) suggesting an almost 9-fold increased risk of death if there 
was tumour recurrence at 6 months following radical radiotherapy in the BCON 
cohort (p<0.001).  Of those who had tumour recurrences (30 cases), significantly 
more were observed in the AIMP3-negative group (p<0.001).  The findings support 
the hypothesis that AIMP3 may be a significant predictor of clinical outcomes in 
patients who undergo radical radiotherapy for MIBC. 125 
 
 
 
5  Chapter 5 
 
 
AIMP3 expression is not prognostic of survival in patients who have 
undergone Radical Cystectomy 126 
 
 
5.1  Introduction to Chapter 5 
In the previous chapter (Chapter 4), immunostaining analyses of the BCON 
radiation trial TMA set demonstrated that AIMP3 expression is predictive of 
outcome in patients with MIBC who had undergone radical radiotherapy.  AIMP3 
staining status was significantly correlated to the risk of tumour recurrence and 
overall survival.  However, to answer the question whether AIMP3 was predictive of 
radiotherapy outcome or whether it was simply predictive of survival from MIBC in 
this cohort, it was necessary to interrogate AIMP3 staining in a “control” patient 
cohort with MIBC who had not been treated with radiotherapy.  The best “control” 
cohort would be one where patients with similar clinicopathologic characteristics 
were not exposed to any treatment.  However, to randomise MIBC patients to “no 
treatment” would be unethical and indeed, there is no such “control” cohort 
available.  Therefore, we used a cohort of patients with MIBC who had undergone 
radical cystectomy.  Radical cystectomy achieves survival benefit by a different 
mechanism to radical radiotherapy.  Whereas in radiotherapy the mechanism of 
tumour eradication involves exposure to ionising radiation and interference with the 
DDR pathway, radical surgery achieves tumour eradication by surgical excision of 
the whole organ (cystectomy) containing the tumour and surrounding lymph nodes 
(lymphadenectomy). 
 
A TMA comprising cores from 151 TURBT biopsies from patients who 
subsequently underwent radical cystectomy was obtained from the University of 
Southampton.  All cases were diagnosed and treated between January 2000 and 127 
 
January 2011.  Cases exposed to neoadjuvant chemotherapy, adjuvant chemotherapy 
or radiotherapy were excluded. 
 
5.2  Characteristics of patients in the Radical Cystectomy cohort 
The clinicopathologic characteristics of the radical cystectomy cohort, stratified by 
AIMP3 staining, are summarised below (Table 5.1). 
 
Table 5.1:  AIMP3 staining status in the Radical Cystectomy cohort 
   All patients 
(n=151) 
AIMP3 negative 
(n=94) 
Number (percent) 
AIMP3 positive 
(n=57) 
 
 
Age, years 
Median age 
range 
  
 
73 
33-87 
  
 
73 
33-87 
  
 
74 
47-86 
Sex 
Male 
Female 
  
118 (78) 
33 (22) 
  
71 (60) 
21 (64) 
  
47 (40) 
12 (36) 
Stage 
ӿ 
0 
is 
1 
2 
3 
4 
Node +ve 
  
7 (5) 
24 (16) 
8 (5) 
23 (15) 
58 (38) 
10 (7) 
21 (14) 
  
7 (100) 
9 (40) 
3 (40) 
14 (61) 
45 (78) 
5 (50) 
9 (43) 
 
0 (0) 
15 (60) 
5 (60) 
9 (39) 
13 (22) 
5 (50) 
12 (57) 
Grade 
¥ 
2 
3 
  
10 (7) 
120 (79) 
  
6 (60) 
70 (58) 
 
4 (40) 
50 (42) 
 
ӿ pathological staging from radical cystectomy; 0 (pT0): no residual tumour following 
previous TURBT; is (pTis or CIS): carcinoma in situ 
¥ does not include pT0 and cases which were exclusively pTis 
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5.3  AIMP3 immunostaining in the Radical Cystectomy cohort 
AIMP3 immunostaining was scored using the same methodology described for the 
BCON TMA set.  Examples of AIMP3-negative and AIMP3-positive TMA cores 
from the Radical Cystectomy set are shown below (Figure 5.1). 
 
 
Figure 5.1:  AIMP3-negative cores (top panel) and AIMP3-positive cores (bottom panel).  
Left panel cores are at 10X magnification and Right panel cores are at 200X magnification. 
 
5.4  Kaplan-Meier estimates of survival in the Radical Cystectomy cohort 
Survival estimates by Kaplan-Meier method demonstrated no significant difference 
in survival between the AIMP3-positive and AIMP3-negative cases in the Radical 
Cystectomy set (Figure 5.2). 
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Figure 5.2:  Kaplan-Meier plots for survival in the AIMP3-postive (green) and AIMP3-
negative (blue) groups 
 
5.5  Univariate analysis 
Univariate analysis of AIMP3 staining status in the Radical Cystectomy set (Table 
5.2) confirmed the above Kaplan-Meier estimated that AIMP3 is not predictive of 
survival outcome in this set (p=0.986). 
 
Table 5.2:  Univariate analysis of AIMP3 in the Radical Cystectomy set 
Variable    Standard 
Error 
    Significance  Hazard Ratio 
(HR) 
95.0% CI for 
Hazard Ratio 
   Lower  Upper 
AIMP3 status    .221      .986  1.004  .650  1.549 
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5.6  Multivariate analysis 
Multivariate analyses by Cox proportional hazards modelling, taking into account all 
relevant clinico-pathologic variables, confirmed that AIMP3 is not prognostic for 
survival in the Radical Cystectomy cohort.  The results are summarised below 
(Table 5.3).  The size effect for AIMP3 in this analysis was 0.91, equating to a 9% 
survival advantage in the AIMP3-positive group; however, this was not significant 
(p=0.702; 95% CI: 0.562 to 1.474). 
 
The statistically significant clinic-pathologic factors were Tumour Stage (p<0.001), 
Patient Age (p=0.045) and Patient Sex (p=0.046).  With respect to Tumour Stage, 
relative to those with Stage 1 disease (G3pT1), those who had Stage 4 disease 
(G3pT4) had a 5.756-fold increased risk of death (95% CI: 2.645 to 12.523; 
p<0.001).  With respect to Age, there was a 2.3% increased risk of death per year 
increase in a patient’s age (95% CI: 1.000 to 1.046; p=0.046).  With respect to Sex, 
there was a 77% increased risk of death for Male patients compared to Female 
patients (95%: 1.012 to 3.097; p=0.045). 
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Table 5.3: Multivariate analysis of AIMP3 staining status in the Radical Cystectomy 
cohort 
Variables in Cox modelling 
     Standard 
Error 
    Significance  Hazard 
Ratio (HR) 
95.0% CI for 
Hazard Ratio 
   Lower  Upper 
Stage          .000       
Stage 1    .420      .856  .927  .406  2.112 
Stage 2    .350      .005  2.685  1.353  5.329 
Stage 3    .505      .008  3.782  1.405  10.185 
Stage 4    .397      .000  5.756  2.645  12.523 
Grade          .996       
Grade 2    .899      .989  .988  .170  5.754 
Grade 3    .793     .957  .958  .203  4.528 
Gender    .285     .045  1.770  1.012  3.097 
Age    .011     .046  1.023  1.000  1.046 
AIMP3 
status 
  .246     .702  .910  .562  1.474 
 
 
5.7  Discussion of results 
The main objectives of the work presented in this chapter were to analyse the 
Radical Cystectomy dataset, analyse the immunostaining of the TMA cores and to 
correlate the immunostaining status to the clinical outcomes in the dataset.  With 
respect to the sample size of the dataset, a total of 64 cases were required to detect a 132 
 
50% difference (e.g. 40 months versus 30 months) in the survival between two 
groups (AIMP3-positive versus AIMP3-negative) with a power of 80% and a p-
value of 0.05.  The sample size of the Radical Cystectomy set was good with a 
cohort of 151 patients.  This compared to 217 patients in the BCON set and this 
meant that both the cohorts were similar in terms of sample size for adequately 
powered statistical analyses.   
 
The Radical Cystectomy set was obtained from within the UK which has advantages 
in terms of allowing a better comparison to the BCON cohort.  Firstly, the risk 
profile of a population within the same country for a particular disease (bladder 
cancer) is likely to have less variability than when comparing the risk profile of 
populations from different countries.  For instance, the demographics of bladder 
cancer in the UK are not comparable to Egypt.  There is a far higher incidence of 
schistosomiasis-related bladder cancer and a higher incidence of squamous cell-type 
bladder cancer in Egypt.  Secondly, the clinical management of a disease from the 
same country is likely to hold less variability.  National guidelines mean that 
clinicians in the UK are less likely to deviate from agreed standards.  Therefore, in 
terms of managing patients with organ-confined MIBC, clinicians in the UK would 
be expected to adopt similar practices.  Hence, selection of patients for radiotherapy 
or surgery would be expected to be reasonably similar throughout the UK.  In this 
respect, the BCON cohort selection is robust by virtue of strict criteria inherent in a 
large randomised clinical trial.  Ideally, the radical cystectomy cohort would also 
have been derived from a clinical trial set but this was not available.  In fact, the 
only clinical trial devised to randomise patients to either radical radiotherapy or 
radical cystectomy (SPARE trial: selective bladder preservation against radical 133 
 
excision trial) was unsuccessful (Huddart RA et al, 2010).  In the absence of such a 
trial cystectomy cohort, a large series from within the UK was felt to be a suitable 
“control set” to compare against the BCON “treatment set”.   
 
Another advantage of the radical cystectomy set used was that it was contemporary 
to the BCON series.  This allows for a better comparison for most of the reasons 
explained above - the disease demographics within the population and the clinical 
practices in managing the disease at a given period in time are likely to be less 
variable.  One criticism of the control set may be that a larger series could have been 
obtained by incorporating contemporary cohorts from multiple centres.  However, 
this task was beyond the scope of this current project.  In any case, the sample size 
of 151 was deemed adequately powered for statistical analyses. 
 
An important concern with the radical cystectomy set was to ensure that any 
confounding factors for radiotherapy effect would be minimised.  In this respect, 
patients who had undergone chemotherapy or radiotherapy either in the neoadjuvant, 
adjuvant or salvage setting were excluded from the radical cystectomy series.  For 
instance, cisplatin-based neoadjuvant chemotherapy prior to radical treatment was 
being increasingly introduced in the earlier part of the era of this series and is 
currently the established standard.  Similarly, patients who had had prior radical 
radiotherapy as the primary treatment and subsequently radical cystectomy as 
salvage treatment had to be excluded.  Also, patients who had had salvage 
radiotherapy following radical cystectomy or patients who had received adjuvant 
radiotherapy or chemotherapy had to be excluded.  Thus, by excluding any radical 134 
 
cystectomy patient who had had radiotherapy or chemotherapy, the confounding 
effects these DNA damaging modalities would have in terms of allowing a 
comparison with the BCON “treatment set” is minimised. 
 
When the characteristics of the patients in the radical cystectomy set (Table 5.1) are 
analysed, the clinic-pathological demographics are what would be expected of a 
large radical cystectomy series.  The median age was 73 years (range: 33 to 87 
years) in this series.  This compares to a median age of 74 years (range: 51 to 90 
years) in the BCON set (Table 2.5).  The female to male gender distribution was 
20% and 80% in the BCON set; this was 28% (females) and 72% (males) in the 
Radical Cystectomy set.  Therefore, both the BCON and Radical Cystectomy sets 
are similar in terms of Age and Gender distribution.  However, there was a 
difference with respect to the Stage distribution of the treated patients.  In the BCON 
set, 76% (166/217) of the tumours were Stage T2 or less (T0, Tis, T1, and T2 
inclusive were 62 out of the total sample size of 217).  In the Radical Cystectomy 
set, 41% (62/151) of the tumours were Stage T2 or less.  In other words, there were 
more tumours of higher Stages (T3, T4) in the Radical Cystectomy set compared to 
the BCON set.  This would be expected to translate to a relatively better survival 
outcome in the BCON set.  The estimated median survival of the Radical 
Cystectomy set was 49.0 +/- 9.9 months (95% CI: 29.6 to 68.4 months); this was 
greater than the estimated median survival in the BCON set which was 40.8 +/- 9.4 
months (95% CI: 22.3 to 59.3 months).  However, the difference in the median 
survival estimates between the two groups, taking into account the standard errors in 
the estimates and the 95% confidence intervals, was not statistically significant. 135 
 
 
In terms of assessing the potential prognostic value of AIMP3 staining status in the 
Radical Cystectomy set, it was important that there were no significant differences 
between the AIMP3-positive and AIMP3-negative groups as far as the distribution 
of clinic-pathological characteristics were concerned (Table 5.1).  There were 94 
patients in the AIMP3-negative group and 57 in the AIMP3-positive group.   The 
median ages in the two groups were similar – 73 years (range: 33 to 87 years) in the 
AIMP3-negative group compared to 74 years (range: 47 to 86 years) in the AIMP3-
positive group.  22% (21/94) were females in the AIMP3-negative group compared 
to 21% (12/57) in the AIMP3-positive group.  35% (33/94) patients in the AIMP3-
negative group had tumours which were Stage T2 or less compared to 51% (29/57) 
in the AIMP3-positive group. 
 
In the Radical Cystectomy set, there was no significant difference in survival 
between the AIMP3-negative and AIMP3-positive groups (Figure 5.2).  Univariate 
(Table 5.2) and multivariate (Table 5.3) confirmed this lack of significant 
difference in survival.  The findings indicate that AIMP3 status is not a prognostic 
factor for survival in patients with MIBC.  In fact, in conjunction with the findings 
of the previous chapter demonstrating that AIMP3 was predictive of survival in the 
BCON set, the lack of significance in survival difference in the “control” Radical 
Cystectomy set, suggests that AIMP3 is a predictive factor for radiotherapy 
response.  In other words, AIMP3 status is predictive of radiotherapy outcome as 
hypothesised rather than just being a prognostic factor of survival in all patients with 
organ-confined MIBC regardless of the radical treatment modality received. 136 
 
 
 
6  Chapter 6 
 
 
Immunostaining profiling of Mre11, ERCC1 and p53 in the BCON and 
Radical Cystectomy TMA sets 137 
 
 
6.1  Introduction to Chapter 6 
The previous two results chapters demonstrated that AIMP3 is a predictive factor for 
radiotherapy response and that it is not simply prognostic for survival in patients 
with bladder cancer; this was based on interrogation of both the BCON radiotherapy 
set and the control Radical Cystectomy set.  We wanted to investigate whether other 
biomarkers, which are reported to be predictive of radiotherapy outcome based on 
TMA immunostaining platforms used, could be interrogated on the BCON and 
Radical Cystectomy TMA sets.  This would help to ascertain the predictive and/or 
prognostic value of the tested biomarkers. 
 
Mre11 and ERCC1 were chosen as described previously.  p53 expression was also 
interrogated as p53 is reported to be an important prognostic factor for survival in 
many cancers including bladder.  In a radical cystectomy series including 243 
patients, nuclear accumulation of p53 was strongly correlated to decreased 
recurrence-free survival and overall survival (Esrig D et al, 1994).  In another series 
of 164 patients who had undergone radical cystectomy, p53 was demonstrated to be 
an independent predictor of tumour recurrence and overall survival (Chatterjee SJ et 
al, 2004).  However, others have argued that p53 expression may be significant in 
the pT1 disease subset of patients undergoing radical cystectomy in terms of 
stratifying the risk of disease recurrence and disease-specific mortality (Shariat SF et 
al, 2009).  Adding p53 status into a multi-marker model was also found to improve 
prognostication in a large series comprising 692 patients with locally-advanced, non-
metastatic bladder cancer (Shariat SF et al, 2010).  Furthermore, other studies have 138 
 
suggested that p53 expression may be predictive of clinical outcome following 
chemotherapy or radiotherapy for bladder cancer.  In a series of 82 consecutive 
patients undergoing combined-modality treatment, incorporating cisplatin-based 
systemic chemotherapy and radical radiotherapy, p53 expression was found to be 
significantly correlated with bladder-preservation and cancer-specific survival 
(Garcia del Muro X et al, 2004).  Similarly, another series of 96 patients undergoing 
cisplatin-based chemo-radiotherapy, demonstrated a significant correlation between 
p53 expression and both cancer-specific and cystectomy-free survival (Shinohara A 
et al, 2009).  However, p53 was not found to be a significant predictor of outcome in 
another series of 73 patients undergoing cisplatin-based chemo-radiotherapy as part 
of the Radiation Therapy Oncology Group trial (Chakravarti A et al, 2005).   
 
6.2  Mre11 expression 
Mre11 immunostaining was performed as described previously in the Materials & 
Methods section.  Whereas for AIMP3, a median H score was used as the cut-off 
threshold to stratify into AIMP3-positive and AIMP3-negative groups, a 25
th 
percentile threshold was used for Mre11 as described by Choudhury A et al. 
 
6.2.1  Mre11 expression in the BCON set 
Mre11 immunostaining in the BCON TMA cores is exemplified below (Figure 6.1).  
Mre11 staining was present only in the nucleus as expected. 
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Figure 6.1: Mre11 immunostaining in the BCON TMA cores.  Mre11-negative (Top 
panel) and Mre11-positive (Bottom panel) are demonstrated at 10x (Left panel) and 200x 
(Right panel) magnification. 
 
6.2.2  Mre11 expression in the Radical Cystectomy set 
Mre11 immunostaining in the Radical Cystectomy TMA cores is exemplified below 
(Figure 6.2). 
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Figure 6.2:  Mre11 expression in the Radical Cystectomy TMA cores.  Mre11-negative 
(Top panel) and Mre11-positive (Bottom panel) are demonstrated at 10x (Left panel) and 
200x (Right panel) magnification. 
 
6.2.3  Mre11 is predictive of radiotherapy outcome in the BCON set 
Kaplan-Meier estimates of survival outcome differences, between Mre11-positive 
and Mre11- negative groups, are demonstrated below.  Using the 25
th percentile cut-
off method, of Choudhury et al as explained above, there was a significant survival 
advantage in the Mre11-positive group compared to the Mre11-negative group.  The 
median survival in the Mre11-positive group was 53.6+/- 9.6 months (95% CI: 34.9 
to 72.3 months) as compared to 19.5 +/- 3.4 months (95% CI: 12.8 to 26.2 months) 
in the Mre11-negative group (Table 6.1B).  This difference was statistically 
significant (p=0.03) (Table 6.1C) and was evident in the Kaplan-Meier plots for the 
two groups (Figure 6.3).   
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Table 6.1: Case-processing summary (Table 6.1A), survival estimates (Table 6.1B) and log 
rank estimates (Table 6.1C) based on Mre11 immunostaining status in the BCON TMA set 
Table 6.1A: The distribution of Mre11-negative (-) and Mre11-positive (+) cases is 
tabulated below. 
 
 
 
 
 
Table 6.1B: The survival estimates for the Mre11-negative (-) and Mre11-positive (+) 
cases are tabulated below.  For the whole cohort (217 patients), the median survival was 
40.8 +/- 9.4 months (95% CI: 22.3 to 59.3 months). 
 
 
 
 
Mre11 status  Number  Number of 
Events 
Censored 
Number  Percent 
Mre11 (-)  35  23  12  34.3% 
Mre11 (+)  182  103  79  43.4% 
Overall  217  126  91  41.9% 
Means and Medians for Survival Time 
Mre11 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence 
Interval 
Estimate  Standard 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Mre11 
(-) 
35.676  5.223  25.439  45.913  19.500  3.430  12.777  26.223 
Mre11 
(+) 
49.102  2.507  44.188  54.016  53.600  9.549  34.884  72.316 
Overall  47.266  2.346  42.668  51.865  40.800  9.423  22.330  59.270 142 
 
Table 6.1C:  Log-rank of the K-M estimates and significance. The significance (p value) 
for the above survival estimates (Table 6.1B) is calculated at 0.03 meaning that there is a 
significant difference in survival between the Mre11-negative and Mre11-positive cases. 
 
 
 
 
 
 
 
 
 
Figure 6.3:  Kaplan-Meier plots for Mre11 staining status in the BCON set.  Mre11-
negative (blue) and Mre11-positive (green) cases suggesting a greater survival in the Mre11-
positive group; this is confirmed on the log rank estimates (see Table 6.1C) 
 
 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)  4.714    .030 143 
 
6.2.4  Univariate and multivariate modelling of Mre11 immunostaining and outcome in 
the BCON set 
Cox proportional hazards modelling demonstrated that Mre11 status, on univariate 
analysis, was a significant predictor of radiotherapy outcome in the BCON set 
(Table 6.2).  Mre11-positivity conferred a 39% (1 minus 0.61) survival advantage 
relative to those with Mre11-negative status (95% CI: 0.39 to 0.96; p=0.032). 
 
On multivariate analysis, with all clinical variables in the model, this statistical 
significance was lost (p=0.372) (Table 6.3).  Therefore, as opposed to AIMP3, 
where significance was retained on multivariate analysis, Mre11 status could not be 
confirmed as being significantly predictive of radiotherapy outcome in the BCON 
set. 
 
Table 6.2:  Univariate analysis of Mre11 immunostatining in the BCON set demonstrating 
significance (p=0.032). 
Variable 
     Standard 
Error 
    Significance  Hazard Ratio  95.0% CI for 
Hazard Ratio 
   Lower  Upper 
Mre11    .232      .032  .608  .386  .957 
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Table 6.3:  Multivariate analysis of Mre11 immunostaining in the BCON set 
demonstrating loss of significance (p=0.372) when the known clinic-pathological variables 
are input into the model. 
Variables in Cox modelling 
    Standard 
Error 
    Significance  Hazard Ratio  95.0% CI for Hazard 
Ratio 
  Lower  Upper 
Randomisation    .198      .758  .941  .638  1.387 
Tumour Recurrence    .246      .000  9.619  5.940  15.577 
Previous Cancer    .257      .056  1.632  .987  2.697 
Hb    .200      .344  1.208  .817  1.787 
Stage          .339       
Stage 1    .416      .202  1.701  .752  3.846 
Stage 2    .463      .771  1.145  .461  2.839 
Stage 3    .606      .391  1.681  .513  5.510 
Grade    .268      .779  1.078  .637  1.824 
TURBT          .828       
TURBT complete    .279      .553  1.180  .683  2.037 
TURBT partial    .253      .799  1.066  .649  1.751 
Gender    .240      .250  .759  .475  1.214 
Age    .013      .004  1.039  1.012  1.067 
Mre11 status    .262      .372  .791  .473  1.323 
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6.2.5  Mre11 immunostaining analyses using the median H score method 
To investigate whether Mre11 status may be predictive of outcome in the BCON set, 
the dataset was further interrogated using the median H score method as per AIMP3.  
Given that Mre11 status demonstrated significance, in the Kaplan-Meier method and 
also on Univariate analysis, which was subsequently lost on multivariate analysis, it 
was important to investigate whether there was truly a significant finding which was 
only lost due to the immunoscoring methodology used.  Hence, the decision to 
analyse additionally by using the median H score method too. 
 
Analyses of survival outcomes stratified by Mre11 status based on the median H-
score method is illustrated below (Figure 6.4).  In the Mre11-positive group, the 
median survival estimate was 53.6 months (95% CI: 32.2 to 79.9 months).  This was 
greater than the median survival estimate in the Mre11-negative group (33.9 months; 
95% CI: 7.2 to 60.6 months) (Table 6.4B).  Kaplan-Meier plots of the two groups 
suggested a difference which may be significant (Figure 6.4).  However, this 
difference was not statistically significant (p=0.254) (Table 6.4C).  This was 
confirmed on Cox analysis where the hazard ratio for Mre11 status was 0.815 (95% 
CI: 0.573 to 1.159; p=0.255) (Table 6.5). 
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Table 6.4:  Case-processing summary (Table 6.4A), survival estimates (Table 6.4B), and 
log rank estimates (Table 6.4C) for Mre11 immunostaining status as per the median H score 
method, in the BCON set, are tabulated below.  
Table 6.4A: The distribution of Mre11-negative (-) and Mre11-positive (+) cases is 
tabulated below. 
 
Mre11 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
Mre11 (-)  99  58  41  41.4% 
Mre11 (+)  118  68  50  42.4% 
Overall  217  126  91  41.9% 
 
 
Table 6.4B: The survival estimates for the Mre11-negative (-) an Mre11-positive (+) cases 
is tabulated below.  For the whole cohort (217 patients), the median survival is 40.80 +/- 
9.42 months (95% CI: 22.33 to 59.27 months). 
Means and Medians for Survival Time 
Mre11 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower Bound  Upper Bound  Lower Bound  Upper Bound 
Mre11 
(-) 
42.946  3.140  36.792  49.101  33.900  13.605  7.235  60.565 
Mre11 
(+) 
49.732  3.100  43.656  55.809  53.600  10.915  32.207  74.993 
Overall  47.266  2.346  42.668  51.865  40.800  9.423  22.330  59.270 
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Table 6.4C:  The significance (p value) for the above survival estimates (Table 6.4B) is 
calculated at 0.254 meaning that there is no significant difference in survival between the 
Mre11-negative and Mre11-positive cases (see Figure 6.4). 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)  1.302    .254 
 
 
 
Figure 6.4:  Kaplan-Meier plots for Mre11 staining status in the BCON set based on 
median H score method.  Mre11-negative (blue) and Mre11-positive (green) cases 
suggesting the possible trend of greater survival in the Mre11-positive group; however, this 
is not confirmed on the log rank estimates (see Table 6.3C) or univariate analysis (see Table 
6.4). 
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Table 6.5:  Univariate analysis of Mre11 status, by H score method, demonstrating lack of 
significant survival differences (p=0.255) in the BCON set. 
Variable 
    Standard Error      Significance  Hazard Ratio  95.0% CI for Hazard 
Ratio 
  Lower  Upper 
Mre11 status    .180      .255  .815  .573  1.159 
 
 
6.2.6  Mre11 status is not predictive of outcome in the Radical Cystectomy set 
Interrogation of Mre11 expression status in the BCON set demonstrated that Mre11 
status was not predictive of radiotherapy outcome.  In order to answer the question 
whether Mre11 status was prognostic of survival in patients with bladder cancer, as 
for AIMP3, the Radical Cystectomy “control” set was interrogated.  There was 
suggestion of a survival difference between the Mre11-negative and Mre11-positive 
groups but the difference narrowly missed statistical significance (p=0.063) (Table 
6.6C).  The estimated median survival in the Mre11-negative group was 63.00 +/- 
20.68 months (95% CI: 22.47 to 103.53 months) which was greater than that in the 
Mre11-positive group which was 35.00 +/- 10.71 months (95% CI: 14.01 to 55.99 
months) (Table 6.6B).  
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Table 6.6:  Case processing summary (Table 6.6A), median survival estimates (Table 
6.6B), and log rank estimates (Table 6.6C) for Mre11 expression status in the radical 
cystectomy set are tabulated below. 
Table 6.6A:  The distribution of Mre11-negative (-) and Mre11-positive (+) cases is 
tabulated below. 
Mre11 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
Mre11 (-)  90  48  42  46.7% 
Mre11 (+)  61  38  23  37.7% 
Overall  151  86  65  43.0% 
 
 
Table 6.6B:  The survival estimates for the Mre11-negative (-) an Mre11-positive (+) 
cases is tabulated below.  For the whole cohort (151 patients), the median survival is 49.00 
+/- 9.92 months (95% CI: 20.68 to 10.71 months). 
Means and Medians for Survival Time 
Mre11 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Mre11 
(-) 
72.096  6.434  59.485  84.706  63.000  20.678  22.471  103.529 
Mre11 
(+) 
47.349  5.643  36.288  58.410  35.000  10.710  14.009  55.991 
Overall  64.583  4.947  54.886  74.280  49.000  9.919  29.559  68.441 
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Table 6.5C:  The significance (p value) for the above survival estimates (Table 6.3B) is 
calculated at 0.063 meaning that there is no significant difference in survival between the 
Mre11-negative and Mre11-positive cases (Figure 6.5). 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           3.470    .063 
 
 
 
Figure 6.5:  Kaplan-Meier plots for Mre11 staining status in the Radical Cystectomy set.  
Mre11-negative (blue) and Mre11-positive (green) cases suggesting a likelihood of greater 
survival in the Mre11-positive group; however, this is not confirmed on the log rank 
estimates (Table 6.6C) or univariate analysis (Table 6.7). 
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Table 6.7:  Univariate analysis of Mre11 expression in the radical cystectomy set 
demonstrating that the difference in survival between groups is not significant (p=0.066). 
Variables  
    Standard 
Error 
    Significance  Hazard 
Ratio 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
Mre11 
status 
  .221      .066  1.500  .973  2.311 
 
 
6.3  ERCC1 expression 
ERCC1 immunostaining was performed as described previously in the Materials and 
methods section.  As with AIMP3, a median H score cut-off was used to stratify 
cases into ERCC1-positive and ERCC1-negative groups.  As expected, ERCC1 
immunostaining was exclusively nuclear. 
 
6.3.1  ERCC1 expression in the BCON set 
ERCC1 immunostaining in the BCON TMA cores is exemplified by the ERCC1-
negative and ERCC1-positive cores below (Figure 6.6). 
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Figure 6.6:  ERCC1 immunostaining in the BCON set.  ERCC1-negative (Top panel) and 
ERCC1-positive (Bottom panel) are demonstrated at 10x (Left panel) and 200x (Right 
panel) magnification. 
 
6.3.2  ERCC1 expression in the Radical Cystectomy set 
ERCC1 immunostaining in the Radical Cystectomy cores is exemplified by the 
ERCC1-negative and ERCC1-positive cores below (Figure 6.7). 
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Figure 6.7:  ERCC1 immunostaining in the Radical Cystectomy TMA cores.  ERCC1-
negative (Top panel) and ERCC1-positive (Bottom panel) are demonstrated at 10x (Left 
panel) and 200x (Right panel) magnification. 
 
6.3.3  ERCC1 is predictive of radiotherapy outcome in the BCON set 
ERCC1 immunostaining status was found to be strongly predictive of overall 
survival in the BCON set.  In contrast to AIMP3, where positivity conferred a 
survival advantage, ERCC1-negativity was strongly correlated with a survival 
advantage. 
 
The log rank estimates for the median survival in the ERCC1-negative group was 
72.4 months (95% CI: 64.8 to 80.0; p<0.001) (Table 6.8B).  This was significantly 
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greater than the ERCC1-positive group where the estimate was 22.9 months (95% 
CI: 16.5 to 29.4 months; p<0.001) (Table 6.8B). 
 
Table 6.8:  Case processing summary (Table 6.8A), median survival estimates (Table 
6.8B), and log rank estimates (Table 6.8C) for ERCC1 expression status in the BCON set 
are tabulated below. 
Table 6.8A:  The distribution of ERCC1-negative (-) and ERCC1-positive (+) cases is 
tabulated below. 
 
 
 
 
 
Table 6.8B:  The survival estimates for the ERCC1-negative (-) an ERCC1-positive (+) 
cases is tabulated below.  For the whole cohort (217 patients), the median survival is 40.80 
+/- 9.42 months (95% CI: 22.33 to 59.27 months). 
Means and Medians for Survival Time 
ERCC1 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence 
Interval 
Estimate  Standard 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
ERCC1 (-)  63.992  3.406  57.315  70.668  72.400  3.889  64.777  80.023 
ERCC1 (+)  34.536  2.651  29.340  39.732  22.900  3.293  16.446  29.354 
Overall  47.266  2.346  42.668  51.865  40.800  9.423  22.330  59.270 
 
ERCC1 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
ERCC1 (-)  93  34  59  63.4% 
ERCC1 (+)  124  92  32  25.8% 
Overall  217  126  91  41.9% 155 
 
Table 6.8C: The significance (p value) for the above survival estimates (Table 6.8B) is 
calculated at <0.001 meaning that there is a significant difference in survival between the 
ERCC1-negative and ERCC1-positive cases (see Figure 6.8). 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           38.07    .00 
 
 
 
Figure 6.8:  Kaplan-Meier plots for ERCC1 staining status in the BCON set.  ERCC1-
negative (blue) and ERCC1-positive (green) cases demonstrating a greater survival in the 
ERCC1-negative group.  This is confirmed on the log rank estimates (see Table 6.8C) and 
univariate analysis (see Table 6.9). 
6.3.4  Univariate analysis of ERCC1 in the BCON set 
The highly significant difference in the median survival estimates between the 
ERCC1-negative and ERCC1-positive groups was confirmed on Cox proportional 
hazards modelling.  On univariate analysis, the hazard ratio was 3.22 (95% CI: 2.17 156 
 
to 4.79) and this was highly significant (p<0.001) (Table 6.9).  This indicated that, 
relative to those who were ERCC1-negative, there was a 3.22-fold increased risk of 
death in those who were ERCC1-positive. 
 
Table 6.9:  Univariate analysis of ERCC1 expression in the BCON set demonstrating that 
the difference in survival between groups is significant (p<0.001).  The hazard ratio is 3.22 
(95% CI: 2.17 to 4.79) indicating a 3-fold risk of death in the ERCC1-positive group relative 
to the ERCC1-negative group. 
Variables 
    Standard 
Error 
    Significance  Hazard 
Ratio 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
ERCC1 status    .202     .000  3.224  2.169  4.791 
 
 
6.3.5  Multivariate analysis of ERCC1 in the BCON set 
When all clinical variables were input into the Cox model for multivariate analysis, 
ERCC1 status was found to retain statistical significance in the model (Table 6.10).  
This was similar to AIMP3 where significance was retained on multivariate analysis 
and different to Mre11, where significance found on univariate analysis was lost in a 
multivariate model. 
 
The hazard ratio on multivariate analysis (Table 6.10) was 3.15 (95% CI: 2.05 to 
4.84) which suggested that, relative to those in the ERCC1-negative group, those 157 
 
who were ERCC1-positive had a 3.15-fold increased risk of death and this was 
highly significant (p<0.001). 
 
Table 6.10:  Multivariate analysis for ERCC1 in the BCON set demonstrating that ERCC1 
status retains significance (p<0.001) when all other known clinic-pathological factors are 
input into the model.  The hazard ratio is 3.15 (95% CI: 2.05 to 4.84). 
Variables in Cox modelling 
    Standard Error      Significance  Hazard 
Ratio 
95.0% CI for 
Hazard Ratio 
  Lower  Upper 
ERCC1    .219      .000  3.147  2.047  4.839 
Age    .014      .024  1.031  1.004  1.059 
Gender    .238      .367  .807  .506  1.286 
TURBT          .330       
TURBT complete    .270      .501  1.199  .707  2.033 
TURBT partial    .249      .532  .856  .525  1.395 
Stage          .447       
Stage 1    .413      .154  1.801  .801  4.048 
Stage 2    .463      .465  1.402  .566  3.473 
Stage 3    .603      .368  1.719  .528  5.600 
Hb    .196      .615  1.104  .751  1.622 
Previous Cancer    .252      .063  1.598  .975  2.620 
Randomisation    .197      .699  .927  .631  1.363 
Tumour Recurrence    .254      .000  11.045  6.712  18.176 
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6.4  ERCC1 validation with intra- and inter-observer analyses 
As with AIMP3, it was necessary to test the validity of the observed significant 
findings for ERCC1, through repeated experiments, performed by both the primary 
observer as well as different observers.   
6.4.1  ERCC1: intra-observer 
The survival analyses from a different experiment, for the primary observer, are 
presented below.  In this experiment, the median survival estimate for the ERCC1-
negative group was 73.5 +/- 3.2 months (95% CI: 67.2 to 79.8 months) compared to 
21.5 +/- 3.0 months (95% CI: 15.5 to 27.5 months) in the ERCC1-positive group 
(Table 6.11B).  This difference was significant (p<0.001) (Table 6.11C).   The 
significant difference in survival between the groups is easily appreciable in the 
Kaplan-Meier survival plots for the two groups (Figure 6.9). 
 
Table 6.11:  Case processing summary (Table 6.11A), median survival estimates (Table 
6.11B), and log rank estimates (Table 6.11C) for ERCC1 expression status in the BCON set 
are tabulated below. 
Table 6.11A:   The distribution of ERCC1-negative (-) and ERCC1-positive (+) cases is 
tabulated below. 
ERCC1  Total 
Number 
Number of 
Events 
Censored 
Number  Percent 
ERCC1 (-)  94  33  61  64.9% 
ERCC1 (+)  123  93  30  24.4% 
Overall  217  126  91  41.9% 
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Table 6.11B:   The survival estimates for the ERCC1-negative (-) and ERCC1-positive (+) 
cases is tabulated below.  For the whole cohort (217 patients), the median survival is 40.80 
+/- 9.42 months (95% CI: 22.33 to 59.27 months). 
Means and Medians for Survival Time 
ERCC1 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower Bound  Upper Bound  Lower Bound  Upper Bound 
ERCC1 
(-) 
66.530  3.090  60.474  72.587  73.500  3.198  67.233  79.767 
ERCC1 
(+) 
32.109  2.581  27.050  37.169  21.500  3.042  15.537  27.463 
Overall  47.266  2.346  42.668  51.865  40.800  9.423  22.330  59.270 
 
 
Table 6.11C:   The significance (p value) for the above survival estimates (Table 6.11B) is 
calculated at <0.001 meaning that there is a significant difference in survival between the 
ERCC1-negative and ERCC1-positive cases (see Figure 6.9). 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           54.760    .000 
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Figure 6.9:   Kaplan-Meier plots for ERCC1 staining status in the BCON set: intra-
observer.  ERCC1-negative (blue) and ERCC1-positive (green) cases demonstrating a 
greater survival in the ERCC1-negative group.   
 
The significant difference in survival between the ERCC1-negative and ERCC1-
positive groups is confirmed on univariate analysis (Table 6.12).  The hazard ratio 
was 4.11 (95% CI: 2.75 to 6.16) indicating a 4-fold increased risk of death in the 
ERCC1-positive group relative to the ERCC1-negative group. 
 
Table 6.12:   Univariate analysis of ERCC1 expression in the BCON set demonstrating 
that the difference in survival between groups is significant (p<0.001).   
Variables  
    Standard Error      Significance  Hazard 
Ratio 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
ERCC1 status    .206      .000  4.113  2.747  6.156 
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When multivariate analysis was performed, the significance of ERCC1 status was 
maintained (Table 6.13).  The hazard ratio was calculated at 3.48 (95% CI: 2.23 to 
5.46) indicating a 3-fold increased risk of death in the ERCC1-positive group 
relative to the ERCC1-negative group.  The level of significance was maintained at 
p<0.001. 
 
Table 6.13:   Multivariate analysis for ERCC1 in the BCON set demonstrating that 
ERCC1 status retains significance (p<0.001) when all other known clinic-pathological 
factors are input into the model.   
Variables in Cox modelling 
    Standard 
Error 
    Significance  Hazard Ratio  95.0% CI for Hazard 
Ratio 
  Lower  Upper 
ERCC1 status    .229      .000  3.482  2.223  5.456 
Randomisation    .197      .912  .978  .665  1.440 
Tumour Recurrence    .253      .000  8.951  5.450  14.702 
Previous Cancer    .255      .020  1.807  1.096  2.979 
Hb    .199      .720  1.074  .727  1.588 
Stage          .594       
Stage 1    .412      .192  1.713  .763  3.844 
Stage 2    .466      .410  1.469  .589  3.664 
Stage 3    .599      .407  1.642  .508  5.310 
TURBT          .517       
TURBT complete    .267      .730  1.096  .649  1.851 
TURBT partial    .250      .519  .851  .522  1.389 
Gender    .241      .771  .932  .581  1.496 
Age    .014      .031  1.030  1.003  1.057 
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6.4.2  ERCC1: inter-observer 
 
Analyses of ERCC1 scoring for a different observer are presented below.  In this 
experiment, the median survival estimate for the ERCC1-negative group was 72.4 
+/- 9.6 months (95% CI: 53.6 to 91.2 months) compared to 27.0 +/- 3.8 months 
(95% CI: 19.5 to 34.5 months) in the ERCC1-positive group (Table 6.14B).  This 
difference was significant (p<0.001) (Table 6.14C).   The significant difference in 
survival between the groups is easily appreciable in the Kaplan-Meier survival plots 
for the two groups (Figure 6.10). 
 
Table 6.14:  Case processing summary (Table 6.14A), median survival estimates (Table 
6.14B), and log rank estimates (Table 6.14C) for ERCC1 expression status in the BCON set 
are tabulated below. 
Table 6.14A:   The distribution of ERCC1-negative (-) and ERCC1-positive (+) cases is 
tabulated below. 
ERCC1 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
ERCC1 (-)  106  47  59  55.7% 
ERCC1 (+)  111  79  32  28.8% 
Overall  217  126  91  41.9% 
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Table 6.14B:   The survival estimates for the ERCC1-negative (-) an ERCC1-positive (+) 
cases is tabulated below.  For the whole cohort (217 patients), the median survival is 40.80 
+/- 9.42 months (95% CI: 22.33 to 59.27 months). 
Means and Medians for Survival Time 
ERCC1 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower Bound  Upper Bound  Lower Bound  Upper Bound 
ERCC1 (-)  53.525  3.019  47.608  59.442  72.400  9.613  53.559  91.241 
ERCC1 (+)  39.349  3.012  33.446  45.252  27.000  3.839  19.476  34.524 
Overall  47.266  2.346  42.668  51.865  40.800  9.423  22.330  59.270 
 
 
Table 6.14C:   The significance (p value) for the above survival estimates (Table 6.10B) is 
calculated at <0.001 meaning that there is a significant difference in survival between the 
ERCC1-negative and ERCC1-positive cases (see Figure 6.10). 
 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)  13.058    .000 
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Figure 6.10:   Kaplan-Meier plots for ERCC1 staining status on the BCON set: inter-
observer.  ERCC1-negative (blue) and ERCC1-positive (green) cases demonstrating a 
greater survival in the ERCC1-negative group.   
 
The observed significant difference in survival between the ERCC1-negative and 
ERCC1-positive groups was confirmed on univariate analysis (Table 6.15).  The 
hazard ratio was 1.93 (95% CI: 1.34 to 2.78) indicating a 2-fold increased risk of 
death in the ERCC1-positive group relative to the ERCC1-negative group. 
 
Table 6.15:   Univariate analysis of ERCC1 expression in the BCON set: inter-observer.  
demonstrating that the difference in survival between groups is significant (p<0.001).   
Variables  
    Standard 
Error 
    Significance  Hazard Ratio  95.0% CI for Hazard 
Ratio 
  Lower  Upper 
ERCC1 status    .185      .000  1.931  1.343  2.777 
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On multivariate analysis, ERCC1 status maintained significance.   The hazard ratio 
was calculated at 1.79 (95% CI: 2.05 to 4.84) indicating an almost 2-fold increased 
risk of death in the ERCC1-positive group relative to the ERCC1-negative group.  
The level of significance was p<0.004. 
 
Table 6.16:   Multivariate analysis for ERCC1 in the BCON set: inter-observer. 
demonstrating that ERCC1 status retains significance (p<0.004) when all other known 
clinic-pathological factors are input into the model.   
Variables in Cox modelling 
    Standard 
Error 
    Significance  Hazard Ratio  95.0% CI for Hazard 
Ratio 
  Lower  Upper 
Randomisation    .197      .917  .980  .666  1.442 
Tumour Recurrence    .246      .000  10.000  6.178  16.187 
Previous Cancer    .255      .053  1.638  .994  2.699 
Hb    .197      .455  1.158  .788  1.703 
Stage          .394       
Stage 1    .414      .198  1.704  .757  3.836 
Stage 2    .464      .665  1.222  .493  3.032 
Stage 3    .604      .326  1.810  .554  5.918 
TURBT          .833       
TURBT 1    .270      .624  1.142  .672  1.938 
TURBT 2    .249      .965  1.011  .620  1.647 
Gender    .239      .394  .815  .510  1.304 
Age    .013      .005  1.038  1.011  1.066 
ERCC1 status    .198      .003  1.790  1.215  2.638 
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6.4.3  ERCC1: Kappa analyses 
Cross tabulations of the scores for the different experiments were performed to 
evaluate the level of agreement in the scoring between the experiments (Table 6.17, 
Table 6.19, Table 6.21).  As previously described, Kappa scores were calculated to 
quantitate the level of agreement (Table 6.18, Table 6.20, Table 6.22).  The 
crosstabulation comparisons were as follows: two different experiments 
(experiments 1 and 2) for the same primary observer 1 (Table 6.17 and Table 6.18); 
two different observers 1 and 2 (Table 6.19 and Table 6.20); and, two different 
observers 1 and 3 (Table 6.21 and Table 6.22). 
 
Table 6.17:  Kappa analyses - cross-tabulation of ERCC1-positive (+) and ERCC1-
negative scores (-) in experiments 1 (Expt 1) and 2 (Expt 2) for the same observer 
ERCC1Expt1 and ERCC1Expt2 Scores Cross-tabulation 
 
    ERCC1Expt2  Total 
    (-)  (+) 
ERCC1Expt1  (-)  82  12  94 
(+0  11  112  123 
Total  93  124  217 
 
 
The Kappa value was calculated for the above (Table 6.17) scores to measure the 
intra-observer agreement.  There was strong intra-observer agreement as 
demonstrated by a Kappa value of 0.784 and this was highly significant (p<0.001) 
(Table 6.18). 167 
 
 
Table 6.18:  Cross-tabulation for Kappa value calculation in the intra-observer scores 
    Kappa 
Value 
 Standard 
Error 
  Significance 
Measure of 
Agreement 
Kappa  .784  .043    .000 
Number of Cases  217       
 
 
When analysing the observations for Observer 1 against Observer 2 (Table 6.19), 
there was good inter-observer agreement as demonstrated by a Kappa value of 0.436 
(Table 6.20).  This was highly significant (p<0.001). 
 
Table 6.19:  Kappa analyses - cross-tabulation of ERCC1-positive (+) and ERCC1-
negative scores (-) in experiments in between different observers (Observer 1-Expt2 and 
Observer 2). 
ERCC1observer2 and ERCC1Expt2 Scores Cross-tabulation 
 
    ERCC1Expt2  Total 
    (-)  (+) 
ERCC1observer2  (-)  69  37  106 
(+)  24  87  111 
Total  93  124  217 
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Table 6.20:  Cross-tabulation for Kappa value calculation in the inter-observer (Observer 
1-Expt2 and Observer2-Expt2) scores 
    Value  Standard 
Error 
  Significance 
Measure of 
Agreement 
Kappa  .436  .061    .000 
Number of Cases  217       
 
 
When analysing the observations for Observer 1 against Observer 3 (Table 6.21), 
there was good inter-observer agreement with a Kappa value of 0.568 (Table 6.22).  
This was highly significant (p<0.001). 
 
Table 6.21:  Kappa analyses - cross-tabulation of ERCC1-positive (+) and ERCC1-
negative scores (-) in experiments in between different observers (Observer 1-Expt 2 and 
Observer 3). 
ERCC1observer2 and ERCC1Expt2 Scores Cross-tabulation 
Count 
    ERCC1Expt2  Total 
    (-)  (+) 
ERCC1observer3  (-)  71  24  95 
(+)  22  100  122 
Total  93  124  217 
 
 
 
 
 
Table 6.22:  Cross-tabulation for Kappa value calculation in the inter-observer (Observer 
1-Expt2 and Observer3) scores 169 
 
    Kappa 
Value 
Standard 
Error 
  Significance 
Measure of 
Agreement 
Kappa  .568  .056    .000 
Number of Cases  217       
 
 
 
6.4.4  ERCC1 may be predictive of outcome in the radical cystectomy set 
Interrogation of ERCC1 expression in the BCON set indicated that ERCC1 status 
was significantly predictive of radiotherapy outcome (Section 6.3).  In the BCON 
set, those who were ERCC1-positive were approximately 3-fold more likely to die 
following radiotherapy than those who were ERCC1-negative.  As for AIMP3, 
ERCC1 expression was interrogated in the Radical Cystectomy set in order to 
answer the question whether ERCC1 status was simply prognostic of survival in 
bladder cancer or whether it was truly predictive of radiotherapy outcome.   
 
Survival analyses in the Radical Cystectomy set, stratified by ERCC1 status, 
demonstrated that there was a difference in outcome.  The median survival estimate 
for those who were ERCC1-positive was 66.0 +/- 13.4 months (95% CI: 39.8 to 92.2 
months) compared to 37.0 +/- 9.3 (18.7 to 55.3 months) for those who were ERCC1-
negative (Table 6.23B).  Interestingly, as opposed to ERCC1-negativity conferring 
survival advantage in the BCON set, the opposite observation was true in the 
Radical Cystectomy set.  However, the difference in survival in the Radical 
Cystectomy set was just statistically significant with a p value of 0.049 (Table 
6.23C). 
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Table 6.23:  Case processing summary (Table 6.23A), median survival estimates (Table 
6.23B), and log rank estimates (Table 6.24C) for ERCC1 expression status in the Radical 
Cystectomy set are tabulated below. 
Table 6.23A:  The distribution of ERCC1-negative (-) and ERCC1-positive (+) cases is 
tabulated below. 
 
ERCC1 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
ERCC1 (-)  78  52  26  33.3% 
ERCC1 (+)  73  34  39  53.4% 
Overall  151  86  65  43.0% 
 
 
 
Table 6.23B:  The survival estimates for the ERCC1-negative (-) an ERCC1-positive (+) 
cases is tabulated below.  For the whole cohort (151 patients), the median survival is 49.00 
+/- 9.92 months (95% CI: 29.56 to 68.44 months). 
 
 
 
 
Means and Medians for Survival Time 
ERCC1 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
ERCC1 (-)  54.075  5.909  42.493  65.658  37.000  9.338  18.698  55.302 
ERCC1 (+)  75.216  7.496  60.525  89.907  66.000  13.371  39.792  92.208 
Overall  64.583  4.947  54.886  74.280  49.000  9.919  29.559  68.441 171 
 
Table 6.23C:  The significance (p value) for the above survival estimates (Table 6.23B) is 
calculated at 0.049 meaning that there is no significant difference in survival between the 
ERCC1-negative and ERCC1-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           3.881    .049 
 
 
The difference in survival between the ERCC1-positive group and the ERCC1-
negative group in the Radical Cystectomy set was also evident on the Kaplan-Meier 
plots (Figure 6.11).  The difference was narrowly statistically significant (p=0.049) 
(Table 6.23C). 
 
Figure 6.11:   Kaplan-Meier plots for ERCC1 staining status on the Radical Cystectomy 
set. There appears to be better survival in the ERCC1-positive group (green survival plot) 
than the ERCC1-negative group (blue survival plot). 
 
Univariate and multivariate analyses of ERCC1 status in the Radical Cystectomy set 
produced marginally conflicting results.  On univariate analysis, ERCC1 status 
narrowly missed statistical significance with a p value of 0.052 (Table 6.24).  This 172 
 
calculation was in agreement with the log-rank estimates (p =0.049) (Table 6.23C).  
However, on multivariate analysis, ERCC1 status was found to be statistically 
significant with a p value of 0.026 (Table 6.25).  The hazard ratio was 0.60 (95% 
CI: 0.38 to 0.94) indicating a 40% survival advantage in the ERCC1-positive group 
relative to the ERCC1-negative group. 
 
Table 6.24:   Univariate analysis of ERCC1 expression in the Radical Cystectomy set 
Variables in the Equation 
    Standard 
Error 
    Significance  Hazard Ratio 
(HR) 
95.0% CI for HR 
  Lower  Upper 
ERCC1 status    .221      .052  .651  .423  1.004 
 
Table 6.25:   Multivariate analysis of ERCC1 expression in the radical cystectomy set 
Variables in the Equation 
    Standard 
Error 
    Significance  Hazard 
Ratio (HR) 
95.0% CI for HR 
  Lower  Upper 
ERCC1 status    .229      .026  .601  .383  .942 
Age    .012      .025  1.026  1.003  1.050 
Sex    .295      .081  1.673  .938  2.983 
Grade          .991       
Grade 1    .931      .966  1.040  .168  6.452 
Grade 2    .832      .982  .982  .192  5.015 
Stage          .000       
Stage 1    1.032      .095  5.603  .741  42.365 
Stage 2    1.057      .090  6.005  .756  47.681 
Stage 3    1.016      .013  12.570  1.715  92.109 
Stage 4    1.113      .015  14.989  1.693  132.680 
Stage 5    1.033      .001  26.974  3.563  204.205 
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6.5  p53 expression 
p53 immunostaining was performed as described above in the Materials and 
Methods section.  The validated method of using a 10% cut-off as the threshold for 
assigning p53-positive or p53-negative core was used (Esrig D et al, 1994).  p53 
immunostaining was examined in both the BCON and Radical Cystectomy TMA 
sets.  As expected, p53 immunostaining was exclusively nuclear (Figure 6.12 and 
Figure 6.13). 
 
6.5.1  p53 expression in the BCON set 
Examples of p53 immunostaining in the BCON cores are demonstrated below 
(Figure 6.12). 
 
 
Figure 6.12:  p53 immunostaining in the BCON set.  Top panel shows p53-negative cores 
at 10x (Left panel) and 200x (Right panel) magnification.  Bottom panel shows a p53-
positive core at 10x (Left) and 200x (Right) magnification. 
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6.5.2  P53 expression in the Radical Cystectomy set 
 Examples of p53-positive and p53-negative cores in the Radical Cystectomy set are 
demonstrated below (Figure 6.13).   
 
 
Figure 6.13:  p53 immunostaining in the Radical Cystectomy TMA set. Top panel shows 
p53-negative cores at 10x (Left panel) and 200x (Right panel) magnification.  Bottom panel 
shows a p53-positive core at 10x (Left) and 200x (Right) magnification. 
 
6.5.3  P53 is not predictive of outcome in the BCON set 
Survival analyses in the BCON set, stratified by p53 staining status, demonstrated a 
difference in survival between the p53-positive and p53-negative groups.  The 
median survival estimate for those in the p53-positive group was 47.0 +/- 10.0 
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months (95% CI: 27.5 to 66.5 months) compared to 26.1 +/- 3.4 months (95% CI: 
19.4 to 32.8 months) for those in the p53-negative group (Table 6.26B).  This 
difference was appreciable in the Kaplan-Meier plots (Figure 6.14).  However, the 
difference was not statistically significant (p=0.103) (Table 6.26C). 
 
Table 6.26: Case processing summary (Table 6.26A), median survival estimates (Table 
6.26B), and log rank estimates (Table 6.26C) for p53 expression status in the BCON set are 
tabulated below.  
Table 6.26A:   The distribution of p53-negative (-) and p53-positive (+) cases is tabulated 
below. 
p53 status  Number  Number of 
Events 
Censored 
Number  Percent 
p53 (-)  63  41  22  34.9% 
p53 (+)  154  85  69  44.8% 
Overall  217  126  91  41.9% 
 
 
Table 6.26B:  The survival estimates for the p53-negative (-) and p53-positive (+) cases 
are tabulated below.  For the whole cohort (217 patients), the median survival is 40.80 +/- 
9.42 months (95% CI: 22.33 to 59.27 months). 
Means and Medians for Survival Time 
p53 
status 
Mean  Median 
Estimate  Standard
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower Bound  Upper Bound  Lower Bound  Upper Bound 
p53 (-)  40.352  3.802  32.900  47.804  26.100  3.401  19.434  32.766 
p53 (+)  49.680  2.815  44.161  55.198  47.000  9.966  27.467  66.533 
Overall  47.266  2.346  42.668  51.865  40.800  9.423  22.330  59.270 
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Table 6.26C:  The significance (p value) for the above survival estimates (Table 6.25B) is 
calculated at 0.103 meaning that there is no significant difference in survival between the 
p53-negative and p53-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           2.664    .103 
 
 
The suggestion of a difference in survival between the p53-positive and p53-
negative groups in the BCON set was appreciable in the Kaplan-Meier plots (Figure 
6.14).  However, the difference missed statistical significance with a p value of 
0.103 (Table 6.26C). 
 
Figure 6.14:   Kaplan-Meier plots for p53 staining status in the BCON set. Survival 
appears to be greater in the p53-positive group (green survival plot) compared to the p53-
negative group (blue survival plot). 177 
 
The absence of a statistically significant difference in survival between the p53-
positive and p53-negative groups in the BCON set was confirmed by univariate 
analysis (Table 6.27).  The hazard ratio was 0.73 (95% CI: 0.51 to 1.1) and the p 
value for this was 0.104. 
 
Table 6.27:   Univariate analysis of p53 expression in the BCON set 
Variables 
    Standard 
Error 
    Significance  Hazard Ratio 
(HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
p53 status    .191      .104  .734  .505  1.066 
 
 
6.5.4  P53 expression by the median H score method in the BCON set 
As there was a suggestion of a small difference in outcomes between the p53-
positive and p53-negative, an alternative analysis of staining status was performed 
using the median H score method, as for AIMP3 and ERCC1 (Table 6.28).  By this 
method, survival outcomes between the groups were also not significantly different.  
The estimated median survival in the p53-negative group was 37.7 +/- 13.1 months 
(95% CI: 12.0 to 63.4 months) compared to 44.6 +/- 10.1 months (95% CI: 24.9 to 
64.3 months) in the p53-positive group (Table 6.28B).  There was no difference in 
survival between the groups (p=0.775) (Table 6.28C).  In fact, the size effect of the 
difference in survival between the groups was far less pronounced for the median H 
score method; in other words, there was less difference between the groups when the 
H score method was used. 178 
 
Table 6.28:  Case-processing summary (Table 6.28A), survival estimates (Table 6.28B), 
and log rank estimates (Table 6.28C) for p53 immunostaining status, as per the median H 
score method, in the BCON set. 
Table 6.28A:   The distribution of p53-negative (-) and p53-positive (+) cases is tabulated 
below. 
p53 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
p53 (-)  129  77  52  40.3% 
p53 (+)  88  49  39  44.3% 
Overall  217  126  91  41.9% 
 
Table 6.28B:  The survival estimates for the p53-negative (-) and p53-positive (+) cases 
are tabulated below.  For the whole cohort (217 patients), the median survival is 40.80 +/- 
9.42 months (95% CI: 22.33 to 59.27 months). 
Means and Medians for Survival Time 
p53 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
p53 (-)  46.159  2.952  40.373  51.946  37.700  13.104  12.017  63.383 
p53 (+)  47.248  3.467  40.452  54.044  44.600  10.072  24.859  64.341 
Overall  47.266  2.346  42.668  51.865  40.800  9.423  22.330  59.270 
 
Table 6.28C:  The significance (p value) for the above survival estimates (Table 6.28B) is 
calculated at 0.775 meaning that there is no significant difference in survival between the 
p53-negative and p53-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)  .082    .775 
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The absence of difference in the survival outcomes between the p53-positive and 
p53-negative groups in the BCON set, analysed by the median H score method, was 
appreciable in the Kaplan-Meier plots for the two groups (Figure 6.15). 
 
 
Figure 6.15:   Kaplan-Meier plots for p53 staining status, by the median H score method, 
in the BCON set.  
 
Univariate analysis confirmed the observed lack of difference between the groups.  
The hazard ratio was 0.95 (95% CI: 0.66 to 1.36) with a p value of 0.775 (Table 
6.29). 
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Table 6.29:   Univariate analysis of p53 expression, by the median H score method, in the 
BCON set 
Variables  
    Standard Error      Significance  Hazard 
Ratio (HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
p53 status    .183      .775  .949  .662  1.360 
 
6.5.5  p53 expression in the radical cystectomy set 
In order to evaluate the prognostic value of p53 staining status, the Radical 
Cystectomy set was interrogated (Table 6.30).  There was a difference in the 
survival outcomes between the p53-positive and p53-negative groups in this set.  
The estimated median survival for the p53-negative group was 62.0 +/- 12.2 months 
(95% CI: 31.1 to 86.0 months) compared to 37.0 +/- 7.6 months (95% CI: 22.1 to 
51.9 months) for the p53-positive group (Table 6.30B).  However, the difference in 
survival was not statistically significant (Table 6.30C). 
 
Table 6.30:  Case-processing summary (Table 6.30A), survival estimates (Table 6.30B), 
and log rank estimates (Table 6.30C) for p53 immunostaining status in the Radical 
Cystectomy set 
Table 6.30A:   The distribution of p53-negative (-) and p53-positive (+) cases is tabulated 
below. 
p53 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
P53 (-)  73  36  37  50.7% 
P53 (+)  77  49  28  36.4% 
Overall  150  85  65  43.3% 
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Table 6.30B:  The survival estimates for the p53-negative (-) and p53-positive (+) cases 
are tabulated below.  For the whole cohort (150 patients), the median survival is 56.00 +/- 
10.43 months (95% CI: 35.55 to 76.45 months). 
Means and Medians for Survival Time 
p53 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
p53 (-)  69.448  6.717  56.283  82.613  62.000  12.221  38.047  85.953 
p53 (+)  57.199  6.414  44.628  69.769  37.000  7.584  22.136  51.864 
Overall  64.987  4.964  55.256  74.717  56.000  10.432  35.554  76.446 
 
 
Table 6.30C:  The significance (p value) for the above survival estimates (Table 6.29B) is 
calculated at 0.148 meaning that there is no significant difference in survival between the 
p53-negative and p53-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           2.093    .148 
 
 
The difference in survival between the p53-negative and p53-positive groups on the 
Radical Cystectomy set, suggested by the median estimates (Table 6.30B), was 
appreciable on the Kaplan-Meier plots for the groups (Figure 6.16).  However, the 
difference was not statistically significant (p=0.148) (Table 6.30C). 182 
 
 
Figure 6.16:   Kaplan-Meier plots for p53 staining status in the Radical Cystectomy set.  
Those in the p53-neagtive group (blue survival plot) appear to have greater survival 
compared to those in the p53-positive group (green survival plot). 
 
The absence of a significant difference in survival outcomes between the p53-
negative and p53-positive groups was confirmed on univariate analysis.  The hazard 
ratio was 1.37 (95% CI: 0.89 to 2.11) with a p value of 0.152 (Table 6.31). 
 
Table 6.31:   Univariate analysis of p53 expression in the Radical Cystectomy set 
Variables  
    Standard Error      Significance  Hazard 
Ratio 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
p53 status    .220      .152  1.370  .890  2.109 183 
 
 
6.6  Discussion of results 
The main objectives of the work outlined in this chapter were to evaluate the 
predictive or prognostic value of Mre11, ERCC1 and p53.  Therefore, these markers 
were interrogated on both the BCON radiotherapy set as well as the Radical 
Cystectomy set.   
 
Firstly, interrogation of Mre11status on the BCON set intially appeared to be 
significant.  In the BCON set, those in the Mre11-positive group had a greater 
survival compared to those in the Mre11-negative group.  This was observed on the 
Kaplan-Meier median survival estimates as well as on univariate anlysis with the 
level of significance calculated at p=0.03.  This finding was in agreement with the 
findings of Choudhury et al where Mre11 status was found to be significantly 
predictive of radiotherapy outcome.  Furthermore, in agreement with the findings of 
Choudhury et al, Mre11-positive patients were found to have greater survival 
relative to those in the Mre11-negative group.  However, on multivariate analysis of 
the BCON set, the difference in survival outcomes between the two groups was not 
found to be significant (p=0.37).  It is noteworthy that the levels of significance (p 
values), for the findings of Choudhury et al, were p=0.01 and p=0.02 for their test 
and validation sets, respectively.  When the findings of this chapter are analysed in 
the context of the findings of Choudhury et al, one of the conclusions that may be 
drawn is that Mre11 is indeed a predictive marker of radiotherapy outcome.  
However, the clinico-pathological demographics of the BCON set, being a clinical 
trial set, may be slightly different to the Choudhury et al radiotherapy series, and this 
may have led to the loss of significance on multivariate analysis of Mre11 in the 184 
 
BCON set when all the clinico-pathologic variables were input into the model for 
proportional hazards modelling.  It is unlikely that the loss of significance is due to 
an inadequate sample size in the BCON set, with 217 patients, given that the 
Choudhury et al series had 86 and 93 patients each in their test and validation 
radiotherapy sets, respectively.   
 
It was important to pose the question whether the immunoscoring methodology used 
may have influenced the outcomes; in other words, a potential significance was lost 
due to the 25
th percentile cutoff method used as per Choudhury et al.  Therefore, 
additional analyses were peformed for Mre11 using the median H score method as 
for AIMP3 previously.  However, the difference in survival between the groups was 
even less pronounced when using the median H score method lending credence to 
the validity of Choudhury et al’s 25
th percentile method to optimally assign patients 
into the Mre11-positive and Mre11-negative groups. 
 
Next, Mre11 status was interrogated on the Radical Cystectomy set in order to 
evaluate whether Mre11 was a prognostic factor for survival in patients with bladder 
cancer.  Interestingly, Mre11 status narrowly missed significance, on both Kaplan-
Meier estimates (p=0.06) and univariate anlysis (p=0.07), in terms of differentiating 
a survival difference between the groups.  Furthermore, as opposed to a greater 
survival in the Mre11-positive group in the BCON set, the converse was found to be 
the case in the Radical Cystectomy set.  In other words,  those in the Mre11-negative 
group, in the Radical Cystectomy set, had an improved survival.  These observations 
narrowly missed significance and therefore, strong conclusions cannot be drawn 185 
 
from them.  However, it is noteworthy that this finding, of Mre11-negativity 
conferring improved survival in the Radical Cystectomy set, was in agreement with 
Choudhury et al’s finding in their study.  Although not supported by statistically 
significant findings in the present study, there is a suggestion that Mre11 is a 
predictive marker of radiotherapy outcome and that it is not prognostic of survival in 
those with bladder cancer. 
 
Next, ERCC1 status was interrogated in the BCON set.  The findings suggested that 
ERCC1-negativity conferred a highly significant survival advantage in the BCON 
set.  Those in the ERCC1-positive group had an approximately 3-fold increased risk 
of death compared to those in the ERCC1-negative group.  The findings were highly 
significant (p<0.001).  The significance was maintained on multivariate analyses.  
The experiments were repeated for the same observer and compared with the scoring 
pattern of different observers.  The agreements in the scorings in between the same 
observer and different observers were also evaluated to ensure strong concordance in 
the measurements.  The level of significance was maintained for the survival 
analyses arising from the different observations for ERCC1 in the BCON set.  There 
were two obvious findings with respect to ERCC1 when compared to the findings of 
AIMP3 in the BCON set.  Firstly, ERCC1 was a stronger predictor of survival 
outcome than AIMP3.  This was based on the size effect of the findings.  Whereas 
for AIMP3, the survival advantage was approximately 47% (0.47) for one group 
relative to another, this was approximately 300% (3-fold) for ERCC1.  However, 
both findings were highly significant (p<0.001 for both).  Secondly, as opposed to 
AIMP3, where AIMP3-positivity conferred a survival advantage, the converse was 
true for ERCC1.  In the case of ERCC1, ERCC1-negativity conferred a survival 186 
 
advantage.  This finding was in agreement with validated reports from a large, multi-
national, randomised controlled trial confirming that ERCC1-negativity confers a 
survival advantage (Olaussen KA et al, 2006).  The findngs of Olaussen et al were 
in the context of lung cancer and the expanation provided for this observation was 
that tumours with reduced levels of ERCC1 were likely to have reduced capacity for 
repair of DNA damage leading in turn to reduced likelihood of survival of the 
tumours.  Consequently, this would result in better survival outcomes for the patients 
with the tumours.  Conversely, tumours with higher expression of ERCC1 (ERCC1-
positive) would have the capacity to repair DNA damage and survive thereby 
leading to poor survival outcome for the patients with such tumours.  The predictive 
value of ERCC1 in the context of radical radiotherapy for bladder cancer has not yet 
been reported.  However, Kawashima et al have reported that ERCC1 may predict 
the efficacy of chemoradiation therapy for muscle-invasive bladder cancer 
(Kawashima A et al, 2011).  The conclusions of Kawashima et al were based mainly 
on the basis of their in vitro assays interrogating siRNA knock-down of ERCC1 in 
bladder cancer cell lines; however, they did interrogate ERCC1 staining status on a 
small clinical set of 22 patients with organ-confined MIBC and found that ERCC1-
negativity was likely to confer a survival advantage. 
 
When ERCC1 was interrogated on the Radical Cystectomy set, some intriguing 
findings were observed.  Firstly, survival analyses appreared to indicate that 
ERCC1-positivity conferred a survival advantage (Table 6.23).  This was 
appreciable on the Kaplan-Meier plots for the two groups (Figure 6.11).  However, 
the log rank estimates (p=0.049) and univariate analysis (p=0.052) seemed to 
indicate that the difference in survival observed was not statistically significant.  187 
 
However, on multivariate analysis, ERCC1 status was found to retain statistical 
significance with a p value of 0.026 (Table 6.23).  The hazard ratio was 0.60 (95% 
CI: 0.38 to 0.94) indicating that not only was the difference significant but that there 
was a 40% survival advantage in the ERCC1-positive group relative to the ERCC1-
negative group.  The observation that ERCC1-positivity, rather than ERCC1-
negativity, conferred survival advantage in the Radical Cystectomy set suggests that 
ERCC1 is truly predictive of radiotherapy outcome rather than just being a 
prognostic marker of survival outcome in MIBC.  If ERCC1-negativity, as in the 
BCON set, had instead been found to have conferred survival advantage in the 
Radical Cystectomy set, it might have suggested that ERCC1 was only a prognostic 
factor of survival in MIBC. 
 
Survival analyses for p53 status in the BCON and Radical Cystectomy sets did not 
reveal any statistically significant findings.  In the BCON set, there was a non-
significant survival advantage in favour of the p53-positive group (p=0.103 and 
p=0.104 on log rank estimates and univariate analysis, respectively).  Additional 
survival analyses, by using the median H score method, did not demonstrate any 
statistically significant results (p=0.775).  In the Radical Cystectomy set, there was a 
non-significant survival advantage in favour of the p53-negative group (p=0.148).  
As the findings in both the BCON and Radical Cystectomy sets were clearly 
statistically non-significant, it would be reasonable to conclude that p53 is neither 
predictive of radiotherapy outcome nor prognostic of survival in bladder cancer. 
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7  Chapter 7 
 
 
Combinational modelling of AIMP3 and ERCC1 stratifies patients into 
groups with differential responses to radiotherapy 
 189 
 
 
7.1  Introduction to Chapter 7 
The previous chapters demonstrated that, amongst the molecular markers tested on 
the BCON and Radical Cystectomy sets, AIMP3 and ERCC1 predicted response to 
radiotherapy.  This was true of AIMP3 and ERCC1 when analysed separately by the 
Kaplan-Meier method and by univariate analysis or when analysed by multivariate 
analysis with the other clinic-pathological variables.  Mre11 was also predictive of 
radiotherapy outcome in the BCON set on Kaplan-Meier and univariate analysis but 
the statistical significance was marginal and was lost on multivariate analysis.   
 
The primary objective of this chapter was to identify whether a combination of the 
four markers could be used to improve the prediction of response to radiotherapy.  In 
order to explore this, the markers were input into a Cox proportional hazards 
combinational model in a step-wise fashion.  Step-wise entry into the model was 
interrogated by both the “forward” as well as “backward” methods where variables 
were either added into the model in the case of “forward” or removed step-wise from 
a combination of all variables in a “backward” manner, respectively.  The consistent 
finding was that only AIMP3 and ERCC1, in combination, improved prediction with  
statistical significance.  In other words, any combinational permutation which 
included Mre11 or p53 was found not to yield statistically significant outcomes 
when applied on the BCON set to interrogate survival outcomes. 
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7.2  AIMP3 and ERCC1 combination 
When AIMP3 and ERCC1 were combined, four possible permutations were 
obtained: (1) AIMP3-positive and ERCC1-negative (AIMP3+ERCC1-); (2) AIMP3-
negative and ERCC1-positive (AIMP3-ERCC1+); (3) AIMP3-positive and ERCC1-
positive (AIMP3+ERCC1+); and, (4) AIMP3-negative and ERCC1-positive 
(AIMP3-ERCC1+) (Table 7.1A).  Of these permutations, based on the findings of 
the previous chapters, the combination that would be expected to confer the highest 
survival advantage in the BCON set would be AIMP3+ERCC1- and that which 
would be expected to confer the lowest survival advantage would be AIMP3-
ERCC1+, respectively.  In terms of survival advantage, the sequence of 
combinations expected to predict survival, from highest survival to lowest, would be 
expected to be (1), (2), (3) and (4), respectively. 
 
7.2.1  Log rank and Kaplan-Meier estimates 
As hypothesised, the estimates of the median survival for the four combinations 
were in the sequence (1), (2), (3) and (4), respectively, where (1) had the highest 
median survival at 77.1 +/- 5.3 months (95% CI: 66.7 to 87.5 months) and (4) had 
the lowest median survival at 13.5 +/- 1.5 months (95% CI: 10.5 to 16.5 months) 
(Table 7.1B).  The estimated median survival for combination (2) was 62.2 +/- 7.5 
months (95% CI: 47.4 to 77.0 months) and that for combination (3) was 40.5 +/- 
13.0 months (95% CI: 15.1 to 66.0 months).  The differences between the groups 
was significant on the log rank estimates (p<0.001) (Table 7.1C).   
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Table 7.1:  Case-processing summary (Table 7.1A), survival estimates (Table 7.1B), and 
log rank estimates (Table 7.1C) for AIMP3 and ERCC1 combinations in the BCON set 
Table 7.1A:   The distribution of AIMP3+ERCC1- (1), AIMP3-ERCC1- (2), 
AIMP3+ERCC1+ (3) and AIMP3-ERCC1+ (4) cases is tabulated below. 
 
 
AIMP3 and ERCC1 
status 
 Number  Number of 
Events 
Censored 
Number  Percent 
1 (AIMP3+ERCC1-)  51  16  35  68.6% 
2 (AIMP3-ERCC1-)  42  18  24  57.1% 
3 (AIMP3+ERCC1+)  60  38  22  36.7% 
4 (AIMP3-ERCC1+)  64  54  10  15.6% 
Overall  217  126  91  41.9% 
 
Table 7.1B:  The survival estimates for the AIMP3-ERCC1 combinations are tabulated 
below.  For the whole cohort (217 patients), the median survival is 40.80 +/- 9.42 months 
(95% CI: 22.33 to 59.27 months) 
Means and Medians for Survival Time 
AIMP3 and 
ERCC1 status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower Bound  Upper Bound  Lower Bound  Upper Bound 
1  69.637  4.040  61.720  77.555  77.100  5.322  66.670  87.530 
2  52.908  4.280  44.519  61.297  62.200  7.535  47.430  76.970 
3  46.743  3.706  39.479  54.006  40.500  12.965  15.089  65.911 
4  22.473  2.924  16.741  28.205  13.500  1.511  10.538  16.462 
Overall  47.266  2.346  42.668  51.865  40.800  9.423  22.330  59.270 
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Table 7.1C:  The significance (p value) for the above survival estimates (Table 7.1B) is 
calculated at p<0.001 meaning that there is a significant difference in survival between the 
AIMP3 and ERCC1 combination of cases (see Figure 7.1). 
 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           78.554    .000 
 
 
The difference in survival outcomes between the four combinations was appreciable 
on the Kaplan-Meier plots (Figure 7.1).  Combination (1), depicted by the blue 
survival plot, had the highest survival followed by combination (2), depicted by the 
green survival plot, and then combination (3), depicted by the light-yellow survival 
plot.  Combination (4), depicted by the purple survival plot, had the lowest survival. 
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Figure 7.1:   Kaplan-Meier plots for the AIMP3 and ERCC1 combinations in the BCON 
set. Combination (1) is AIMP3+ERCC1- depicted in blue.  Combination (2) is AIMP3-
ERCC1- depicted in green.  Combination (3) is AIMP3+ERCC1+ depicted in light-yellow.  
Combination (4) is AIMP3-ERCC1+ depicted in purple.  Horizontal perforated line 
represents the median survival (50% cumulative survival) cut-off.  Vertical perforated line 
represents the 5-year (60 months) overall survival cut-off. 
 
The above Kaplan-Meier plot was analysed in Life Table format to ascertain the 
exact proportion of patients, in each combination, surviving at designated time 
intervals (Table 7.2).  For instance, at 12 months, 98% of patients in the 
combinations (1) and (2) were still alive compared to 88% and 55% of patients in 
the combinations (3) and (4), respectively.  In other words, 45% of patients had 194 
 
already died within one year in the worst prognostic combination (AIMP3-ERCC1+) 
compared to only 2% of patients in the best prognostic combination 
(AIMP3+ERCC1-).  Similarly, when looking at the 3-year (36 months) time interval, 
the cumulative survival was only 15% (i.e. 85% dead) in the worst prognostic 
combination (AIMP3-ERCC1+) compared to 76% cumulative survival (i.e. 24% 
dead) in the best prognostic combination (AIMP3+ERCC1-).  Likewise, when 
looking at the 5-year (60 months) time interval, the cumulative survival was 15% in 
the worst prognostic combination (AIMP3-ERCC1+) compared to 69% cumulative 
survival (i.e. 31% dead) in the best prognostic combination (AIMP3-ERCC1+).  
When comparing the best (AIMP3+ERCC1-) and worst (AIMP3-ERCC1+) 
prognostic groups, it was notable that, from both the Kaplan-Meier plots (Figure 
7.1) as well as the Life Table (Table 7.2), the median survival in the best prognostic 
group (AIMP3+ERCC1-) was more than 5 years whereas it was less than 2 years in 
the worst prognostic group (AIMP3-ERCC1+). 
Table 7.2:  Life table tabulation of the cumulative proportion of cases surviving at the end 
of each designated interval for the AIMP3-ERCC1 combinations in the BCON set. (1) 
AIMP3+ERCC1- (2) AIMP3-ERCC1- (3) AIMP3+ERCC1+ (4) AIMP3-ERCC1+ 
Life Table 
Statistics = Cumulative Proportion Surviving at End of Interval 
First-order Controls  Interval Start Time (months) 
0  12  24  36  48  60  72  84 
AIMP3 and 
ERCC1 status 
PN (1)  .98  .94  .84  .76  .74  .69  .34  .34 
NN (2)  .98  .76  .66  .63  .59  .41  .41   
PP (3)  .88  .75  .54  .48  .46  .30  .08   
NP (4)  .55  .25  .17  .15  .15  .15  .15   195 
 
 
7.2.2  Multivariate analysis 
When the four combinations were analysed in combination with all the known 
clinic-pathologic variables, there were statistically significant survival differences 
between the groups (Table 7.3).  When group (1) (AIMP3+ERCC1-) was compared 
to group (4) (AIMP3-ERCC1+), there was an approximate 6-fold difference in 
survival.  The hazard ratio for this comparison was 6.10 (95% CI: 3.27 to 11.29) 
indicating a 6.1-fold increased risk of death in group (4) (AIMP3-ERCC1+) 
compared to group (1) (AIMP3+ERCC1-).  This was statistically highly significant 
(p<0.001).  When group (1) (AIMP3+ERCC1-) was compared to group (3) 
(AIMP3+ERCC1+), there was an approximate 3-fold difference in survival.  The 
hazard ratio for the comparison was 3.05 (95% CI: 1.62 to 5.75) indicating a 3.1-fold 
increased risk of death in group (3) (AIMP3+ERCC1+) relative to group (1) 
(AIMP3+ERCC1-).  This comparison was also highly significant (p<0.002).  
However, there was no statistically significant difference when comparing the 
survival outcomes between group (1) (AIMP3+ERCC1-) and group (2) (AIMP3-
ERCC1-).  The hazard ratio for this comparison was 1.85 (95% CI: 0.90 to 3.81) and 
this was not significant (p=0.095).  Although direct comparisons between group (2) 
(AIMP3-ERCC1-) and group (3) (AIMP3+ERCC1+) could not be made on this 
modelling, the 95% confidence intervals for both hazard ratios overlapped; 
therefore, it was likely that the survival differences between the two groups was 
unlikely to be significant. 
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Table 7.3:  Multivariate analysis of AIMP3-ERCC1 combinations in the BCON set. For AIMP3-
ERCC1combinations: (1) AIMP3+ERCC1-, (2) AIMP3-ERCC1-, (3) AIMP3+ERCC1+, (4) AIMP3-
ERCC1+ 
Variables  
    Standard 
Error 
    Significance  Hazard Ratio 
(HR) 
95.0% CI for Hazard 
Ratio 
              Lower  Upper 
Randomisation    .196      .796  1.052  .716  1.546 
Tumour Recurrence    .261      .000  .105  .063  .175 
Previous Cancer    .251      .045  .605  .370  .989 
Hb    .195      .779  .947  .646  1.387 
Stage          .536       
Stage 1    .600      .367  .582  .180  1.885 
Stage 2    .469      .939  1.037  .413  2.601 
Stage 3    .517      .785  .868  .315  2.390 
TURBT          .707       
TURBT complete    .251      .744  1.085  .664  1.774 
TURBT partial    .233      .405  1.214  .769  1.917 
Gender    .243      .542  1.160  .720  1.869 
Age    .014      .023  1.032  1.004  1.060 
(1) AIMP3+ERCC1-          .000       
(2) AIMP3-ERCC1-    .368      .095  1.850  .899  3.807 
(3) AIMP+ERCC1-    .323      .001  3.052  1.621  5.745 
(4) AIMP3-ERCC1+    .319      .000  6.095  3.262  11.391 
 
 
 197 
 
 
7.3  Discussion of results 
In this chapter, step-wise modelling of the markers demonstrated AIMP3 and 
ERCC1 to be a compatible combination in order to discriminate radiotherapy 
outcome in the BCON set.  Mre11 and p53 were rejected from the combinational 
modelling as any permutation with their presence did not yield statistical 
significance to allow discrimination in survival outcomes.  In the panel of the four 
markers tested, ERCC1 was the strongest, in terms of predicting radiotherapy 
outcome in the BCON set, followed by AIMP3, Mre11 and p53.  p53 was not 
significant and Mre11 was significant but narrowly missed significance on 
multivariate analysis.  Ideally, a molecular selection panel would comprise of a 
number of markers, rather than just two (here, AIMP3 and ERCC1), so that the 
discriminatory power of any cases selected through such a panel would be greater.  
One of the limitations of the current study was that more markers were not evaluated 
on the BCON set.  However, the panel used in this study comprised of AIMP3, 
which had a sound in vitro basis from the initial work conducted in the study, as well 
as ERCC1, Mre11 and p53 which have been recently reported in the literature as 
having predictive value in the context of radiotherapy outcome in bladder cancer.  
Other markers, reported as predictors of radiotherapy outcomes, albeit in other 
cancers, could have been explored but that was beyond the scope of the current 
project due to limitations of time and resources. 
 
Allowing for the above points, what was noteworthy from the findings of this 
chapter was that a dual marker panel, comprising ERCC1 and AIMP3, was able to 
segregate the BCON set into four prognostic sub-groups such that there were 198 
 
significant differences in the radiotherapy survival outcomes between the groups.  
The best prognostic group (AIMP3+ERCC1-) had an approximate 6-fold reduced 
risk of death following radiotherapy compared to the worst prognostic group 
(AIMP3-ERCC1+).  The second-best prognostic group (AIMP3-ERCC1-) had an 
approximate 3-fold reduced risk of death following radiotherapy compared to the 
worst prognostic group (AIMP3-ERCC1+).  These findings were statistically highly 
significant (p<0.001 and p<0.002, respectively).   Looking at the actual estimates of 
survival duration, rather than the odds of survival described above, the median 
survival of the best prognostic group (AIMP3+ERCC1-) was approximately 77 
months.  This compared to 62 months in the second-best prognostic group (AIMP3-
ERCC1-) and only 14 months in the worst prognostic group (AIMP3-ERCC1+).  In 
other words, patients in the best prognostic group would be expected to live over 5 
years longer than those in the worst prognostic group.  These findings suggest that 
the dual panel of AIMP3 and ERCC1 is sufficiently discriminatory in selecting 
patients into good or poor radiotherapy outcome groups in the BCON set. 
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8  Chapter 8 
 
 
AIMP3 expression predicts response to cisplatin-exposure in vitro but 
AIMP3 and ERCC1 are not predictive of cisplatin-based chemotherapy 
outcome in the Neoadjuvant chemotherapy or the LaMB trial 
chemotherapy sets 
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8.1  Introduction to Chapter 8 
In Chapter 3, the functional impact of downregulation of AIMP3, through siRNA 
transfection, on radiation exposure outcome was explored.  In the panel of bladder 
cancer cells used (T24, 253J, RT112 and RT4; including HeLa as control), siRNA 
knockdown of AIMP3 resulted in an increase in the clonogenic survival following 
respective IC50 doses of irradiation of the cell lines.  The findings led to the 
hypothesis that AIMP3 expression status may be predictive of survival outcome in 
patients who had been treated with radical radiotherapy for bladder cancer.  This 
hypothesis was tested in the preceding chapters with the conclusion that, in the 
BCON set, AIMP3 and ERCC1 were significant predictors of survival. 
 
As discussed in the introductory chapter (Chapter 1, section 1.5), radical 
radiotherapy and radical cystectomy are the established curative treatment 
modalities for organ-confined muscle-invasive bladder cancer (MIBC).  Systemic 
chemotherapy alone cannot offer cure.  However, cisplatin-based chemotherapy, in 
the neoadjuvant setting, is increasingly being offered to patients with MIBC, prior to 
radical treatment (with either surgery or radiotherapy), as there is an improvement in 
survival.  In addition, organ-preservation strategies such as multi-modality 
treatment, that incorporate cisplatin-based systemic chemotherapy concurrently with 
radical radiotherapy, are also gaining popularity.  Furthermore, cisplatin-based 
systemic chemotherapy is the mainstay of management of metastatic bladder cancer 
where disease control and improved progression-free survival are the aims.  
However, not all patients respond well to cisplatin.  Any biomarker which could 201 
 
help select patients who are likely to respond to cisplatin treatment would help 
stratify patients into treatment algorithms.   
 
The primary objective of this chapter was to investigate whether downregulation of 
AIMP3 expression, by siRNA transfection, would influence cisplatin sensitivity in 
bladder cancer cell lines.  Cisplatin causes DNA damage by forming cisplatin-DNA 
adducts and, AIMP3, by virtue of its role in the DNA damage response pathway, can 
be hypothesised to mediate response to this.  The bladder cancer cell lines used were 
RT112 and RT112CP (Table 2.1).  As described previously (Chapter 2, section 
2.1), RT112CP is a cisplatin-resistant subline of RT112.  They were chosen as a 
panel to represent a spectrum of cisplatin-sensitive and cisplatin-resistant bladder 
cancer cell lines.  The methodology used, to investigate the primary objective of 
whether AIMP3 downregulation would influence cisplatin-response, was similar to 
the one used to investigate radiotherapy response (Chapter 3).  Firstly, the 
respective IC50 doses for RT112 and RT112CP were calculated by profiling their 
dose-response characteristics to cisplatin exposure.  Then, their respective 
clonogenic survivals, with or without (control with scrambled siRNA) siRNA 
knockdown of AIMP3, were measured following IC50 dose exposure to cisplatin.  
With controls for cisplatin exposure (transfection media without cisplatin), the 
differences in survival outcomes, by colony forming assays, were measured. 
 
The secondary objective of this chapter was to investigate the predictive value of 
AIMP3 and ERCC1 expression status on survival outcomes in the Neoadjuvant and 
LaMB sets.  As described previously (Chapter 2, sections 2.10 and 2.11), the 202 
 
Neoadjuvant and LaMB sets were collated to provide platforms, of patients treated 
with cisplatin-based systemic chemotherapy for bladder cancer, for analyses of 
clinical outcomes.  In the Neoadjuvant set, patients with organ-confined MIBC were 
administered cisplatin-based chemotherapy in the neoadjuvant setting.  In the LaMB 
set, patients with metastatic bladder cancer were administered cisplatin-based 
chemotherapy as a palliative measure in a trial setting.  As for the BCON and 
Radical Cystectomy sets, the methodology used was to stratify the clinical sets by 
AIMP3 and ERCC1 immunostaining status and to perform survival analyses to 
ascertain whether there was improved predictive performance of the markers in 
these sets. 
 
8.2  Cisplatin-sensitivity in RT112 and RT112CP cells 
Dose-response measurements to cisplatin exposure in RT112 and RT112CP cells 
confirmed that RT112CP was more resistant to cisplatin than RT112 (Figure 8.1).  
The IC50 value for RT112CP was calculated at 8.8 µg/mL and that for RT112 was 
1.6 µg/mL.  This meant that RT112CP was approximately 5.5-fold more resistant to 
cisplatin than RT112.  At the IC50 dose for RT112 (1.6 µg/mL), there was no effect 
on the clonogenic survival of RT112CP cells.  In other words, all RT112CP cells 
would be expected to survive at 1.6 µg/mL (Figure 8.1).  Similarly, it was also 
observed that exposure to the IC50 dose of cisplatin for RT11CP (8.8 µg/mL) would 
result in all RT112 cells to be exterminated. 
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Figure 8.1:  Dose-response to cisplatin in RT112 and RT112CP cell lines.  RT112 cells are 
more sensitive to cisplatin than RT112CP cells.  The results are based on 3 independent 
experiments.  In each experiment, cells were plated in triplicate dishes.  Values indicate the 
means and the error bars indicate the standard errors of the means. 
 
8.3  AIMP3 expression in RT112 and RT112CP  
Western blot analyses of AIMP3 expression were compared from lysates obtained 
from RT112 and RT112CP.  The rationale behind this was to explore whether 
differences in AIMP3 expression may provide an explanation for the differing 
cispatin chemosensitivity in these cell lines.  There was no significant difference in 
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the protein expression of AIMP3 between RT112 and RT112CP at differing loading 
doses of lysates (Figure 8.2).   
 
 
 
 
 
 
 
 
 
 
Figure 8.2:  Western blot comparison of AIMP3 expression in RT112 and RT112CP cells. 
Levels of AIMP3 protein expression are compared at lysate loading doses of 10µg, 20µg 
and 30µg. For comparison at each lysate loading dose, RT112 lysates are on the left panel 
and RT112CP on the right panel.  Experiments were repeated independently three times. 
 
8.4  AIMP3 knockdown and cisplatin-sensitivity 
In RT112, when comparing the cisplatin-sensitivity following siRNA knockdown of 
AIMP3, there was a significant difference between the treated and control groups 
(one-way ANOVA) (Figure 8.3).  Relative to the control groups (IC50 cisplatin; 
scrambled siRNA), there was a significant increase in clonogenic survival in the 
treated group (AIMP3 siRNA + IC50 cisplatin) in Experiment 2 (p=0.001) and 
Experiment 3 (p=0.007).  In Experiment 1, the difference was not statistically 
significant (p=0.066).   
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Figure 7.2:  
Figure 8.3:  Clonogenic survival in RT112 cells after siRNA knockdown of AIMP3 and 
IC50 cisplatin exposure.  The results for three independent experiments are presented.  The 
total surviving colony counts are presented in the y-axis.  For each experiment, four 
treatment groups are presented: (i) Untreated – no treatment with either cisplatin or siRNA, 
(ii) Cisplatin at IC50 – treatment with IC50 dose (1.6 µg/mL) of cisplatin, (iii) AIMP3 
siRNA + Cisplatin at IC50 – knockdown of AIMP3 with siRNA followed by treatment with 
IC50 dose (1.6 µg/mL) of cisplatin, (iv) Scrambled siRNA + Cisplatin at IC50 – treatment 
with non-targeting, scrambled siRNA followed by treatment with IC50 dose of cisplatin.      
ӿ (p=0.001); ӿ ӿ (p=0.007)  
 
In RT112CP, when comparing the cisplatin-sensitivity following siRNA knockdown 
of AIMP3, there was a significant difference between the groups (one-way 
ANOVA) (Figure 8.4).  Relative to the control groups (IC50 cisplatin; scrambled 
siRNA), there was a significant increase in clonogenic survival in the treatment 
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group (AIMP3 siRNA + IC50 cisplatin) in Experiment 1 (p=0.003) and Experiment 
2 (p=0.006).  In Experiment 3, the difference was not statistically significant 
(p=0.102).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4:  Clonogenic survival in RT112CP cells after siRNA knockdown of AIMP3 and 
IC50 cisplatin exposure.  The results for three independent experiments are presented.  The 
total surviving colony counts are presented in the y-axis.  For each experiment, four 
treatment groups are presented: (i) Untreated – no treatment with either cisplatin or siRNA, 
(ii) Cisplatin at IC50 – treatment with IC50 dose (8.8 µg/mL) of cisplatin, (iii) AIMP3 
siRNA + Cisplatin at IC50 – knockdown of AIMP3 with siRNA followed by treatment with 
IC50 dose (8.8 µg/mL) of cisplatin, (iv) Scrambled siRNA + Cisplatin at IC50 – treatment 
with non-targeting, scrambled siRNA followed by treatment with IC50 dose of cisplatin (8.8 
µg/mL).  ӿ (p=0.003); ӿ ӿ (p=0.006) 
 
Experiments
1 2 3
Surv
iv
ing Colonie
s
0
20
40
60
80
100
120
140
Untreated
Cisplatin at IC50
AIMP3 siRNA + Cisplatin at IC50
Scrambled siRNA + Cisplatin at IC50
ӿ 
ӿ ӿ 207 
 
 
8.5  AIMP3 and ERCC1 in the Neoadjuvant chemotherapy TMA set 
8.5.1  Patient characteristics and immuno-staining characteristics of the Neoadjuvant 
set 
The clinico-pathological characteristics of the Neoadjuvant set are previously 
summarised (Table 2.7).  In brief, there were a total of 84 patients; mean age was 66 
years (range: 35 to 82 years); 64 were males and 20 females.  Following neoadjuvant 
cisplatin-based chemotherapy, 46 patients (55%) underwent Radical Cystectomy 
compared to 38 patients (45%) who received Radical Radiotherapy. 
 
The immuno-staining characteristics of AIMP3, ERCC1, Mre11 and p53 are shown 
below (Figure 8.5). 
A 
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Figure 8.5:  Neoadjuvant set: Negative cores (top panel) and Positive cores (bottom 
panel).  Left panel cores are at 10X magnification and Right panel cores are at 200X 
magnification. (A) AIMP3, (B) ERCC1, (C) Mre11, (D) p53. 
 
8.5.2  AIMP3 in the Neoadjuvant set 
Kaplan-Meier analysis of the survival differences in the Neoadjuvant set, stratified 
by AIMP3 status, demonstrated no significant differences between the AIMP3-
positive and AIMP3-negative groups (Table 8.1).  The estimated median survival in 
the AIMP3-negative group was 62.0 +/- 12.2 months (95% CI: 38.0 to 86.0 months) 
compared to 51.0 +/- 8.1 months (95% CI: 35.2 to 66.8 months) (Table 8.1B).  This 210 
 
difference was not significant (p=0.660) (Table 8.1C).  The absence of a significant 
difference was appreciable on the Kaplan-Meier survival plots (Figure 8.6). 
 
Table 8.1: Case-processing summary (Table 8.1A), survival estimates (Table 8.1B) and log 
rank estimates (Table 8.1C) based on AIMP3 immunostaining status in the Neoadjuvant 
TMA set 
Table 8.1A: The distribution of AIMP3-negative (-) and AIMP3-positive (+) cases is 
tabulated below. 
AIMP3 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
AIMP3 (-)  46  22  24  52.2% 
AIMP3 (+)  38  18  20  52.6% 
Overall  84  40  44  52.4% 
 
Table 8.1B: The survival estimates for the AIMP3-negative (-) and AIMP3-positive (+) 
cases are tabulated below.  For the whole cohort (84 patients), the median survival was 53.0 
+/- 8.2 months (95% CI: 36.9 to 69.1 months). 
Means and Medians for Survival Time 
AIMP3 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
AIMP3 (+)  63.942  7.766  48.721  79.162  62.000  12.242  38.006  85.994 
AIMP3 (-)  61.263  9.474  42.694  79.832  51.000  8.051  35.220  66.780 
Overall  62.358  5.954  50.689  74.028  53.000  8.236  36.858  69.142 
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Table 8.1C:  Log-rank of the K-M estimates and significance. The significance (p value) 
for the above survival estimates (Table 8.1B) is calculated at 0.660 meaning that there is no 
significant difference in survival between the AIMP3-negative and AIMP3-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)  .194    .660 
 
 
 
Figure 8.6:   Kaplan-Meier plots for the AIMP3 in the Neoadjuvant set.  There is no 
difference in survival between the AIMP3-negative group (blue survival plot) and the 
AIMP3-positive group (green survival plot). 
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Univariate analysis confirmed the lack of significant difference in survival outcomes 
between the AIMP3-positive and AIMP3-negative groups (Table 8.2).  The hazard 
ratio was 1.15 (95% CI: 0.62 to 2.15) (p=0.663). 
 
Table 8.2:  Univariate analysis of AIMP3 in the Neoadjuvant set 
Variables  
    Standard 
Error 
    Significance  Hazard 
Ratio 
(HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
AIMP3 status    .319      .663  1.149  .615  2.148 
 
 
 
8.5.3  ERCC1 in the Neoadjuvant set 
Kaplan-Meier analysis of the survival differences in the Neoadjuvant set, stratified 
by ERCC1 status, demonstrated no significant differences between the ERCC1-
positive and ERCC1-negative groups (Table 8.3).  The estimated median survival in 
the ERCC1-negative group was 53.0 +/- 7.8 months (95% CI: 37.7 to 68.3 months) 
compared to 62.0 +/- 21.8 months (95% CI: 19.4 to 104.7 months) (Table 8.3B).  
This difference was not significant (p=0.304) (Table 8.3C).  The absence of a 
significant difference was appreciable on the Kaplan-Meier survival plots (Figure 
8.7). 
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Table 8.3: Case-processing summary (Table 8.3A), survival estimates (Table 8.3B) and log 
rank estimates (Table 8.3C) based on ERCC1 immunostaining status in the Neoadjuvant 
TMA set 
Table 8.3A: The distribution of ERCC1-negative (-) and ERCC1-positive (+) cases is 
tabulated below. 
ERCC1 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
ERCC1 (-)  49  26  23  46.9% 
ERCC1 (+)  35  14  21  60.0% 
Overall  84  40  44  52.4% 
 
 
 
Table 8.3B: The survival estimates for the ERCC1-negative (-) and ERCC1-positive (+) 
cases are tabulated below.  For the whole cohort (84 patients), the median survival was 53.0 
+/- 8.2 months (95% CI: 36.9 to 69.1 months). 
Means and Medians for Survival Time 
ERCC1 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower Bound  Upper Bound  Lower Bound  Upper Bound 
ERCC1 
(-) 
54.179  6.081  42.260  66.097  53.000  7.809  37.695  68.305 
ERCC1 
(+) 
73.402  9.679  54.430  92.373  62.000  21.758  19.354  104.646 
Overall  62.358  5.954  50.689  74.028  53.000  8.236  36.858  69.142 
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Table 8.3C:  Log-rank of the K-M estimates and significance. The significance (p value) 
for the above survival estimates (Table 8.3B) is calculated at 0.304 meaning that there is no 
significant difference in survival between the ERCC1-negative and ERCC1-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           1.058    .304 
 
 
 
 
 
Figure 8.7:   Kaplan-Meier plots for ERCC1 in the Neoadjuvant set.  There is no 
difference between the ERCC1-negative (blue survival plot) and ERCC1-positive 
(green survival plot) groups. 
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Univariate analysis confirmed the lack of significant difference in survival outcomes 
between the ERCC1-positive and ERCC1-negative groups (Table 8.4).  The hazard 
ratio was 0.71 (95% CI: 0.36 to 1.38) (p=0.310). 
 
Table 8.4:  Univariate analysis of ERCC1 in the Neoadjuvant set 
Variables  
    Standard 
Error 
    Significance  Hazard Ratio 
(HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
ERCC1 status    .341      .310  .708  .363  1.379 
 
 
 
8.5.4  Mre11 in the Neoadjuvant set 
Kaplan-Meier analysis of the survival differences in the Neoadjuvant set, stratified 
by Mre11 status, demonstrated no significant differences between the Mre11-
positive and Mre11-negative groups (Table 8.5).  The estimated median survival in 
the Mre11-negative group was 58.0 +/- 10.0 months (95% CI: 38.5 to 77.5 months) 
compared to 51.0 +/- 14.0 months (95% CI: 23.5 to 78.5 months) (Table 8.5B).  
This difference was not significant (p=0.400) (Table 8.5C).  The absence of a 
significant difference was appreciable on the Kaplan-Meier survival plots (Figure 
8.8). 
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Table 8.5: Case-processing summary (Table 8.5A), survival estimates (Table 8.5B) and log 
rank estimates (Table 8.5C) based on Mre11 immunostaining status in the Neoadjuvant 
TMA set 
Table 8.5A: The distribution of Mre11-negative (-) and Mre11-positive (+) cases is 
tabulated below. 
Mre11 status  Number  Number of 
Events 
Censored 
Number  Percent 
Mre11 (-)  28  13  15  53.6% 
Mre11 (+)  56  27  29  51.8% 
Overall  84  40  44  52.4% 
 
 
Table 8.5B: The survival estimates for the Mre11-negative (-) and Mre11-positive (+) 
cases are tabulated below.  For the whole cohort (84 patients), the median survival was 53.0 
+/- 8.2 months (95% CI: 36.9 to 69.1 months). 
Means and Medians for Survival Time 
Mre11 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Mre11 
(-) 
68.929  9.927  49.473  88.386  58.000  9.949  38.501  77.499 
Mre11 
(+) 
56.380  6.489  43.661  69.099  51.000  14.008  23.543  78.457 
Overall  62.358  5.954  50.689  74.028  53.000  8.236  36.858  69.142 
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Table 8.5C:  Log-rank of the K-M estimates and significance. The significance (p value) 
for the above survival estimates (Table 8.5B) is calculated at 0.03 meaning that there is a 
significant difference in survival between the Mre11-negative and Mre11-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           .708    .400 
 
 
 
 
Figure 8.8:   Kaplan-Meier plots for the Mre11 in the Neoadjuvant set.  There is no 
significant difference between the Mre11-negative group (blue survival plot) and the Mre11-
positive group (green survival plot). 
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Univariate analysis confirmed the lack of significant difference in survival outcomes 
between the AIMP3-positive and AIMP3-negative groups (Table 8.6).  The hazard 
ratio was 1.34 (95% CI: 0.68 to 2.64) (p=0.405). 
 
Table 8.6:  Univariate analysis of Mre11 in the Neoadjuvant set 
Variables 
    Standard 
Error 
    Significance  Hazard Ratio 
(HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
Mre11 status    .348      .405  1.335  .676  2.639 
 
 
 
8.5.5  p53 in the Neoadjuvant set 
Kaplan-Meier analysis of the survival differences in the Neoadjuvant set, stratified 
by p53 status, demonstrated a significant difference between the p53-positive and 
p53-negative groups (Table 8.7).  The estimated median survival in the p53-
negative group was 38.0 +/- 14.1 months (95% CI: 10.4 to 65.6 months) compared 
to 74.0 +/- 9.5 months (95% CI: 55.4 to 90.7 months) (Table 8.7B).  This difference 
was statistically significant (p=0.016) (Table 8.7C).  The presence of a probable 
significant difference was appreciable on the Kaplan-Meier survival plots (Figure 
8.9). 
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Table 8.7: Case-processing summary (Table 8.7A), survival estimates (Table 8.7B) and log 
rank estimates (Table 8.7C) based on p53 immunostaining status in the Neoadjuvant TMA 
set 
Table 8.7A: The distribution of p53-negative (-) and p53-positive (+) cases is tabulated 
below. 
p53 status  Number  Number of 
Events 
Censored 
Number  Percent 
p53 (-)  34  18  16  47.1% 
p53 (+)  50  22  28  56.0% 
Overall  84  40  44  52.4% 
 
 
Table 8.7B: The survival estimates for the p53-negative (-) and p53-positive (+) cases are 
tabulated below.  For the whole cohort (84 patients), the median survival was 53.0 +/- 8.2 
months (95% CI: 36.9 to 69.1 months). 
Means and Medians for Survival Time 
p53 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
p53 (-)  44.971  8.796  27.731  62.210  38.000  14.075  10.414  65.586 
p53 (+)  70.656  7.309  56.330  84.982  74.000  9.515  55.351  92.649 
Overall  62.358  5.954  50.689  74.028  53.000  8.236  36.858  69.142 
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Table 8.7C:  Log-rank of the K-M estimates and significance. The significance (p value) 
for the above survival estimates (Table 8.7B) is calculated at 0.016 meaning that there is a 
significant difference in survival between the p53-negative and p53-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           5.810    .016 
 
 
 
 
Figure 8.9:   Kaplan-Meier plots for p53 in the Neoadjuvant set.  There appears to be a 
significant difference between the p53-positive group (green survival plot) and the p53-
neagtive group (blue survival plot). 
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Univariate analysis confirmed the above findings that there was a significant 
difference in survival between the p53-negative and p53-positive groups (Table 
8.8).  The hazard ratio was 0.46 (95% CI: 0.24 to 0.88) indicating that there was a 
64% (1 minus 46) survival advantage in the p53-positive group relative to the p53-
negative group.  The statistical significance was maintained (p=0.019). 
 
Table 8.8:  Univariate analysis of p53 in the Neoadjuvant set 
Variables  
    Standard 
Error 
    Significance  Hazard 
Ratio (HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
p53 status    .336      .019  .456  .236  .880 
 
 
 
8.5.6  Multivariate analysis in the Neoadjuvant set 
Multivariate analysis was performed to investigate whether p53 status retained 
statistical significance with all other variables included in the analysis (Table 8.9).  
p53 status narrowly missed statistical significance (p=0.051).  The hazard ratio for 
p53 was 0.51 (95% CI: 0.26 to 1.00); the inclusion of 1 in the upper limit of the 
confidence interval denoted non-significance.   
 
The only variable to demonstrate statistical significance was “pT0” status.  The 
hazard ratio was 4.01 (95% CI: 1.58 to 10.17) (p=0.003) suggesting a 4-fold 
increased risk of death in the “pT0”-positive group.  In other words, in those who 222 
 
had persistence of tumour post-treatment (either cystectomy or radiotherapy), there 
was a 4-fold increased risk of death.   There was no significant difference in survival 
between radical treatment modalities (surgery or radiotherapy) (p=0.321). 
 
Table 8.9:  Multivariate analysis in the Neoadjuvant set 
Variables  
    Standard 
Error 
    Significance  Hazard Ratio 
(HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
Age    .018      .403  1.015  .980  1.051 
Gender    .391      .353  .695  .323  1.496 
Surgery    .495      .321  .612  .232  1.615 
pT0    .475      .003  4.007  1.579  10.167 
AIMP3    .349      .648  .852  .430  1.691 
ERCC1    .371      .094  .537  .259  1.113 
Mre11    .369      .675  1.167  .566  2.408 
p53    .347      .051  .507  .257  1.002 
 
 
8.6  AIMP3 and ERCC1 in the LaMB trial TMA set 
8.6.1  Patient characteristics and immuostaining characteristics of the LaMB set 
The clinico-pathological characteristics of the LaMB trial (ISRCTN35418671) set 
are previously summarised (Table 2.8).  In brief, there were a total of 72 patients; 
mean age was 67 years (range: 42 to 82 years); 59 were males (82%) and 18 females 
(18%).  In this group of 72 patients, 33 (46%) were randomised to the “standard” 223 
 
treatment arm and 39 (54%) were randomised to the “experimental” arm comprising 
treatment with Lapatinib + standard.  
 
The immune-stainining characteristics of AIMP3, ERCC1, Mre11 and p53 in the 
LaMB TMA cores are illustrated below (Figure 8.10). 
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Figure 8.10:  LaMB set: Negative cores (top panel) and Positive cores (bottom panel).  
Left panel cores are at 10X magnification and Right panel cores are at 200X magnification. 
(A) AIMP3, (B) ERCC1, (C) Mre11, (D) p53. 
 
 
8.6.2  AIMP3 in the LaMB set 
Kaplan-Meier analysis of the survival differences in the LaMB set, stratified by 
AIMP3 status, demonstrated no significant differences between the AIMP3-positive 
and AIMP3-negative groups (Table 8.10).  The estimated median survival in the 
AIMP3-negative group was 15.0 +/- 2.0 months (95% CI: 11.2 to 18.9 months) 
compared to 23.0 +/- 7.3 months (95% CI: 8.8 to 37.2 months) in the AIMP3-226 
 
positive group (Table 8.10B).  This difference was not significant (p=0.883) (Table 
8.10C).  The absence of a significant difference was appreciable on the Kaplan-
Meier survival plots (Figure 8.11). 
 
Table 8.10: Case-processing summary (Table 8.10A), survival estimates (Table 8.10B) 
and log rank estimates (Table 8.10C) based on AIMP3 immunostaining status in the LaMB 
TMA set 
Table 8.10A: The distribution of AIMP3-negative (-) and AIMP3-positive (+) cases is 
tabulated below. 
AIMP3 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
AIMP3 (-)  38  11  27  71.1% 
AIMP3 (+)  34  12  22  64.7% 
Overall  72  23  49  68.1% 
 
Table 8.10B: The survival estimates for the AIMP3-negative (-) and AIMP3-positive (+) 
cases are tabulated below.  For the whole cohort (72 patients), the median survival was 16.0 
+/- 2.6 months (95% CI: 10.9 to 21.1 months). 
Means and Medians for Survival Time 
AIMP3 
status 
Mean  Median 
Estimate  Standar
d Error 
95% Confidence Interval  Estimate  Standard 
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
AIMP3 (-)  20.755  3.448  13.997  27.513  15.000  1.963  11.153  18.847 
AIMP3 (+)  19.018  2.257  14.594  23.442  23.000  7.251  8.789  37.211 
Overall  20.876  2.322  16.325  25.427  16.000  2.595  10.914  21.086 
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Table 8.10C:  Log-rank of the K-M estimates and significance. The significance (p value) 
for the above survival estimates (Table 8.10B) is calculated at 0.883 meaning that there is no  
significant difference in survival between the AIMP3-negative and AIMP3-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           .022    .883 
 
 
 
 
 
Figure 8.11:   Kaplan-Meier plots for the AIMP3 in the LaMB set.  There is no significant 
difference between the AIMP3-negative group (blue survival plot) and the AIMP3-positive 
group (green survival plot) 
Univariate analysis confirmed the lack of significant difference in survival outcomes 
between the AIMP3-positive and AIMP3-negative groups (Table 8.11).  The hazard 
ratio was 0.94 (95% CI: 0.41 to 2.16) (p=0.885). 228 
 
 
Table 8.11:  Univariate analysis of AIMP3 in the Neoadjuvant set 
Variables  
    Standard 
Error 
    Significance  Hazard 
Ratio (HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
AIMP3 status    .424      .885  .941  .410  2.158 
 
 
 
8.6.3  ERCC1 in the LaMB set 
Kaplan-Meier analysis of the survival differences in the Neoadjuvant set, stratified 
by AIMP3 status, demonstrated no significant differences between the ERCC1-
positive and ERCC1-negative groups (Table 8.12).  The estimated median survival 
in the ERCC1-negative group was 15.0 +/- 2.9 months (95% CI: 9.4 to 20.6 months) 
(Table 8.12B).   This could not be compared directly to the ERCC1-positive group 
as the median survival in the group could not be calculated due to the cumulative 
survival in the group being more than 50% at the point of censorship (Table 8.12B).   
However, differences in survival between the groups could be estimated by log rank 
and this difference was not significant (p=0.660) (Table 8.12C).  The absence of a 
significant difference was appreciable on the Kaplan-Meier survival plots (Figure 
8.12). 
 
 
Table 8.12: Case-processing summary (Table 8.12A), survival estimates (Table 8.12B) 
and log rank estimates (Table 8.12C) based on ERCC1 immunostaining status in the LaMB 
TMA set 229 
 
Table 8.12A: The distribution of ERCC1-negative (-) and ERCC1-positive (+) cases is 
tabulated below. 
ERCC1 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
ERCC1 (-)  43  15  28  65.1% 
ERCC1 (+)  29  8  21  72.4% 
Overall  72  23  49  68.1% 
 
 
 
Table 8.12B: The survival estimates for the ERCC1-negative (-) and ERCC1-positive (+) 
cases are tabulated below.  For the whole cohort (72 patients), the median survival was 16.0 
+/- 2.6 months (95% CI: 10.9 to 21.1 months). 
Means and Medians for Survival Time 
ERCC1 
status 
Mean  Median 
Estimate  Std. 
Error 
95% Confidence Interval  Estimate  Std. 
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
ERCC1 
(-) 
18.739  2.690  13.467  24.011  15.000  2.853  9.408  20.592 
ERCC1 
(+) 
20.564  2.622  15.425  25.703  .  .  .  . 
Overall  20.876  2.322  16.325  25.427  16.000  2.595  10.914  21.086 
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Table 8.12C:  Log-rank of the K-M estimates and significance. The significance (p value) 
for the above survival estimates (Table 8.12B) is calculated at 0.419 meaning that there is no 
significant difference in survival between the ERCC1-negative and ERCC1-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           .654    .419 
 
 
 
 
 
Figure 8.12:   Kaplan-Meier plots for the ERCC1 in the LaMB set.  There is no significant 
difference between the ERCC1-negative (blue survival plot) and the ERCC1-positive group 
(green survival plot). 
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Univariate analysis confirmed the lack of significant difference in survival outcomes 
between the ERCC1-positive and ERCC1-negative groups (Table 8.13).  The hazard 
ratio was 0.71 (95% CI: 0.30 to 1.67) (p=0.428). 
 
Table 8.13:  Univariate analysis of ERCC1 in the LaMB set 
Variables  
    Standard 
Error 
    Significance  Hazard 
Ratio (HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
ERCC1 status    .438      .428  .706  .299  1.668 
 
 
 
8.6.4  Mre11 in the LaMB set 
Kaplan-Meier analysis of the survival differences in the LaMB set, stratified by 
Mre11 status, demonstrated no significant differences between the Mre11-positive 
and Mre11-negative groups (Table 8.14).  The estimated median survival in the 
Mre11-negative group was 16.0 +/- 2.5 months (95% CI: 11.1 to 20.9 months).  In 
the Mre11-positive group, the estimated median survival was 27.0 months but the 
confidence intervals around this estimate could not be calculated (Table 8.14B).  
However, the difference between the groups could be estimated by log rank and this 
difference was not significant (p=0.821) (Table 8.14C).  The absence of a 
significant difference was appreciable on the Kaplan-Meier survival plots (Figure 
8.13). 
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Table 8.14: Case-processing summary (Table 8.14A), survival estimates (Table 8.12B) 
and log rank estimates (Table 8.14C) based on Mre11 immunostaining status in the LaMB 
TMA set 
Table 8.14A: The distribution of Mre11-negative (-) and Mre11-positive (+) cases is 
tabulated below. 
Mre11 
status 
Number  Number of 
Events 
Censored 
Number  Percent 
Mre11 (-)  48  18  30  62.5% 
Mre11 (+)  24  5  19  79.2% 
Overall  72  23  49  68.1% 
 
 
 
Table 8.14B: The survival estimates for the Mre11-negative (-) and Mre11-positive (+) 
cases are tabulated below.  For the whole cohort (72 patients), the median survival was 16.0 
+/- 2.6 months (95% CI: 10.9 to 21.1 months). 
Means and Medians for Survival Time 
Mre11 
status 
Mean  Median 
Estimate  Standard
Error 
95% Confidence Interval  Estimate  Standard
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Mre11 
(-) 
20.682  2.620  15.546  25.817  16.000  2.504  11.092  20.908 
Mre11 
(+) 
19.833  3.342  13.283  26.383  27.000  .000  .  . 
Overall  20.876  2.322  16.325  25.427  16.000  2.595  10.914  21.086 
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Table 8.14C:  Log-rank of the K-M estimates and significance. The significance (p value) 
for the above survival estimates (Table 8.14B) is calculated at 0.821 meaning that there is no  
significant difference in survival between the Mre11-negative and Mre11-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           .051    .821 
 
 
 
 
Figure 8.13:   Kaplan-Meier plots for the Mre11 in the LaMB set.  There is no significant 
difference between the Mre11-negative (blue survival plot) and the Mre11-positive group 
(green survival plot). 
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Univariate analysis confirmed the lack of significant difference in survival outcomes 
between the Mre11-positive and Mre11-negative groups (Table 8.15).  The hazard 
ratio was 0.89 (95% CI: 0.33 to 2.43) (p=0.824). 
 
Table 8.15:  Univariate analysis of Mre11 in the LaMB set 
Variables  
    Standard 
Error 
    Significance  Hazard ratio 
(HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
Mre11 status    .511      .824  .892  .328  2.429 
 
 
 
8.6.5  P53 in the LaMB set 
Kaplan-Meier analysis of the survival differences in the LaMB set, stratified by p53 
status, demonstrated no significant differences between the p53-positive and p53-
negative groups (Table 8.16).  The estimated median survival in the p53-negative 
group was 15.0 +/- 1.9 months (95% CI: 11.3 to 18.7 months) compared to 18.0 +/- 
4.2 months (95% CI: 9.9 to 26.2 months) in the p53-positive group (Table 8.16B).  
This difference was not significant (p=0.692) (Table 8.16C).  The absence of a 
significant difference was appreciable on the Kaplan-Meier survival plots (Figure 
8.14). 
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Table 8.16: Case-processing summary (Table 8.16A), survival estimates (Table 8.16B) 
and log rank estimates (Table 8.16C) based on p53 immunostaining status in the LaMB 
TMA set 
Table 8.16A: The distribution of p53-negative (-) and p53-positive (+) cases is tabulated 
below. 
p53 status  Number  Number of 
Events 
Censored 
Number  Percent 
p53 (-)  33  9  24  72.7% 
p53 (+)  39  14  25  64.1% 
Overall  72  23  49  68.1% 
 
 
 
Table 8.16B: The survival estimates for the p53-negative (-) and p53-positive (+) cases are 
tabulated below.  For the whole cohort (72 patients), the median survival was 16.0 +/- 2.6 
months (95% CI: 10.9 to 21.1 months) 
Means and Medians for Survival Time 
p53 
status 
Mean  Median 
Estimate  Standard 
Error 
95% Confidence Interval  Estimate  Standard
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
p53 (-)  20.905  3.934  13.194  28.617  15.000  1.898  11.279  18.721 
p53 (+)  18.165  2.053  14.141  22.189  18.000  4.160  9.846  26.154 
Overall  20.876  2.322  16.325  25.427  16.000  2.595  10.914  21.086 
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Table 8.16C:  Log-rank of the K-M estimates and significance. The significance (p value) 
for the above survival estimates (Table 8.16B) is calculated at 0.692 meaning that there is no  
significant difference in survival between the p53-negative and p53-positive cases. 
  Chi-Square    Significance 
Log Rank (Mantel-Cox)           .157    .692 
 
 
 
 
Figure 8.14:   Kaplan-Meier plots for the p53  in the LaMB set.  There is no significant 
difference between the p53-negative group (blue survival plot) and the p53-positive group 
(green survival plot). 
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Univariate analysis confirmed the lack of significant difference in survival outcomes 
between the p53-positive and p53-negative groups (Table 8.17).  The hazard ratio 
was 1.18 (95% CI: 0.51 to 2.77) (p=0.697). 
 
Table 8.17:  Univariate analysis of p53 in the LaMB set 
Variables 
    Standard 
Error 
    Significance  Hazard 
Ratio (HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
p53 status    .434      .697  1.184  .506  2.774 
 
 
 
8.6.6  Multivariate analysis of the LaMB set 
On multivariate analysis, the findings of the Kaplan-Meier estimations and 
univariate analyses, for the markers, were confirmed (Table 8.18).  None of the 
markers (AIMP3, ERCC1, Mre11 and p53) were found to demonstrate statistical 
significance in predicting survival difference in the LaMB set. 
 
Of the available demographic clinical variables, Age (p=0.175) and Gender 
(p=0.436) were also not significant.  In this limited cohort (n=72) of the LaMB set, 
Randomisation was also not significant.  The hazard ratio for Randomisation was 
1.06 (95% CI: 0.34 to3.35) with a p value of 0.915. 
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Table 8.18:  Multivariate analysis in the LaMB set 
Variables 
    Standard 
Error 
    Significance  Hazard 
Ratio (HR) 
95.0% CI for Hazard 
Ratio 
  Lower  Upper 
Age    .031      .175  1.042  .982  1.107 
Gender    .569      .436  1.558  .511  4.749 
AIMP3    .482      .754  .860  .334  2.210 
ERCC1    .446      .569  .776  .324  1.859 
Mre11    .582      .455  .647  .207  2.026 
p53    .489      .708  1.201  .461  3.132 
Randomisation    .586      .915  1.064  .338  3.354 
 
 
 
8.7  Discussion of results 
In this chapter, the primary objective was to investigate whether AIMP3 expression 
was predictive of cisplatin-exposure outcome in vitro.  Given the previous in vitro 
findings (Chapter 3) where AIMP3 was predictive of radiation-exposure outcome, 
it was logical to hypothesise that, similarly, AIMP3 knockdown by siRNA 
transfection, would increase the clonogenic survival of bladder cancer cell lines 
following treatment with cisplatin.  To answer this question, RT112 and a cisplatin-
resistant subline, RT112CP, were used in conjunction as a model of the spectrum of 
ciplatin-sensitive to cisplatin-resistant bladder cancer cell lines.  Indeed, dose-
response studies demonstrated that RT112CP was approximately 5-fold more 239 
 
resistant to cisplatin than RT112.  In addition, their dose-response curves did not 
overlap indicating that their cisplatin sensitivities were at two ends of the spectrum.  
Therefore, the model was felt to be satisfactory in terms of testing bladder cancer 
cell lines with significantly different cisplatin-sensitivities.  However, there is an 
argument to be made that it would have been more comprehensive to have 
incorporated other bladder cancer cell lines (e.g. T24, RT4, 253J) into the panel. 
 
It was necessary to characterise the constitutive levels of AIMP3 expression in 
RT112 and RT112CP in order to explain any differences in functional outcomes that 
may be observed.  Western blot analyses demonstrated no significant differences in 
AIMP3 protein expression levels between the two.  Clonogenic assays were 
performed as the functional readouts as previously (Chapter 3) with RT112 and 
RT112CP being treated with IC50 cisplatin (and with controls; e.g. without 
cisplatin) following siRNA knockdown of AIMP3 (and with controls; e.g. with 
GAPDH siRNA and scrambled siRNA).  In both RT112 and RT112CP, in two out 
of three experiments each, there was a significant increase in clonogenic survival 
when AIMP3 was downregulated suggesting that AIMP3 may be important in 
cisplatin-mediated DNA damage response. 
 
The secondary objectives of this chapter were to interrogate the predictive value of 
the panel of markers (AIMP3, ERCC1, Mre11 and p53) in the Neoadjuvant and 
LaMB sets respectively.  In the Neoadjuvant set, there were 84 patients included 
which was felt to be a reasonable sample size.  Approximately half the patients had 
subsequently undergone radical radiotherapy and half radical cystectomy.  The 240 
 
median age, age range and gender distributions were not dissimilar to the BCON and 
Radical Cystectomy sets.  In the Neoadjuvant set, only p53 demonstrated 
significance, in terms of differential survival outcomes, on Kaplan Meier estimates 
and univariate analysis.  However, this significance was lost on multivariate 
analysis.  There was no significant difference in survival outcome between the 
radical cystectomy and radical radiotherapy groups.  This finding is in keeping with 
the contemporary opinion that there is little difference between survival outcomes 
between surgery and radiotherapy for organ-confined MIBC and that, if there is a 
survival advantage in favour of surgery, it is likely small.  The current Neoadjuvant 
set, of 84 patients, would not be adequately powered to delineate this difference and 
this as not the objective of the current study. 
 
In the LaMB trial set, none of the markers demonstrated significance.  However, 
there were a number of limitations with the LaMB set.  First of all, the sample size 
was 72 which meant that differences in survival were only likely to be detected if 
they were sufficiently large differences, i.e. the larger the size effect, the more likely 
it was to be detected with statistical significance (p<0.05).  In other words, a larger 
sample size, such as that for the BCON set (n=217) would have been preferable.  
The main reason for the somewhat small sample size is that the LaMB trial has not 
been completed and the patients included in the TMA set were those who were 
recruited at the beginning of the trial. There were 106 cases initially identified as 
being suitable for incorporation into the TMA set.  However, data and tissue 
availability were also limiting factors in committing more cases into the TMA.  
Furthermore, on account of the incompleteness of the study, follow-up periods for 
the vast majority of patients included were also short.  Similarly, there were only 23 241 
 
events (deaths) recorded for the 72 patients.  As patients with metastatic bladder 
cancer are expected to have a poor prognosis, it was anticipated that a long period of 
follow-up may not be absolutely essential in the cohort of 72 available cases.  
However, with a more “mature” study, with a longer period of follow-up time, this 
event-rate (deaths) would be expected to be higher.  Consequently, survival analyses 
would be more robust.  In the current analysis, based on the 72 patients, there was no 
significant survival difference between the trial arms (standard treatment versus 
Lapatinib + standard treatment).   For the reasons described above, it would be 
“premature” to conclude that there is no significant difference in the LaMB trial 
arms. Furthermore, the LaMB trial is set up to specifically investigate any 
differences in progression-free survival, as the primary objective, rather than 
differences in overall survival. Certainly, the LaMB set, with its full complement of 
recruited patients (n=204) and with a longer period of follow-up would be a more 
robust platform to interrogate the markers of this current study as well as to pose the 
question as to whether there is any significant differences in either progression-free 
or overall survival between the two trial arms. 
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9.1  Methodological considerations 
9.1.1  Cell lines 
The study of complex biological processes, such the effect of altered levels of 
expression of one or more genes on the response of tumours to radiotherapy or 
chemotherapy, is technically challenging in vivo.  Cell lines offer a relatively simple 
model which allows for a quicker and more cost-effective means of interrogating 
questions arising from proposed hypotheses pertaining to such complex biological 
phenomena.  On the other hand, the use of cell lines does have many limitations 
including the lack of genotypic and phenotypic similarities, in some cases, to the 
tissue or tumour that they are meant to represent.  Furthermore, the complexity of 
biological pathways in vivo may mean that the observations in vitro, in a controlled 
experimental setting, may turn out to be significantly different and therefore, 
conclusions drawn from tumour cell lines may not be directly transferrable in the 
clinical setting.   
 
In the current study, a panel of bladder cancer cell lines (T24, RT112, 253J and 
RT4) was used.  For the initial AIMP3 expression characterisation and radiation 
exposure work, the panel of cell lines was felt to be satisfactorily representative of 
bladder cancer cells.  HeLa was used as the reported positive control for AIMP3 
expression.  All the bladder cancer cell lines, as well as HeLa, are well established, 
characterised and are often reported in the literature.  An argument can be made for 
the inclusion of more bladder cancer cell lines to have been made in the panel used 
in this study.  This would certainly have made the findings more comprehensive.  
However, the addition of more cell lines would have significantly increased the 244 
 
workload of each experimental protocol and this was felt, on balance, not likely to 
be time-efficient with respect to the remit of the project. 
 
All the cell lines were obtained from a single, reputable source (Professor John 
Masters) with the passage of each cell line being documented.  All cells were 
maintained in standardised incubation conditions, checked for mycoplasma 
contamination, passaged prior to confluence and used within 10 passages for 
experimental purposes.  These measures ensured that the experimental conditions 
were reliable and replicable.  However, there is an argument to be made for having 
obtained the same cell lines from a different (e.g. commercial) source and to have 
corroborated the experimental observations for each of the cell lines in question.  
Again, this exercise was felt to be not necessary for mainly the same reasons as 
described above. 
 
For the cisplatin sensitivity work, RT112 and RT112CP were used as a panel to 
represent a spectrum of cell lines with two extremes of cisplatin sensitivity.  As 
discussed in the preceding chapter (Chapter 8), this was confirmed to be the case as 
RT112CP was approximately 5-fold more resistant to cisplatin than RT112.  
Furthermore, the dose-response curves for RT112 and RT112CP did not overlap 
suggesting that they represented the two ends of a wide cisplatin sensitivity 
spectrum.  Again, the use of more cell lines would have been desirable, to represent 
cell lines with differing cisplatin sensitivities within the spectrum (or indeed more 
sensitivity than RT112).  However, the dual cell line model was felt to be adequate.   245 
 
9.1.2  Protein expression 
In this study, expression of the gene in question, AIMP3, was studied by the 
measurement of its protein product.  For the cell lines-based work, Western blot 
analysis was used as the method of measuring AIMP3 protein expression.  
Expression of AIMP3 protein was successfully characterised in the panel of bladder 
cancer cell lines (Chapter 3).  This meant that it was arguably not necessary to 
corroborate the findings at RNA level (e.g. through PCR) as proteins are the final 
effectors of biological processes.  One of the criticisms of solely investigating gene 
expression through measurement of RNA levels is that mRNA transcripts may be 
degraded as part of the regulatory process of gene expression and may ultimately not 
be translated to their protein products.  Hence, the decision to perform Western blot 
analyses in this study.  Had there been issues with characterisation of AIMP3 protein 
expression, PCR would have been performed.   
 
An argument can be made for having corroborated the Western findings with 
RTPCR measurements.  However, this was not routinely performed.  There was an 
instance when performing RTPCR was felt to be useful.  When siRNA knockdown 
of AIMP3 was analysed by Western blot analysis (Figure 3.6), one of the controls 
included siRNA transfection with GAPDH siRNA (positive control).  However, 
downregulation of GAPDH, at protein level, on the Western blots was not 
appreciable.  This was most likely due to the constitutively high levels of GAPDH.  
To prove that the positive control (GAPDH siRNA transfection) was indeed causing 
a downregulation of GAPDH expression, RTPCR was performed (Appendix C, 
Supplementary Figure A).  This demonstrated that there was a significant (96%) 
reduction in the GAPDH mRNA levels following GAPDH siRNA transfection.  246 
 
Similarly, RTPCR confirmed significant downregulation of AIMP3 expression 
following AIMP3 siRNA transfection (Appendix C, Supplementary Figure B).  
Therefore, it was considered satisfactory to measure AIMP3 protein expression by 
Western blot analysis. 
 
9.1.3  Functional assays 
Clonogenic survival assays were performed as the functional readouts for most of 
the experiments.  Dose-response characteristics for radiation as well as cisplatin 
treatments were measured by this method.  Following siRNA transfection, 
differences in radiation or cisplatin responses were also measured by this method.  
This methodology (i.e. clonogenic assay) was chosen as it is generally considered to 
be robust.  Indeed, the dose-response and siRNA knockdown experimental findings 
were found to be consistent.  Other assays (e.g. tetrazolium-based colorimetric 
assays) are quicker to perform but have the propensity to produce variable results 
based on experimental conditions affecting the metabolic status of the cells and 
without necessarily affecting cellular viability.  Therefore, clonogenic assays were 
chosen as the viability readouts following cytotoxic treatments (with cisplatin or 
radiation) were likely to be more reliable. 
 
In the siRNA transfection experiments, treatment arms consisted of exposure to 
IC50 doses of irradiation or cisplatin.  This was chosen as the method as the IC50 
doses calculated were consistent for the cell lines and formed the basis on which 
deviations in the readouts (clonogenic survival) compared to that expected (at IC50 
dosing) could be readily detected.  However, for each cell line, differences in the 247 
 
readouts (clonogenic survival) at a range of doses would likely have been more 
comprehensive by demonstrating differing shifts in the dose-response curves for the 
different experimental conditions. 
 
Following siRNA knockdown of AIMP3, rather than just measure the survival 
readouts, alternative readouts could have been performed to analyse the downstream 
functional effects of altered AIMP3 expression.  As elaborated in the introductory 
chapter (Section 1.4), there are many key players in the DNA damage response 
(DDR) pathway including p53, ATM, ATR and Chek proteins. As for AIMP3, 
characterisation of the levels of expression of these proteins in response to radiation 
and cisplatin exposure in the bladder cancer cell lines is a major avenue of further 
research pertinent to the current project.  In addition, the effects of siRNA 
downregulation of AIMP3 on the level of expression of these proteins or on their 
activities (e.g. phosphorylation of p53) could be interrogated.  Although 
conceptualised, this body of work was considered to be beyond the scope of the 
current project due mainly to time-constraints. 
 
In addition to the characterisation of AIMP3 protein levels in the panel of bladder 
cancer cell lines, immunofluorescence was performed to characterise the subcellular 
localisation of AIMP3.  As previously reported in HeLa and fibroblasts, AIMP3 was 
demonstrated to distribute within both the cytosolic as well as nuclear compartments 
in the bladder cancer cell lines used.  HeLa was used as the control.  Following 
irradiation, AIMP3 was observed to be distributed relatively more in the nuclear 
compartment suggesting a possible nuclear translocation of AIMP3 to take part in 248 
 
the DDR pathway as previously reported in HeLa and fibroblasts.  However, due to 
technical difficulties, quantifications of the observed changes were not performed.  
Secondly, subcellular fractionation, following irradiation, was also technically 
challenging given the difficulties of extracting pure subcellular fractions in irradiate 
specimens.  Therefore, the observed phenomenon, which is previously reported in 
HeLa and fibroblasts, could not be corroborated in bladder cancer cell lines in the 
current study. 
 
9.1.4  TMA immunostaining, scoring and statistical analyses 
Immunostaining of all the TMA sets (BCON, Radical Cystectomy, Neoadjuvant and 
LaMB) were performed by the UCL Advanced Diagnostics (UCLAD) laboratory.  
UCLAD is part of the UCL Cancer Institute and provides accredited laboratory 
research facilities internationally.  Immunostaining was considered to be of high 
quality for the antibodies (AIMP3, ERCC1, Mre11 and p53) tested and the results 
were reproducible.  This also meant that the valuable TMA sections, especially the 
BCON and LaMB trial materials, were used with minimal waste. 
 
With respect to the scoring methodology, validated methods were used where 
previously reported.  For instance, the median H score method for ERCC1, the 25
th 
percentile cut-off for Mre11 and the 10
th percentile cut-off for p53.  For AIMP3, the 
median H score method was found to be significant.  Where the results suggested a 
probable difference which narrowly missed significance (for instance, p53 status in 
the BCON set), alternative scoring methods (e.g. additional H score method for p53) 249 
 
were performed in order to endure that potential significant differences were not 
being missed on account of the scoring method used.   
 
The scoring process was repeated adequately by different observers to assure strong 
intra-observer as well as inter-observer agreements and to ensure reliability of the 
results.  However, the significant findings, particularly with respect to AIMP3 and 
ERCC1 in the BCON set, must be validated externally.  In other words, the findings 
in the BCON set must be replicated by external observers.  The ideal way to achieve 
this would be for a different research group to replicate the entire immunostaining 
protocol, including staining, scoring and statistical analyses, using a fresh batch of 
BCON TMA sections. 
 
9.1.5  TMA datasets 
There were no major issues with the BCON trial TMA and trial dataset.  The sample 
size was large (n=217) and the dataset was deemed to be robust, as would be 
expected from a reported clinical trial.  However, the dataset was not considered to 
be large enough to divide into two large “test” and “validation” sets to detect the 
same level of survival differences observed.  Alternatively, it would have been 
desirable to have validated the BCON set findings on another contemporary radical 
radiotherapy set.  However, such a separate radiotherapy validation set was not 
available.   
 250 
 
The Radical Cystectomy set was a useful “control” set to interrogate whether the 
significant findings of AIMP3 and ERCC1 in the BCON set indicated that they were 
truly predictive of radiotherapy outcome or whether they were simply prognostic of 
survival in bladder cancer.  Ideally, this set would also have been obtained from a 
trial setting.  However, this was not possible particularly in view of the unsuccessful 
SPARE trial.  The advantages of the Radical Cystectomy set used were that it was 
large (n=151), contemporary and from a single UK institution.  The dataset was 
deemed to be robust with characteristics that would be typically expected from a 
radical cystectomy series.  However, for the reasons explained above with respect to 
BCON, it would have been desirable to either have had a larger Radical Cystectomy 
set or a similarly-sized separate set for validation purposes although this (a 
validation cystectomy set) is perhaps less important an issue compared to a 
validation radiotherapy set. 
 
The Neoadjuvant set was created, following ethics approval (EC06.11), by collating 
tissue materials and corresponding clinical data from multiple centres in the UK.  
The sample size (n=84) was satisfactory but the targeted sample size (n>150 to make 
it comparable with the BCON and Radical Cystectomy sets) could not be achieved 
due primarily to the difficulties with ensuring local ethics approval at potential 
collaborating sites to release materials and data.  Furthermore, due to the inherent 
nature of retrospectively identifying and collecting materials, not all materials or 
data were available.  However, the clinic-pathological characteristics of the available 
Neoadjuvant set was considered to be robust to use as a platform to interrogate the 
predictive value of the markers in differentiating survival outcomes following 
neoadjuvant cisplatin-based chemotherapy.  It was felt that, although it may not be 251 
 
large and robust enough as the BCON trial set to demonstrate highly significant 
results, it might still be adequate to reveal any signal of significance with respect to 
the markers if there was any present.  In this respect, p53 status narrowly missed 
significance in this set.  ERCC1, AIMP3 and Mre11 were not significant.  It would 
be interesting to investigate whether p53 demonstrated significance in a larger 
Neoadjuvant set.   Another noteworthy point with respect to the Neoadjuvant set is 
that there was no significant difference in overall survival between the radical 
cystectomy and radical radiotherapy groups.  This finding is in keeping with what 
would be expected.  In other words, there should either not be a significant 
difference or, if there were any difference, there should be a marginal difference in 
favour of radical surgery.  A significantly larger sample size would be required to 
demonstrate a significant difference between the two groups and this was not the 
purpose of the Neoadjuvant set.  However, if a larger Neoadjuvant set was created, 
on account of inclusion of patients ultimately either undergoing surgery or 
radiotherapy, it might provide a validation set for both the BCON  “radiation set” 
and the Radical Cystectomy “control set”.  In its current state (n=84), with 46 
patients (55%) in the radical cystectomy group and 38 patients (45%) in the radical 
radiotherapy group, the Neoadjuvant set is not large enough to provide independent 
validation sets for “radiation” and “control” purposes. 
 
The LaMB set had the advantage of arising from a clinical trial and allowed the 
investigation of cisplatin-based chemotherapy in bladder cancer in a different setting 
– palliative treatment to control the progression of locally advanced or metastatic 
disease.  One of the main limitations of the LaMB set is that the trial is not 
completed.  As a result, rather than a potential 214 patients, only 72 could be 252 
 
included in the current TMA set.  Furthermore, the event rate (deaths) was low as a 
significant number of patients included had not had adequate periods of follow-up.  
These issues make interpretation of the LaMB set findings unreliable in its current 
state.  However, once completed and “mature” after a period of follow-up, it would 
be worth interrogating the markers on this set.  The effects of cisplatin on 
progression-free or overall survival may be more pronounced on the LaMB set as 
compared to the Neoadjuvant set.  In the neoadjuvant setting, the survival benefits of 
cisplatin are known to be small (but significant) with the main bulk of the survival 
advantage being accorded by the radical treatment modality, either surgery or 
radiotherapy.  Therefore, the LaMB set is a worthwhile platform to interrogate in the 
future when trying to answer the question of cisplatin-response in the clinical 
setting. 
 
9.2  Summary of the thesis’ findings and future directions 
The main hypothesis of the thesis was “AIMP3 is predictive of response to chemo- 
or radio-therapy in vitro in bladder cancer cell lines and may be predictive of 
clinical outcome following radio- or chemo-therapy in patients with muscle-invasive 
bladder cancer.”  The body of work presented in this thesis aimed to evaluate the 
evidence to support or refute this hypothesis. 
 
In Chapter 3, knockdown of AIMP3 by siRNA transfection, in the panel of bladder 
cancer cell lines used, was demonstrated to affect their radiosensitivity as measured 
by clonogenic survival assays.  Downregulation of AIMP3 resulted in increased 
clonogenic survival following IC50 irradiation supporting the notion that AIMP3 253 
 
may be an important tumour suppressor involved in the radiation-induced DNA 
damage response pathway.  AIMP3 protein expression was characterised in the cell 
lines by Western blot analyses.  The radiation dose-response characteristics of these 
cell lines were also characterised by clonogenic survival assays.  The trafficking of 
AIMP3 from a cytosolic location into the nuclear compartment, following 
irradiation, as explored in this study.  However, conclusive evidence to support this 
phenomenon could not be obtained.  Future lab-based work could validate these 
findings in a wider panel of bladder cancer cell lines.  Alternative methodologies, 
such as RTPCR, could be performed to confirm the Western findings.  Further work 
on refining the immunofluorescence protocol could be done in order to attempt 
quantitation of the subcellular AIMP3 trafficking phenomenon.  Alternatively, 
subcellular fractionation, followed by Western blot quantitation, could be attempted 
to investigate this phenomenon.  There is also a wide scope to investigate the role of 
AIMP3 in the DDR pathway.  The current project focused on measuring direct 
outcomes (e.g. clonogenic survival following AIMP3 knockdown; AIMP3 
subcellular localisation through immunofluorescence following irradiation) related 
to AIMP3 status.  However, the effects of AIMP3 on other DDR pathway molecules 
such as p53, ATM, ATR, and Chek proteins could be investigated and would 
provide important insights into the molecular biology of the complex DDR pathway.  
Such studies would require substantial lab-work and could form the basis of future 
PhD projects. 
 
In Chapter 4, AIMP3 immunostaining status was demonstrated to be significantly 
predictive of radiotherapy outcome in the BCON set.  Patients who were AIMP3-
positive had a 47% survival advantage compared to those who were AIMP3-254 
 
negative.  This was highly significant (p<0.002).  The other significant finding was 
that tumour recurrence at 6 months was highly predictive of overall survival.  Those 
whose tumours recurred, following radiotherapy, had an approximate 9-fold 
increased risk of death compared to those without recurrence (p<0.001).  
Interestingly, significantly more patients with tumour recurrences were also found to 
be AIMP3-negative (p<0.001).  The findings support the hypothesis that AIMP3 is a 
significant predictor of radiotherapy outcome in patients with organ-confined MIBC.  
Future work needs to focus on validating these findings.  This can be done in two 
main ways.  Firstly, the findings can be externally validated using the BCON set 
itself.  Secondly, a separate radical radiotherapy set can be used.  The two pieces of 
work can form the basis of a good clinical research project. 
 
In Chapter 5, the aim was to answer the question as to whether AIMP3 is truly 
predictive of radiotherapy outcome or whether it is simply prognostic for survival of 
patients with bladder cancer.  The survival analyses on the Radical Cystectomy set, 
used as a “control” set for radiation treatment, answered this question.  AIMP3 was 
not predictive of survival in the Radical Cystectomy set.  The corollary of this 
finding is that AIMP3 is a predictive marker of radiotherapy outcome.  There is 
scope for future work on this Radical Cystectomy set.  The findings can be validated 
externally.  Further follow-up may be performed and that will allow for a more 
robust dataset.  More importantly, a separate radical cystectomy set may also be 
created from one or more contemporary series in the UK.  Such work will require 
ethics approval and can form the basis of a clinical research project. 
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In Chapter 6, the aim was to investigate the predictive value of an additional panel of 
reported radiotherapy response markers on the BCON and Radical Cystectomy sets.  
On the basis of the reported literature, it was hypothesised that Mre11, ERCC1 and 
p53 may be predictive of radiotherapy outcome.  The findings in the chapter 
demonstrated that ERCC1 immunostaining status was a highly significant predictor 
of radiotherapy outcome in the BCON set.  Those who were ERCC1-negative had an 
approximate 3-fold (300%) survival advantage relative to those who were ERCC1-
positive (p<0.001).  Interrogation of ERCC1 in the Radical Cystectomy set, as with 
AIMP3, confirmed that ERCC1 status was not simply prognostic of survival.  There 
was a suggestion, on univariate analysis, that Mre11 may also be predictive of 
radiotherapy outcome (p=0.03); however, this significance was lost on multivariate 
analysis (p=0.372).  p53 status was not a significant predictor in either the BCON or 
Radical Cystectomy set.  As with AIMP3, future work needs to be conducted to 
validate these findings, particularly the significance of ERCC1 as a predictor of 
radiotherapy outcome.  As explained above for AIMP3, a validation radiation set 
would be required.  In addition, external validation on the BCON set would be 
important. 
 
In Chapter 7, the main objective was to explore the potential combinational 
permutations of the panel of markers in order to find a combination that could help 
stratify the patients in the BCON set into groups that were most or least likely to 
respond to radiotherapy.  Combinational modelling demonstrated that the only 
significant permutation was a dual panel of AIMP3 and ERCC1 with four possible 
combinations depending on marker-positivity or –negativity respectively.  The best 
prognostic combination (AIMP3+ERCC1-) had an approximate 6-fold survival 256 
 
advantage relative to the worst prognostic combination (AIMP3-ERCC1+) and this 
finding was highly significant (p<0.001).  The main value of this finding is in its 
potential clinical utility.  If patients can be stratified, on the basis of the 
immunostaining profile of their diagnostic TURBT specimens, into a group that is 
likely to do well following radiotherapy, they can be offered radical radiotherapy as 
the best treatment option for them.  The corollary of this is that, if their 
immunostaining profile predicts that they are not likely to respond well to 
radiotherapy, they can be offered radical cystectomy instead.  This type of selection 
strategy would help ensure that patients undergo treatments most likely to benefit 
them and avoid the specific side-effects of other treatments that they are not likely to 
benefit from in the first instance.  Therefore, it is vital for future work to validate the 
AIMP3 and ERCC1 findings.  Validation would provide the platform for the 
markers to be investigated formally in a clinical setting.  This would be best 
achieved in a clinical trial setting.   
 
In Chapter 8, the findings suggested that AIMP3 expression predicts cisplatin 
response in vitro but that AIMP3 and ERCC1 were both not predictive of outcome in 
the Neoadjuvant and LaMB sets.  Firstly, siRNA knockdown of AIMP3 in RT112 
and RT112CP cells resulted in an increase in clonogenic survival following IC50 
cisplatin exposure.  As with AIMP3 in the context of radiation exposure, the 
findings indicated that AIMP3 may play an important role in the cisplatin-mediated 
DNA damage response pathway.  Future lab-based work would need to validate this 
finding preferably in a wider panel of bladder cancer cell lines.  As ERCC1 is 
thought to play an integral role in the cisplatin-mediated DDR pathway, it would 
seem logical to characterise ERCC1 expression in the panel of bladder cancer cell 257 
 
lines and to perform siRNA knockdown of ERCC1 to investigate any changes in 
functional outcome.  The limitations of the Neoadjuvant and LaMB sets are already 
discussed above (Sections 8.7 and 9.1.5).  In brief, there is scope to expand the 
Neoadjuvant set so that it serves as a robust platform in its own right.  Furthermore, 
with a larger size, it has the potential to provide both the radiation and cystectomy 
validation sets.  The LaMB set would be worth revisiting within a few years as this 
would allow the full trial cohort to be included with adequate follow-up for 
censoring events. 
 
9.3  Concluding remarks 
In conclusion, the body of work presented in this thesis support the central 
hypothesis that AIMP3 expression is predictive of radiotherapy outcome in vitro and 
that it is predictive of radiotherapy outcome in patients with organ-confined MIBC.  
However, future work would need to validate the in vitro as well as BCON set 
findings.  AIMP3 was also demonstrated to be predictive of cisplatin-based 
chemotherapy outcome in vitro.  However, it would be useful to validate this on a 
wider panel of bladder cancer cell lines as well as to investigate the role of ERCC1 
expression in these cell lines.   
 
The role of other key DDR pathway effectors could form the basis of future lab-
based projects to improve our understanding of the pathway.  Such studies may also 
highlight other effectors, in the DDR pathway, which may be worth interrogating in 
a clinical setting such as in the radiotherapy, chemotherapy or cystectomy sets.  If 
they are found to be significant, such markers could help to augment the current 258 
 
predictive panel comprising of AIMP3 and ERCC1.  Future work, subsequent to 
validation work, would entail conducting a clinical trial to investigate the predictive 
panel.  The eventual future direction would involve the use of such a predictive 
panel to effect a paradigm change in the contemporary management of organ-
confined MIBC, by helping to stratify patients into effective treatment algorithms. 
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11.2  Appendix A (ii) – Radical Cystectomy TMA Map 
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11.4  Appendix A (iv) – LaMB TMA Map 
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11.5  Appendix A (v) – Control TMA Map 
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th August 2015 in line with the duration of the 
Research Tissue Bank approval. This approval may be renewed for a further period in the 
future. We will be asking you to complete an annual return giving information on the number of 
patients consented and samples taken. We may at any time request to audit your project to 
ensure compliance with the necessary regulatory and governance requirements. 
 
Thank you for your application to the Biobank and if you have any questions, please do not hesitate to 
contact Nadege Presneau (n.presneau@ucl.ac.uk) or Kirstin Goldring (k.goldring@ucl.ac.uk ). 
 
Yours Sincerely 
 
Amanda Gibbon, Chair, B-ERC 
cc Dr Alan Ramsay, Clinical Lead of Histopathology 
Gary Brown, Head Biomedical Scientist/Service Manager - Histopathology 
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13 Appendix C 
 
 
Supplementary RTPCR data299 
 
 
 
Supplementary Figure A:  Relative mRNA expression of GAPDH  in T24 cells 24 hours 
following siRNA transfection.  Lane 1 represents GAPDH expression in untreated cells 
(negative control).  Lane 2 represents cells with AIMP3 (p18) siRNA knockdown (positive 
control).  Lane 3 represents cells with GAPDH siRNA knockdown (treatment/test group).  
Lane 4 represents cells with non-targeting (NT), scrambled siRNA transfection (negative 
control).  GAPDH mRNA levels in Lanes 2, 3 and 4 are calculated relative to the negative 
control (Lane 1).  Relative to Lane 1 (100%), there is a 29% reduction in GAPDH mRNA 
level (Lane 2) following AIMP3 (p18) siRNA knockdown representing off-target effects of 
siRNA transfection.  Relative to Lane 1, there is a 96% reduction in GAPDH demonstrating 
significant downregulation of GAPDH expression following siRNA transfection.  Relative 
to Lane 1, there is a 22% reduction in GAPDH expression in Lane 4 (non-targeting, 
scrambled siRNA) representing off-target effects of siRNA transfection.  The numbers in 
brackets above each bar represent the mRNA copy numbers. 
(This RTPCR work was conducted with the help of Dr Patricia de Winter) 
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Supplementary Figure B:  Relative mRNA expression of AIMP3 in T24 cells 24 hours 
following siRNA transfection.  Lane 1 represents AIMP3 expression in untreated cells 
(negative control).  Lane 2 represents cells with AIMP3 (p18) siRNA knockdown 
(treatment/test group).  Lane 3 represents cells with GAPDH siRNA knockdown (positive).  
Lane 4 represents cells with non-targeting (NT), scrambled siRNA transfection (negative 
control).  AIMP3 mRNA levels in Lanes 2, 3 and 4 are calculated relative to the negative 
control (Lane 1).  Relative to Lane 1 (100%), there is a 12% reduction in GAPDH mRNA 
level (Lane 3) following GAPDH siRNA knockdown representing off-target effects of 
siRNA transfection.  Relative to Lane 1, there is a 5% increase in AIMP3 expression in Lane 
4 (non-targeting, scrambled siRNA) representing either a non-significant change or an off-
target effects of siRNA transfection.  The numbers in brackets above each bar represent the 
mRNA copy numbers. 
(This RTPCR work was conducted with the help of Dr Patricia de Winter) 